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Summary
SUMMARY
The aims of this project were to determine the role of two antisense genes, RL1 and 
ORF P in herpes simplex virus (HSV) virulence and to identify the HSV-2 strain HG52 
ICP34.5 expression.
The first overall aim was to define individual phenotypes associated with ICP34.5 
and ORF P in HSV-1 strain 17+. HSV-1 contains an ORF in the long repeat sequences 
named RL1 (also called yi34.5) which expresses the polypeptide ICP34.5. One RL1 
deletion variant, 1716, is avirulent upon intracranial inoculation in the central nervous 
system (CNS) and the peripheral nervous system (PNS). Replication o f 1716 in vitro was 
shown to be cell type and cell state dependent.
The avirulent phenotype of 1716 based on deletion o f this region of the HSV-1 
genome was originally attributed solely to the RL1 gene. However, transcripts in the 
opposite direction and antisense to RL1 in HSV-1 were identified in 1994. From these 
transcripts two open reading frames (ORF O and ORF P) mapped antisense to RL1. This 
led to the hypothesis that ORF P may be at least partly responsible for the avirulent 
phenotype of ICP34.5 negative mutants.
1716 was used as the backbone to generate three recombinant viruses containing 
either RL1 or ORF P in the nonessential UL43 gene. Two lengths o f RL1 were cloned due 
to uncertainty about the position of the putative RL1 promoter sequence and role of the 5' 
untranslated leader in expression. One RL1 fragment contained only the ORF while the 
other fragment contained the ORF and 134 bp additional upstream sequence. The RL1 or 
ORF P genes were individually sub-cloned downstream of the HSV-1 gD promoter. This 
promoter was used because it has similar kinetics to that of the natural ICP34.5 promoter. 
These RL1 or ORF P cassettes also contained the lacZ gene under the SV40 promoter in the 
opposite orientation for detection of recombinant virus.
The recombinant virus, 1622, contained only the RL1 open reading frame and 
demonstrated an 8 -fold overexpression of ICP34.5 by Western blotting and 
immunoprecipitation. 1622 regained wild type replication kinetics in vitro in cell lines non- 
permissive for ICP34.5 negative viruses. In certain cell types, an in vitro function of 
ICP34.5 is to maintain protein synthesis by using a protein kinase (PKR) pathway. 1716 
showed host protein synthesis shut-off in human neuroblastoma and HeLa cells confirming 
the previously reported data for the HSV-1 strain F ICP34.5 deletion mutant, R3616. 1622 
infected cells demonstrated protein synthesis similar to 17+ by SDS-PAGE. 1622
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demonstrated a small reduction in neurovirulence compared with 17+ by intracranial 
inoculation but was 40-fold more virulent than its parent following infection via the snout 
and trigeminal ganglia as assayed by in vivo replication and immunohistochemsitry.
The recombinant virus, 1623, by Western blotting expressed very low levels of 
ICP34.5 compared to 17+. Based on 2-fold dilutions o f 1623 infected BHK cell extracts, 
ICP34.5 is expressed eight times less than in 17+ and thus 64-fold less than in 1622. 
Interestingly, this low level of expression still enabled 1623 to maintain wild type levels of 
protein synthesis in neuroblastoma and HeLa cells. However, the replication kinetics in 
vitro from 1623 was slower than 1716. This suggests that there may be a second mutation 
elsewhere in the genome.
The recombinant virus, 1624, contained ORF P under the HSV-1 gD promoter. 
Due to difficulties in cloning the ORF P gene, final purification and characterisation of this 
mutant was not carried out. However, expression o f ORF P from 17+ infected cells was 
analysed by an antiserum from a GST/ORF P fusion protein. By Western blotting, ORF P 
was detected in 17+ infected cells during normal lytic infection in vitro. Cells infected with 
a RL1 epitope tagged virus, 1621, demonstrated expression of a slightly larger form of ORF 
P. The temperature sensitive virus, tsK, when grown at 39.5°C expresses a form of ICP4 
which is non-functional and does not bind to the ORF O/P repressor site. A lower Mr form 
of ORF P was detected from tsK.
The second overall aim was to identify ICP34.5 in HSV-2 using two strategies. 
Although distinct from the first aim, this used some o f the same techniques and ideas.
Based on sequence analysis by McGeoch (1991), there is 83% homology between 
the 63 amino acid domain found at the carboxy terminus in RL1 o f HSV-2 strain HG52 
and HSV-1 strain 17+. One unique feature in the HSV-2 strain HG52 RL1 gene is the 
presence of a 154 bp intron. In order to identify the ICP34.5 protein two strategies were 
developed. First, intertypic recombinant viruses were constructed where HSV-2 RL1 was 
inserted under HSV-1 gD promoter in the UL43 locus of 1716. All recombinant plasmids 
contained the lacZ gene for selection of recombination as described above. One 
recombinant virus, 1627, contained RL1 with its natural intron and the other recombinant 
virus, 1628, had the intron deleted. Once these viruses were isolated, their genome 
structure was confirmed by Southern blotting. In vitro studies examining virus replication 
and host protein synthesis from 1627 and 1628 infected cells determined functional 
homology between RL1 of HSV-1 and 2.
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The HSV-1 ICP34.5 protein had previously been identified using antisera raised 
against the HSV-1 RL1 ORF. However, these antisera did not recognise an HSV-2 
ICP34.5 protein from wild type HSV-2 strain HG52, 1627 or 1628.
Second, was to raise antisera against glutathione S-transferase fused to the 
predicted HSV-2 RL1 ORF. Using these antisera, Western blotting and 
immunoprecipitation showed the presence of two proteins, 27 kDa protein and 37 kDa 
(ICP34.5), from HG52 and 1627 infected cells. Only the 37 kDa protein was detected 
following infection with 1628 and 2624, mutants without the RL1 intron. The 27 kDa 
novel protein has been named ICP34.5A. The relationship between these proteins is not 
clear, but expression of the 27 kDa ICP34.5A protein is dependent on the presence of the 
intron. In addition, it was found that like HSV-1 ICP34.5, HSV-2 ICP34.5 also interacts 
with the proliferating cell nuclear antigen (PCNA) and localises primarily in the cytoplasm.
1716 and the recombinant viruses used throughout this study demonstrated some 
unusual features. The genes o f interest, RL1 or ORF P, were bi-directionally inserted into 
the UL43 Nsil site. It was not previously known that this locus would have an effect on an 
inserted gene. The UL43 gene has been shown to be nonessential and a gene antisense to 
UL43, named UL43.5 was later shown to be expressed. Insertion of a cassette into the Nsil 
site positioned the cassette at the 3’ end of UL43.5 but at the 5’ end of UL43. By placing 
the gene or genes of interest in an expression cassette which had two genes in opposite 
orientations, we were able to compare the effect of orientation on the levels of gene 
expression. Genes inserted in the same transcriptional orientation as UL43.5 were 
expressed better than in the opposite orientation. This led to the hypothesis that 
overexpression of ICP34.5 from 1622 infected cells was, at least partly, based on RL1 
orientation in UL43. Two new recombinant viruses were constructed to enable a direct 
comparison to confirm this observation.
Finally, plaque morphology from 1716 and all recombinant viruses constructed 
was observed. Because 3T6 cells are non-permissive for RL1 deleted viruses 1716 gives 
abortive plaques in these cells. Although BHK cells are permissive for RL1 deleted viruses 
and allow equal replication between 17+ and 1716, this study found that 1716 and its 
recombinant viruses produced small plaques on BHK cells. The abortive plaque phenotype 
on 3T6 cells was originally believed to be solely a consequence o f the lack of ICP34.5 
expression. However, 1622 which overexpresses ICP34.5 did not restore wild type plaque 
morphology on 3T6 or BHK cells.
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1.1. The Herpesviridae
Characteristic properties of Herpesviridae includes the ability to enter latency, a 
state in which on infectious progeny are produced and only limited transcription of viral 
genes occurs. In addition, they encode several trans-acting factors which regulate the 
temporal expression of viral genes controlling the phases of infection (Cann, 1993). 
Herpesviridae have a characteristic physical icosahedral virus structure.
1.1.1. Classification
Herpesviridae have been classified into three subfamilies based on their biological 
properties: Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae.
Alphaherpesvirinae have the capacity to establish latent infections primarily in the ganglia. 
Betaherpesvirinae have a long reproductive cycle and the infection progresses slowly in 
culture. The infected cells frequently become enlarged (cytomegalo) and carrier cultures 
are readily established. The virus can be maintained in latent form in secretory glands, 
lymphoreticular cells, kidneys, and other tissues. Gammaherpesvirinae replicate in vitro in 
lymphoblastoid cells. Viruses in this subfamily are specific for either B or T lymphocytes. 
In lymphocytes, infection is frequently arrested at either a pre-lytic or lytic stage, but 
without production of infectious progeny. Latent virus is frequently found in lymphoid 
tissue.
1.2. Herpes Simplex Virion
Herpes viruses all have a similar virion structure which led to their classification 
into one family. Virion particles mature by budding through the altered cellular membranes 
o f infected cells. HSV virions are 150-200 nm in size, consist o f four basic morphologic 
elements (Fig. 1), and are described below.
The Core
The core of a mature HSV virion contains the viral DNA. The HSV-1 DNA
genome is approximately 153 kbp in size and the HSV-2 DNA genome approximately 154
kbp (Dolan et al., 1998). Both HSV-1 and HSV-2 genomes consists of two covalently
linked components, namely, the unique long (Ul ) and unique short (Us) sequences which
are flanked by terminal inverted repeats (TR and IR, respectively; Fig. 2). Most of the
genetic capacity of the virus is protein coding with more than 74 HSV polypeptides being
encoded (McGeoch et al., 1988). Infected cell proteins (ICP), virion proteins (VP), and
1
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Figure 1. HSV virion.
a. Diagrammatic representation of HSV virion, i. capsid,
ii. tegument, iii. lipoprotein envelope, and iv. glycoproteins, b. Electron
micrograph image of a HSV-1 strain 17+ virion (photo provided by F. Rixon).
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Figure 2. A schematic, linear diagram  of the HSV-1 strain  17+ genome (not draw n to scale).
The HSV-1 genome contains two unique regions, unique long (UL) and unique short (Us). These are 
flanked by terminal repeat sequences TRL and and TRS and internal repeat sequences IRL and IRS. The 
sequence where theTR( and TRS join is called the a sequence (not shown in this diagram). The 
junction where IR, and IRS meet is called the a ’ sequence.
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virion molecular weight (Vmw) are the major nomenclatures for HSV proteins. The ICP 
numbering system is determined by order in a polyacrylamide gel (i.e. ICP1 is the heaviest 
and ICP47 is the lightest). A complete list of all known HSV-1 proteins, gene names and a 
brief description is given in Appendix A.
Capsid
Capsids are assembled in the nucleus. They are composed of protein, and are 
approximately 1 0 0  nm in diameter and have an icosahedral symmetry made of 162 
capsomeres. Three types of capsids can be isolated from HSV-1 infected cells. They are 
visualised as light scattering bands in sucrose gradients and are designated A, B and C in 
order of increasing distance sedimented (Gibson and Roizman, 1972). A and C capsids are 
similar in protein content, but only the C capsid contains a genomic equivalent of DNA and 
presumably matures into the infectious virion. The seven proteins which compose the B 
capsid are VP5, VP19c, VP22a, VP21, VP23, VP24 and VP26 (Gibson and Roizman, 
1972). Table 1 gives a complete nomenclature of the proteins and gene names.
Capsids are shaped like hexagonal prisms with a hollow tube through the length of 
the longitudinal axis (Fig. 1; Wildy et al., 1960). VP5 is the major capsid protein, 
comprising approximately 60% of the capsid mass, and forms the hexons and pentons 
present in capsids. VP22a is present only in B capsids, occupies the inner space, and 
functions as a scaffold for assembly of the icosahedral capsid shell. VP19C and VP23 form 
a triplex structure that is required in the formation and stabilisation of the capsid shell. The 
UL26 gene product encodes an essential protease activity, VP24, specified by residues 248 
to 635. VP21 shares sequence identity with the more abundant 22a from residues 307-635 
and also has scaffold activity (Steven and Spear, 1996).
VP26 is the smallest capsid protein (12 kDa) and is encoded by the UL35 ORF
(McNabb and Courtney, 1992a; Davison et al., 1992). It is expressed late in the infectious
cycle after the onset of DNA replication and has been shown to be present in multiple
phosphorylated forms (McNabb and Courtney, 1992b). Desai et al (1998) deleted the
VP26 gene and inserted a lacZ gene in its place and named this mutant virus KA26Z. They
showed that VP26 is dispensable for replication in cell culture. Capsid assembly and the
composition of the synthesised virions appear to be unaffected by the absence of VP26,
although infectious virus yield is decreased by two-fold relative to wild type. Therefore,
VP26 is the only capsid protein that is not required for replication in cell culture (Desai et
al., 1998). KA26Z had plaques which were smaller in size than wild type plaques, although
4
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Table 1. Nomenclature of virion and capsid proteins in HSV-1.
Gene Protein
UL18 VP23
UL19 VP5
UL26 VP21
UL26.5 VP22a
UL35 VP26
UL38 VP19C
UL46 VP11+12
UL47 VP13+14
UL49 VP22
5
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quantitative examination was not carried out. Desai et al (1998) demonstrated that VP26 is 
important for virus replication in vivo. Mutant virus yields were decreased 30- to 100- fold 
in the trigeminal ganglia (TG). Reactivation o f the mutant virus as determined by co­
cultivation was also reduced (Desai et al., 1998).
Tegument
The tegument is an electron dense material located between the capsid and the 
envelope. The amount of tegument in each virion is not equivalent. It is composed of at 
least 20 distinct viral proteins, some of whose properties are not yet fully understood. An 
example of a tegument protein is UL41 which functions as a virion associated host shut-off 
protein (vhs) (Aurelian et a l, 1989).
VP 16, or a  gene trans inducing factor (aTIF), recognises c/s-acting response 
elements, the octamer-GARAT and TAATGARAT sequences, in promoters of IE genes. 
VP 16 does not directly contact its response elements but binds to the cellular protein Oct-1 
attached to the octamer or TAAT portion of the element.
VP22 is one o f the structural proteins that make up this poorly understood region 
of the virion tegument which has been studied (Elliott and O ’Hare, 1997; Dargan, 1986). 
VP22 is unique in its ability to enter surrounding cells with such a high level of efficiency 
that, after endogenous synthesis in a small subpopulation of cells, the protein forms 
gradients in surrounding recipient cells as reported by Elliott and O ’Hare (1997). Elliott 
and O ’Hare showed that uptake o f VP22 does not involve the standard route of endocytosis, 
but a novel pathway that is cytochalasin D sensitive and therefore would seem to require an 
intact actin cytoskeleton.
Envelope
The envelope is the outermost covering of the virus and is composed primarily of 
lipids derived from the host cell membrane, into which are inserted the HSV glycoproteins, 
and are necessary for cellular recognition. Glycoproteins are individually described in 
Section 1.4.1. The diameter of the envelope is approximately 150-200 nm, although the 
exact dimensions depend on visualisation technique.
1.3. Human Herpes Viruses
To date, eight herpesviruses have been isolated from humans: herpes simplex virus
type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), varicella-zoster virus (VZV), human
6
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cytomegalovirus (HCMV), Epstein-Barr vims (EBV), and human herpesvirus 6 , 7 and 8  
(HHV-6 , HHV-7 and HHV-8 ). These herpesvimses fall into all o f the three different 
subfamilies as described in Section 1.1.1. (Table 2).
Table 2. Known human herpesvimses and their classification (Roizman and 
Sear, 1996; Neipel et a l ,  1997).
Human Herpesvirus Official
Name
Common
Name
Subfamily
Herpes simplex vims 1 HHV-1 HSV-1 a
Herpes simplex vims 2 HHV-2 HSV-2 a
Varicella Zoster vims HHV-3 VZV a
Epstein Barr vims HHV-4 EBV Y
Human Cytomegalovirus HHV-5 HCMV p
Human herpes vims 6 HHV - 6 HHV - 6 p
Human herpes vims 7 HHV-7 HHV-7 p
Kaposi’s sarcoma associated 
herpes vims
HHV - 8 KSHV y
1.3.1. Herpes Simplex Virus
Herpes simplex vims (HSV) is a member of the subfamily Alphaherpesvirinae and 
the genus simplexvims. Simplexvimses generally have a wide host range, a relatively short 
reproductive cycle, and the capacity to establish latency. They are among the most 
intensely studied vimses because o f their ability to cause a variety o f infections and to 
reactivate causing lesions at or near the initial site o f infection (Roizman et al., 1996). 
They serve as excellent models for studying translocation o f proteins, synaptic connections 
in the nervous system, membrane stmcture and gene regulation (Roizman et al., 1996).
1.3.2. Genome Structure
The members o f the family Herpesviridae are identified by double-stranded linear 
DNA in the core of the virion. All herpesvirus DNAs studied to date fall into one o f five
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sequence arrangements (Fig. 3). A characteristic feature of herpes virus DNAs extracted 
from virions is the presence of nicks and gaps that cause the DNAs to fragment upon 
denaturation with alkali and formamide. It has been reported that packaged DNA contains 
ribonucleotides, but these do not account for all the sites o f fragmentation of the DNAs.
Genome type Isomers
Figure 3. Diagram of the sequence arrangements in the five types of genomes of 
herpesviridae.
The lines represent unique regions. Reiterated sequences larger than 1 kbp in length other 
than terminal reiterations are shown as rectangles. The arrowhead in rectangles indicates 
whether the sequence is repeated in direct or inverted orientation as in genome type A, C, D 
and E. Where more than one set o f large repeats has been reported, they are designated by 
letter. The shaded boxes represent terminal reiterated sequences reported in genomes types 
B, C, D and E. All terminal reiterations are direct repeats. In the case of the type E 
genomes, the terminal reiterations designated as the a sequence are also repeated in inverted 
orientations internally (a'). Examples of each genome type include; the channel catfish 
herpes virus (A), saimirine herpes virus 2 (B), EBV (C), VSV (D) and HSV (E) (Roizman 
and Sears, 1996).
1.3.3. The HSV-1 and HSV-2 Genome
Morphologically, HSV-1 and 2 are identical and have approximately 50% DNA 
homology. However, HSV-1 and 2 have some biological, biochemical, genomic and 
clinical differences. They differ in restriction endonuclease (RE) cleavage sites and viral 
protein sizes. An example of one RE which differs between HSV-1 and HSV-2 and used 
widely throughout this study is BarriEl, represented in Figure 4. Antigenic differences have 
been demonstrated by serologic assays (Aurelian et al., 1989). An example of a poorly
8
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Figure 4. BamHl restriction enyme digestion pattern of HSV-1 and HSV-2.
a. The HSV-1 strain 17+ BamHl digestion pattern. The fargment “k” is the L/S junction 
fragment containing fragments “s” and “q”. This includes the RL1 and ORF P genes.
b. HSV-2 strain HG52 genome with BamHl fragments indicated. The BamHl 
fragment, g, is the L/S junction fragment covering the v and u sequences.
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conserved gene between HSV-1 and 2 is gG (Frame et al., 1986). The LAT locus of HSV- 
1 and 2  shares more than 80% sequence identity and contains similarly organised groups of 
putative c/s-acting elements (Soares et al., 1996).
1.3.4. The a Sequence
The a sequence is a direct repeat located at T R l and TRs and present as an inverted 
repeat at the L/S junction in the HSV-1 and 2 genome. The a sequence is approximately 
500 bp in HSV-1 (strain F), but its size varies from strain to strain. The HSV-l(F) a 
sequence has a 20 bp direct repeat (DRi), a 65 bp sequence ( U b ) ,  a 21 bp sequence (DR2 ), a 
37 bp sequence (DR4 ), a 53 bp unique sequence (Uc) and another copy o f DRi (Fig. 5; 
Roizman and Sears, 1990). The number of a sequences at the L/S junction and at the L 
terminus o f the DNA varies from 1 up to 10 (Roizman, 1979) but only 1 is present at the S 
terminus (Fig. 5; Wagner and Summers, 1978; Locker and Frenkel, 1979).
In 1985, Chou and Roizman reported that the a sequence acts in cis to cause 
inversion. Deletion of DR4  drastically reduces the frequency of inversion. Deletion of DR2  
and DR4  abolished inversions (Chou and Roizman, 1985). Most o f the DRi sequence can 
be deleted without affecting inversion.
Two highly conserved regions were identified in the Ub and Uc regions, pac-1 and 
pac-2. These were determined to be essential for the cleavage and packaging process 
(Deiss et al., 1986).
A mutant virus was generated by Martin and Weber (1996) to study the 
dispensability o f the a sequence present at the L-S junction. The original copies of the a 
sequence were deleted from this virus by conventional marker transfer. The mutant virus 
which does not contain the L/S a sequence but had one a sequence inserted in the thymidine 
kinase (tk) gene was named HSV-1 ::LAa. It had normal levels o f the four isomeric forms 
o f viral DNA in infected cells, but only two of these genomic isomers could be packaged 
into virions (Martin and Weber, 1996). The restriction was the result o f inversion of the L 
component during isomerization, which prevented two of the four isomers from having 
cleavage and encapsidation signals of the a sequence in the tk gene in a packagable 
orientation.
1.4. HSV Lytic Cycle
During the course of its normal life cycle HSV must infect and replicate in at least
two cell types, epithelial and neuronal. The HSV lytic cycle encompasses the primary
10
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DRI (DR2)
Figure 5. Diagram of the a sequence.
The sequence is divided by repeat domains drawn as blocks. The non-repeated 
sequences include Ub which is a located toward the b“ region and Uc 
located toward the c’ region. DR lb and DRlc are 20 bp elements present 
as direct repeats at the edge of the a sequence. DR2 is a directly repeated 12 bp 
element present in 19-22 copies. The DR4 domain is a directly repeated 37 bp 
element present in 2-3 copies. (Mocarski and Roizman, 1981).
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infection o f host cells and viral DNA replication in epithelial cells. HSV virions in the lytic 
cycle facilitate their replication by the preferential production of viral proteins at the 
expense o f the host cell gene expression (Zelus et al., 1996). In tissue culture, host protein 
synthesis and mRNA levels decline by approximately 90% within 3 hours postinfection 
with either HSV-1 or 2 (Zelus et al., 1996). Destabilisation of mRNA is triggered by the 
virion induced host shut-off (vhs) protein, which is located in the virion tegument (Zelus et 
a l,  1996).
1.4.1. Glycoproteins
Membrane glycoproteins mediate HSV entry into the cell, cell to cell spread, cell 
fusion, envelopment, egress and immune evasion. Glycoproteins also play a role in tissue 
tropism and host range. HSV-1 encodes at least twelve glycoproteins, namely: gB, gC, gD, 
gE, gG, gH, gl, gJ, gK, gL, gM and gN. The precise role o f all the glycoproteins has not 
been fully defined. Five glycoproteins: gB, gD, gH, gK and gL, have been shown to have 
an essential role in virus infectivity (Stannard et al., 1996).
Glycoprotein B has a role in virus adsorption, penetration, cell to cell spread and 
cell fusion (Navarro et al., 1992). It is also a specific determinant of HSV-1 
neuroinvasiveness (Yuhasz and Stevens, 1993). Glycoprotein B binds heparan sulphate 
moieties on the cell surface. Dyer et al (1997) showed that dextran sulphate stimulation of 
infection is primarily mediated by gB. Williams and Strauss (1997) also demonstrated that 
HSV-2 gB interacts with cell surface glycosaminoglycans during virus attachment. 
Conservation o f the gB gene between HSV-1 and 2 has been demonstrated by functional 
equivalence (Lin et al., 1996). Mutations affecting the cytoplasmic C-terminal domain of 
gB induce a syncitial phenotype (DeLuca et al., 1982, Bzik et al., 1984; Cal et al., 1988).
Glycoprotein C is considered nonessential for virus production in tissue culture. 
However, it has a function in attachment to the cell surface through heparan sulphate 
moieties (Padilla et al., 1997). It has recently been shown that gC may not play a vital role 
in adsorption (Williams, 1999; Griffiths et al., 1998). While gC enhances viral entry it is 
not required for syncitium formation and has been shown to inhibit fusion of some cultured 
cells (Manservigi et al., 1977; Novotny et al., 1996). Many syncitial HSV mutants do not 
express gC (Spear, 1993).
Glycoprotein D is an essential envelope glycoprotein required for viral entry
(Willis et al., 1998). Mutant viruses deleted in gD are severely compromised in neuronal
spread (Dingwell et al., 1995). It has been proposed that the role o f gD in cell to cell spread
12
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may be partially associated with its ability to bind mannose-6 -phosphate receptors (MPRs) 
(Brunetti et al., 1998).
Glycoprotein E has been shown to be non-essential (Neidhardt et al., 1987). It is a 
Fc binding glycoprotein (Bauke and Spear, 1979) and forms a non-covalently linked 
heterodimer with gl. Fc binding activity may prevent complement mediated lysis of 
infected cells and enveloped virions and may also protect against Fc-facilitated 
phagocytosis (Bell et al., 1990). The gE:gI complex also facilitates neurone to neurone 
spread o f HSV-1 and its cell to cell spread (Dingwell et al., 1995).
Glycoprotein H is required for membrane fusion but it is dispensable for receptor 
binding. Glycoprotein H negative virus binds to cells while being unable to enter them 
unless PEG treated (Forrester et al., 1992). Adsorption o f gH negative virions to cells 
blocks superinfection (Forrester et al., 1992). Glycoprotein H may have a role in viral 
egress from cells, as it has been demonstrated by Buckmaster et al (1984) that an anti-gH 
antibody inhibits plaque formation when added in the overlay following virus adsorption. 
Mutant viruses with altered gH are retained within cells (Desai et al., 1982). Targeting of 
gH to the rough endoplasmic reticulum results in the release o f non-infectious virions from 
infected cells, while infectious virions containing gH are retained within the cytoplasm 
(Jayachandra et al., 1997). Glycoprotein H may be involved in cell fusion as a gB syncitial 
mutant with a mutation in gH does not produce a syncitial phenotype.
Glycoprotein K, identified by Hutchinson et al (1992), is the product of UL53 
(Debroy et al., 1985; McGeoch et al., 1988). It is not absolutely essential for the 
production o f infectious virus in actively replicating cells, but is needed for efficient 
envelopment and transport of infectious virions to the extranuclear space. Glycoprotein K 
is involved in egress of HSV (Hutchinson et al., 1992) and is thought to play a role in 
regulating membrane fusion and syncitium formation. Syncitial mutations arise more 
frequently within UL53 than in any other HSV gene (Ruyechan et al., 1979; Bond and 
Person, 1984; Poguegeile and Spear, 1987; Jayachandra et al., 1997). In contrast to all 
studied glycoproteins to date, gK accumulates in the perinuclear and nuclear membranes of 
cells; other glycoproteins are transported to the surfaces on infected cells (Hutchinson et al.,
1995).
1.4.2. Adsorption
Adsorption occurs when the glycoproteins on the virion are recognised by one or
more specific cell receptor(s) which leads to binding o f the cell surface. Spear (1993)
13
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identified that cell surface heparan sulphate is a major factor in binding o f HSV to the cell 
surface. Glycoprotein B and C are the major viral glycoproteins to play a role in adsorption 
(Spear, 1993).
1.4.3. Penetration
On the surface of the virion are several glycoproteins which facilitate the 
subsequent penetration o f attached virions into the host cell. Glycoprotein B, gD, gH, and 
gL play an important role in penetration. When the virus has attached to the cell surface the 
viral envelope fuses with the cell membrane and the nucleocapsid is released into the 
cytoplasm.
1.4.4. Gene Expression
Gene expression involves regulatory loops controlled by signals which act either in 
cis or in trans. Details o f each step are described below and are illustrated in context of the 
whole HSV lytic cycle in Figure 6 . Gene expression occurs in a highly regulated order in 
three phases. The mRNAs produced during each of these phases corresponds to three 
classes o f polypeptides; a  (i.e. immediate early), p (i.e. delayed early), and y (i.e. late) 
(Roizman, 1979). The cascade of gene expression is described in detail below.
I.4 .4 .I. HSV DNA Replication and Im m ediate Early, Early, and Late Protein 
Synthesis
In HSV-1, there are three c/s-acting elements, which function as origins of DNA 
replication. The origin o f DNA replication in the long region, oriL, is located between the 
divergent transcripts for the DNA polymerase and the major binding protein (MDB) (UL29 
and UL30) (Quinn and McGeoch, 1985). The origins of DNA replication in the short 
region, oris, are localised to a 90 bp fragment in R s situated between the 5' ends of the 
divergent transcripts for IE3 and IE4/5 (Stow, 1982). The oris is present as 2 identical 
copies in the intact genome, one in IRs and one in TRs. In HSV-1 strain 17+, oris contains 
an imperfect palindrome of 42 bases with an (AT) 6  region and sequence at the centre. This 
central (AT ) 6  region and the sequence surrounding it are essential for viral replication 
(Stow, 1982). As early as 0.5 h postinfection and in the absence of protein synthesis, viral 
DNA accumulates in the nucleus and circularises.
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Figure 6 . HSV lytic cycle replication.
The lytic cycle throughout an infected host cell is illustrated in this diagram. There are 
9 stages which include the following: 1. adsorption and fusion with the cytoplasmic membrane 
for penetration; 2. uncoating of DNA; 3. early transcription; 4. early protein synthesis;
5. viral DNA replication, 6. late protein synthesis; 7. assembly; 8. envelopment by 
nuclear membrane; and 9. transport through the cytoplasm and release from the cell.
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The seven HSV-1 genes which have been found to be necessary for origin-specific 
replication include: UL5, UL 8 , UL9, UL29, UL30, UL42, and UL52 (see Table 3). Once 
the DNA is replicated within the nucleus, the capsid is assembled then released (Lehman 
andBoehmer, 1999).
As described in the previous section, initially only five immediate early (IE) gene 
products are synthesised peaking at 2 to 4 h postinfection. Part o f their function is to allow 
synthesis of early (E) proteins. Beta products are mostly involved in replication of viral 
DNA and proteins synthesis peaks 5 to 7 h postinfection. The temporal cascade of viral 
gene expression ends with the late (L) proteins.
1.4.5. Packaged Virions
Complete virions are transported to the cell membrane via the endoplasmic 
reticulum and the Golgi apparatus. Biosynthesis o f herpesvirus glycoproteins follows that 
o f eukaryotic proteins. Nonglycosylated precursors of herpesvirus membrane proteins are 
synthesised on polyribosomes bound to the rough endoplasmic reticulum (Roizman, 1979) 
and processed by addition of N/O linked sugars in the endoplasmic reticulum and Golgi 
apparatus. Once the DNA is replicated within the nucleus, the capsid is assembled then 
released. In vivo, following the initial lytic infection capsids are transported to the ganglia. 
In the ganglia, the HSV genome circularises and goes into a state known as latency.
1.5. HSV Latency
The latent phase occurs when the HSV genome maintains a quiescent infection in 
neurones o f ganglia. It is thought that the genome takes the physical extrachromosomal 
shape o f a circular episome (Aurelian et a l , 1989). It is estimated that only a small number 
o f neurones contain latent virus with, on average, each latently infected neurone containing 
different number of copies of the HSV genome. The restriction o f gene expression prevents 
cell lysis and is one of the major features o f latency (Cann, 1993). Additionally, reduced 
gene expression diminishes recognition of infected cells by the immune system. The 
restricted gene expression is probably achieved by tight regulation o f a  gene expression 
which is crucial in HSV replication.
In 1997, Sawtell published a method for comprehensive quantitative analysis of 
latently infected tissue at the level of single cells known as CXA. It was reported that the
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Table 3. HSV-1 proteins involved in DNA replication.
(concept from Lehman and Boehmer, 1999)
Protein Function
UL9
UL 8
UL5/52
UL5/52
UL30/42
UL30
UL42
ICP8
UL30
Origin-binding protein 
Helicase-primase loading protein 
Replicative helicase 
Primase
DNA polymerase 
Proofreading exonuclease 
DNA polymerase clamp 
Single-stranded DNA binding protein 
RNase H
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viral genome copy number within individual latently infected neurones is variable, ranging 
over three orders o f magnitude from <10 to >1000. There is a direct correlation between 
increasing viral input titre and the number o f neurones in which latency is established in the 
ganglion (Sawtell, 1997).
Using the latest techniques to study latency, only the latency associated transcripts 
(LATs) have been detected; no HSV antigens or virion particles have been detected. The 
LATs and their promoters (LAP1 and LAP2) are described below.
1.5.1. LAP1 and LAP2
Two LAT promoters have been identified, LAP1 and LAP2. LAP1 is situated at 
the 5' end o f the 8.3 kbp LAT and is 700 bp upstream of the 2 kbp intron (see Section
1.5.2.). It is required to generate a series of LATs in latently infected neurones (Soares et 
a l, 1996). Sequence analysis of this region suggests the existence of several c/s-acting 
elements. Soares et al (1996) studied the LAP1 TATA box and found it to play an essential 
role in transcription initiation in vitro. Further analysis of LAP 1 by in vitro transcription 
primer extension assays indicate that the presence of upstream elements specifically 
contribute to LAP1 function and that sequences 620 nucleotides upstream of the 
transcription start site were responsible for full promoter activity (Soares et a l, 1996). In 
addition to the TATA box, the LAP1 region contains a CCAAT box homology and 
potential recognition sequences for several transcription factors, including Spl, AP-2, YY1, 
CREB, LBF/MLTF/USF, Egr-1, a POU domain protein, and the HSV-1 immediate early 
transactivator, ICP4 (Soares et a l, 1996).
Studies have demonstrated that the LAT promoter sequence plays an important 
role in spontaneous reactivation in the rabbit eye model (Soares et a l , 1996). A mutant 
virus constructed with a deletion of the latency associated promoter (LAP1) at both loci, did 
not express LAT during latency (Soares et a l, 1996) and reactivated poorly. Similar 
findings were observed by Bloom et al (1996).
A second promoter which lies between LAP1 and the 5' end o f the 2 kbp LAT has 
been identified and designated LAP2 (Soares et a l, 1996). There have been no studies 
done, to date, to demonstrate the importance o f this promoter.
1.5.2. Latency Associated Transcripts (LATs)
The LAT locus is located in the long terminal repeat and is therefore present in 2
copies (Pemg et a l , 1996b). The less abundant (i.e. minor) LAT is 8.3 kbp. The most
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abundant (i.e. major) LATs are 2 co-linear, predominately nuclear poly(A)- RNAs of 2 kbp 
and 1.5 kbp which are believed to be introns spliced from the 8.3 kbp LAT. The major 
LATs appear to share 5’ and 3’ termini differing only in the excision o f a small intron with 
the unusual use o f GC instead of the consensus GU at the 5’ cleavage site (Wagner et al., 
1988; Spivack et al., 1991). Protein expression from LATs has not been detected during 
latency. LATs have been detected by Northern blot analysis and their structures analysed 
from cDNA clones and RT-PCR products (Spivack et a l, 1995). LATs can also be easily 
detected by in situ hybridisation (Maggioncalda et a l, 1996). The LAT transcript overlaps 
the ICPO and ICP34.5 genes in an antisense direction (Fig. 7). The role o f LAT in latency 
has yet to be fully understood.
The amount o f viral DNA recovered from rabbit TG latently infected with either 
LAT+ or LAT- virus, when quantified, was found to be equivalent (Bloom et a l, 1996). 
However, the ability o f virus to reactivate from latency was shown to reside within a 350 bp 
region o f LAT (Bloom et a l , 1996). This is in contrast to the data found using the murine 
model (Fraser et a l , 1992).
Arther et al (1998) tested to see if the 2 kbp LAT was produced as an intron in all 
phases of infection by disrupting the LAT splicing signals. Mutation o f the splice acceptor 
abrogates the 2 kbp major LAT generation during productive infection, but does not 
significantly influence major LAT synthesis during neuronal latency. Mutation of the 
splice donor also reduces the 2 kbp major LAT during productive infection.
When it was first determined that major LATs are complementary to part of the 
ICPO mRNA it was hypothesised that these transcripts influenced and maintained latency 
by down regulating ICPO through an antisense mechanism (Farell et a l , 1993). However, 
LAT null mutants were found to establish and maintain latency.
A role for LATs in efficient establishment of latency has been proposed (Sawtell 
and Thompson, 1992a; Thompson and Sawtell, 1997) and moreover, expression of the 2 
kbp LAT has been shown to reduce ICPO transactivation in dual transfection assays (Farrell 
et a l , 1993). This hypothesis was substantiated when it was found that ICPO message 
levels were elevated in BHK cells infected with viruses unable to make the 2 kbp LAT 
(Arther et al., 1998).
Chen et al (1997) used RT-PCR to analyse the effects o f a mutation in the LAT
locus on viral gene expression in latently infected mouse TG. The deletion removed the
promoter, transcriptional start site, and 1,015 bp o f transcribed sequences o f LAT. The
deletion mutant had reduced expression of the major LATs which resulted in an increase in
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Figure 7. A schem atic, linear diagram  of the HSV-1, strain 17% genome (not drawn to scale).
a. The HSV-1 genome (detailed in Fig. 2). b. The 11%, IRS and a ’ sequence is expanded
c. The only transcripts which can be detected during latency (LATs) are shown here.
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accumulation of transcripts from the immediate early gene encoding ICP4. The LAT 
deletion also resulted in an increase in the accumulation o f transcripts from the early gene 
encoding tk, whose expression during productive infection stringently depends on ICP4. 
The levels o f tk positively correlated with the levels of ICP4 transcripts. Chen et al (1997) 
concluded that a viral function associated with the LAT locus represses the accumulation of 
transcripts from at least two productive cycle genes in latently infected mouse ganglia.
Drolet et al (1998) sequenced the first 1.5 kbp of LAT from HSV-1 McKrae, a 
strain with a very high spontaneous reactivation rate. O f the HSV-1 LAT sequences 
available for comparison (17+, KOS, and F) only strain 17+ demonstrated high spontaneous 
reactivation in the rabbit (Pemg et al., 1996a,b). Unexpectedly, Drolet et al (1998) reported 
that a chimeric virus containing the KOS LAT gene in a HSV-1 McKrae genetic 
background had a spontaneous reactivation rate indistinguishable from McKrae. Drolet et 
al showed that the LAT function involved in spontaneous reactivation is mediated by a 
direct DNA or RNA mechanism rather than a protein. LAT- mutants reactivate poorly by 
induced reactivation in the mouse (Sawtell and Thompson, 1992a), by induced reactivation 
in the rabbit (Trousdale et al., 1991) and by spontaneous reactivation in the rabbit (Pemg et 
al., 1996a,b). Drolet et al (1998) showed that expression o f only the first 1.5 kbp of the 
primary 8.3 kbp LAT was required to restore wild type McKrae levels of spontaneous 
reactivation to a McKrae LAT null mutant.
Studies by Garber et al (1997) demonstrated that in acutely infected TG neurones, 
two independent isolates of a LAT- viruses exhibited expression o f immediate early genes 
and had increased numbers of cells expressing early and late transcripts compared to wild 
type and LAT rescued vimses. Moreover, infections with LAT- viruses, which exhibit 
increased expression of productive cycle genes within sensory neurones, showed decreased 
frequencies o f reactivation from latency (Garber et al., 1997).
Goldenberg et al (1997) cloned the entire LAT region from strain F (10.4 kbp) 
under the control of a constitutive promoter and generated a neuronal cell line (NA4) stably 
transfected with the viral LATs region. NA4 cells produced the 2.0 kbp and the 1.5 kbp 
LATs. Northern blotting and RT-PCR of RNA from NA4 cells, and from TG of mice 
latently infected with HSV-1 strain F, revealed that the two abundant LAT species were 
present in the polyribosomal RNA fractions and they hypothesised that these LATs might 
be translated (Goldenberg et al., 1997).
In 1990(a), Mitchell et al reported that a 17+ mutant vims named 1704 had a 3.8
kbp deletion that starts to the left of the 5’ end and extends into the coding sequence of the
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IR l LAT and a 1.2 kbp deletion that is located 5’ to, but outside the coding region o f the 
LAT in TRl. Ganglia of BALB/c mice latently infected with 1704 had no major LATs 
detected by in situ hybridisation (Mitchell et al., 1990a). The amount o f viral DNA in 1704 
and 17+ latently infected ganglia was similar but there was delayed reactivation kinetics 
observed with 1704. This affect was believed to be the result o f a biological function 
affected by the deletion rather than a difference in the number o f genome copies present 
during latency (Mitchell et al., 1990a).
Mitchell et al (1990b) established a model for HSV-2 latency in mice that is 
amenable to molecular studies. Data gained with this model indicated that HSV-2 
transcription during latency is confined to the repeat regions of the viral genome (Mitchell 
et al., 1990b). They identified an HSV-2 LAT and partially mapped it by in situ and 
Northern blot hybridisation experiments. This is possibly the first report identifying LATs 
in HSV-2 (Mitchell et al., 1990b). While LAT transcription during HSV-2 latency has not 
been as widely studied as in HSV-1, a single 2.2 kbp LAT intron is readily detected during 
acute and latent infection (Yoshikawa et al., 1996). In HSV-2, an equivalent to the HSV-1 
1.5 kbp spliced variant has not been detected.
1.5.3. In vitro Latency Models
In vitro cell culture latency systems have been developed and utilised to 
understand the molecular mechanism of latent HSV infection. Early in vitro latency 
systems relied on infection of cells in the presence of inhibitors o f virus replication for 
establishment, and incubation at supraoptimal temperature for maintenance o f latency 
(O’Neill et al., 1972; O ’Neill 1977; Wigdahl et al., 1981, 1982, 1983). Non-productive 
infection by HSV has also been established in a neuroblastoma cell line selected for its 
hyper-resistance to HSV-1 infection. In this instance, HSV-1 was retrieved by 
superinfection with HSV-2 (Nilheden et al., 1985). A lymphoid cell line, which harbours 
latent HSV, has also been described (Youssouffian et al., 1982).
In 1986, Russell et al developed an in vitro latency system for HSV-2. Virus 
replication was suppressed by infection of human foetal lung cells at the supraoptimal 
temperature o f 42°C, and, following transfer of cells to the normal growth temperature of 
37°C, infectious virus was generally not detected for at least six days. HSV-2 was 
reactivated by intertypic superinfection at 38.5°C with temperature sensitive mutants of 
HSV-1, or with HCMV.
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Mutant virus m l814 has an insertion mutation which abolishes trans-activation of 
IE transcription by Vmw65 (Ace et al., 1989). Using the in vitro latency model described 
above, mutant m l814 was retained in HFL cells following infection at low multiplicity of 
infection (m.o.i.) after incubation at 42°C. Reactivation occurred by superinfection of 
monolayers with viruses that express ICPO (Steiner et al., 1990). Latency was established 
by m l814 at 37°C and 42°C in a non-linear genome form (Jamieson et al., 1995; Preston et 
al., 1994). It was proposed that lack of Vmw65 function pre-disposes HSV to latency, as 
opposed to lytic growth in HFL cells, resulting in the retention o f the genome similarly 
found in vivo (Harris and Preston, 1991; Valyi-Nagy et al., 1991).
Danaher et al (1999) developed an in vitro model of a non-productive HSV-1 
infection in neurally differentiated (Nd)-PC12 (rat pheochromocytoma) cells which allowed 
for inducible virus replication upon forskolin treatment or heat stress. They demonstrated 
that the quiescent state was characterised by the absence of cell-associated virus, capsids, 
and viral antigens. They also showed that heat stress (43°C for 3h) efficiently reactivated 
virus from quiescently infected Nd-PC12 (QIF-PC12) cells (Danaher et al., 1999). This 
demonstrated that the proportion of cultures that activate virus production is dependent 
upon the m.o.i. Reactivation was a rare event limited to only a minority o f the QIF-PC12 
cell population (1:400-1:22,000) when latency was established at m.o.i.*s o f 30 and 3, 
respectively. Twenty-four h post heat stress the expression of HSV-1 productive genes 
(ICPO, ICP4 and ICP27, UL30 and UL18) switched from undetectable or very low levels to 
detectable or elevated levels in a sequential order with ICP4 induction occurring as early as 
3 h post induction. Viral antigen and infectious virus became detectable in cells as early as 
24 h post heat stress. In this model, a quiescent state between HSV-1 and Nd-PC12 is 
established with the transient use of acycloguanosine (ACV). Inhibitory levels are not 
present in QIF-PC12 cell cultures at the time of virus induction as measured by viral growth 
curves. Neither heat stress nor forskolin enhanced viral growth rates or yields in Nd-PC12 
cells. This indicates that these agents acts at the level o f induction, rather than altering cell 
permissivity. Furthermore, the absence of viral structures prior to induction suggests that 
the block in lytic pathway is between viral uncoating and capsid maturation (Danaher et al., 
1999). The absence o f immune based cells in the cultures indicated that induced activation 
o f HSV-1 within neural cells can occur independent of immunological signals. The 
analysis by Danaher et al (1999) of gene expression by RT-PCR permitted the detection of 
as few as 9 to 140 target sequences per 1500 cells, yet gene products of ICPO, ICP4 and
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UL30 could not be detected during the quiescent infection at 20 days post infection. In 
contrast, low levels o f ICP27 and UL18 were detected during the quiescent infection. The 
presence o f low levels of some immediate early and early gene RNAs during quiescence is 
not surprising as Kramer and Coen (1995) reported similar findings in murine TG latently 
infected with HSV-1. During the response to heat stress the immediate early HSV-1 ICP4 
and host HSP72 genes demonstrated induced expression within the first 3 h of treatment. 
Unlike the expression of the host HSP72 gene, which peaked at 2 h post heat stress and 
dropped to control levels by 38 h post heat stress, the level of ICP4 transcription continually 
increased throughout the assay. The level of transcription of other HSV-1 genes was not 
enhanced during the heat stress but increased at various times following recovery at 37°C. 
These data implicate ICP4 in the early role of co-ordinating reactivation from latency and 
argue against an early role of ICP27, ICPO and the non-stable LAT in this process. In 
contrast, ICP27 has been detected as early as 4 h following epinephrine induced 
reactivation in rabbit models (Bloom et al., 1994), and ICP4 has not always been detected 
rapidly post-explant o f latently infected murine ganglia (Minagawa et al., 1994).
1.5.4. In vivo Latency Models
The mouse footpad model was the first in vivo latency system to be developed 
(Stevens et al., 1972; Walz et al., 1974). HSV inoculation of a mouse rear footpad results 
in a local cutaneous infection and following anterograde transfer of virus through the 
peripheral and central nervous systems to the brain, an acute infection develops in the 
nervous system. The outcome of which may be a temporary or permanent posterior 
paralysis and possibly death of the mouse. Mice which recover from paralysis within three 
weeks are used for latency studies with latency established in the lumbar/sacral ganglia 
which supply the nerves to the footpad. During acute infection (1 to 10 days post 
inoculation) HSV can be recovered from the sciatic nerve, sacrosciatic spinal ganglia, 
dorsal roots, spinal cord and brain. Thereafter, infectious HSV has not been detected in 
homogenates o f nervous tissue.
In the mouse (Knotts et al., 1974; Walz et al., 1974) and rabbit (Stevens et al., 
1972) eye models, HSV resides in a latent state in the TG after infection of the cornea via 
scarification. Latent infections have also been established in the TG and cervical dorsal 
root ganglia (DRG) of mice following lip and ear inoculation, respectively (Walz et a l , 
1974; Hill et al., 1975).
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Several studies have been conducted to determine transcription and/or expression 
of virus proteins from ganglia latently infected with HSV. To date, the LATs have been the 
only consistently detected transcripts (Section 1.5.2.).
1.6. Reactivation
Reactivation of HSV from ganglia results in the appearance of infectious virus at 
the site o f the initial primary infection. In experimental animal models, reactivation has 
been reported to occur following traumatization of peripheral tissues (Valyi-Nagy et al., 
1991). Viral gene products reported to govern the establishment and maintenance o f latency 
and facilitate reactivation include thymidine kinase, ribonucleotide reductase and the 
immediate early protein (ICPO) (Aurelian et a l, 1989). Stimuli that induce reactivation are 
non-specific and include axonomy, elevations in cyclic AMP (cAMP), UV light, 
hyperthermia, iontophoresis of epinephrine, or possible hormonal fluctuations. Reactivation 
of latent virus following axonal injury has been shown to occur within 3-5 days.
Several models have been developed to study in vivo and in vitro reactivation. 
Different animal models have been used such as guinea pigs, rabbits and mice. The guinea 
pig model exhibits a high level of spontaneous reactivation. In contrast, the rabbit eye 
model seldomly shows spontaneous reactivation. In mice, spontaneous reactivation does 
not occur and it is difficult to induce reactivation. The lack of spontaneous reactivation in 
mice is valuable and for this reason most reactivation studies have been carried out using 
mice. In the mouse model, effective sites for viral inoculation in the periphery include the 
eye, and the ear, from which latency is established in the TG. Other peripheral sites of 
inoculation are the flank and the footpad where latency is established in the DRG. Once 
latency is established different methods for inducing reactivation have been developed. For 
example, reactivation in the eye model is induced by UV light. Feeding heavy metals (e.g. 
cadmium) or heat stress can be used to reactivate virus following any route of inoculation.
The tk gene has been studied to determine its role in reactivation. After comeal 
inoculation o f mice, tk deleted vims mutants replicated to high titres in the eye, but were 
severely impaired for acute replication in TG established latency but failed to reactivate 
from ganglia upon co-cultivation with permissive cells (Coen et al., 1989). This is contrary 
to the popular hypothesis that tk- mutants establish latent infections and implies that neither 
tk activity nor ganglionic replication is necessary for establishment of latency. Rather, tk 
appears to be necessary for reactivation from latency (Coen et al., 1989).
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1.6.1. In vitro Reactivation Models
One method to induce reactivation in vitro is to explant ganglia latently infected 
with HSV. This reactivates the virus in culture. The in vitro explant culture is useful for 
looking at possible in vivo reactivation trends (Trousdale et a l, 1991), but is probably more 
a measure of latent virus than reactivation per se.
Moriya et al (1994) described a culture system which was used as an in vitro model 
of stress induced reactivation. In the presence of an antiviral drug, primary cell cultures 
were established from latently infected mouse TG. Latency was maintained following 
removal of the antiviral drug, and the investigators found that HSV-1 could be reactivated 
from TG cells by heat stress. Halford et al (1996) developed primary cultures of TG cells 
from HSV-1 latently infected mice to study reactivation. Infectious virus appeared in 75% 
of culture supernatants within 120 h post heat stress. HSV-1 lytic phase mRNA and 
proteins were detectable 24 h after heat stress. The effect o f heat stress duration on 
reactivation was determined to be 0, 40 or 67% of cultures after 1, 2 or 3 h post heat stress, 
respectively. The results that Halford et al (1996) attained indicate that TG cell cultures 
mimic important aspects of in vivo latency and reactivation and this model may be useful 
for studying signalling pathways that lead to HSV-1 reactivation. However, this model also 
may have spontaneous levels o f reactivating virus pre- heat stress treatment (Halford et al., 
1996).
The immune profile o f primary TG cell cultures latently infected with HSV-1 and 
uninfected prior to and after stress was studied by Carr et al (1998) by measuring cytokine 
and chemokine production. Cytokines which are extracellular signalling proteins act as a 
local modulators in cell-cell communication. Supernatants from TG cell cultures contained 
detectable interleukin (IL ) - 6  but not IL -lp, IL-2, IL-10, interferon (IFN)-y or tumour 
necrosis factor (TNF)-a as determined by enzyme linked immunosorbant assay (ELISA). 
IL - 6  is produced from some helper T cells and macrophages and targets activated B cells or 
T cells by promoting B cell maturation to Ig secreting cells. IL-1 and IL - 6  are also made by 
non-blood cells and act on many types of target cells other than blood cells; they therefore 
are called cytokines. Supernatants from TG cell cultures also contained detectable levels of 
C-10, MCP-1 and eotoxin but little (to no) M IP-la, M IP-ip or MIP-2. While there were no 
differences in the basal level of MCP-1 and eotoxin in TG cell cultures from HSV-1 
infected and uninfected mice, C-10 levels were significantly higher in TG cultures 
originating from infected mice compared to uninfected ones (Carr et al., 1998).
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Hyperthermic stress was used to reactivate virus and demonstrated that there was no 
correlation between cytokine/chemokine levels in HSV-1 reactivation. Whereas no 
spontaneous reactivation has been reported in mice, spontaneous reactivation occurred in 
4.5% (10/220) o f TG cell cultures surveyed over a 20 day period (Carr et al., 1998).
Local control of the acute infection includes the presence of CD4+ and CD8 + 
lymphocytes (Nash et al., 1987; Bonneau and Jennings, 1989) neutrophils (Tumpey et al., 
1996), IFN-a (Hendricks et al., 1991) and IFN-y and TNF-a (Cantin et al., 1995). Cytokine 
profiles, following acute HSV-1 infection, suggest that the cellular immune response is 
primarily o f the Thl type (Stuats and Lausch, 1993; Boulet et al., 1995; Kanangat et al., 
1996). The role o f these cytokines in latent HSV-1 infection or in the reactivation of the 
virus from latency has not been addressed. It has been proposed that TNF-a (Liu et al., 
1996) and IFN-y (Cantin et al., 1995) may control reactivated HSV-1. It is also thought that 
humoral immunity is involved in the maintenance of HSV-1 latency (Stevens et al., 1972). 
The lack o f dendritic cells, Thl cytokines and TNF-a which are found in situ may, in part, 
explain the increase in hyperthermic induced reactivation o f HSV-1 (McKrae strain) in 
these cultures (50-80%) compared to the in vivo model of HSV-1 (McKrae strain) latency 
where hyperthermic induced reactivation rarely exceeds 30% (Noisakran et al., 1998).
1.6.2. In  vivo Reactivation Models
The in vitro methods developed which explant ganglia and induce reactivation in 
vitro have some disadvantages. These methods do not necessarily reflect a true reactivation 
response in vivo. Moreover, in vitro explantation maintains a constant level and supply of 
the reactivating stimulus. In vivo reactivation gives a more comprehensive analysis of the 
natural virus cycle and pathogenicity.
An in vivo stress model for inducing reactivation in Swiss Webster mice by 
hyperthermia induction was developed by Sawtell and Thomspon (1992b). The heat shock 
response includes a regulatory cascade resulting in the rapid accumulation o f a specific set 
o f proteins (e.g. HSP70) and a decrease in others. Using hyperthermia induction to 
reactivate HSV in mice, Sawtell and Thompson (1992b) found HSV specific antigen in 
isolated large ganglionic neurones within 24 hours. Work during this thesis included 
learning this method from Dr. Sawtell during a sabbatical and a summary of this procedure 
is included as Appendix B.
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Using the rabbit eye model as the site of initial infection and inducing reactivation 
by iontophoresis with adrenaline, Trousdale et al (1991) showed a combination of host 
strain and viral strain is critical. These results differed to those done in the mouse eye 
model. Furthermore, not all wild type HSV strains reactivate by iontophoresis.
Transcription during in vivo reactivation has been analysed using RNA from 
latently infected rabbit TG isolated at various times following epinephrine iontophoresis. 
The maximum signal intensity was normally 8  h post induction and most neurones 
established latency again 16 hours post induction (Bloom et a l, 1996). Bloom et al (1996) 
used a rabbit corneal model for virus reactivation in vivo. LAT- and LAT+ promoter 
viruses were studied. LAT- reactivated with low frequency upon epinephrine induction. 
Transcription of lytic phase genes could be detected within 4 h following induction of 
rabbits latently infected with either LAT- or LAT+ virus: transcription diminished 16 h post 
induction. In the rabbit eye model, epinephrine induced viral reactivation was monitored by 
the ability to recover virus in tear film (Farrell et a l, 1993; Hill et a l , 1986 and Hill et a l ,
1996). There is a low level o f spontaneous reactivation of LAT- viruses that occurs in this 
model. No reproducible net increase in relative levels of viral DNA was seen in the 
reactivation in vivo suggesting that only a small proportion o f stimulated neurones go on to 
replicate viral genomes and that any infectious virus produced in the ganglia is transported 
to a peripheral site and reinitiates infection very efficiently.
It has been demonstrated that ocular iontophoresis o f epinephrine induced
reactivation from BALB/c mice infected with HSV-1 strain McKrae (Willey et a l , 1984),
and ultraviolet irradiation of corneal epithelium induced reactivation of McKrae strain from
NIH mice (Laycock et a l ,  1991). However, these methods were applied to only one mouse
strain. Fawl et al (1996) studied different mouse strains in a cadmium (Cd) in vivo
reactivation method. All mice were inoculated with HSV-1 strain F at 3x106  pfu/eye,
except for strain A mice which were inoculated with 5x l0 5 pfu/eye, because of the strains
increased virulence. Beginning at 30 days after inoculation latently infected mice were
given a footpad injection of 50 pi Cd (2 mg CdS0 4 .H2 0 /ml sterile saline solution) daily for
3 days. Within 18 to 24 h after the third Cd injection the mice were sacrificed and each TG
was removed to a culture tube containing media with 5% newborn calf serum. For assay of
infectious virus each TG upon removal was immediately frozen in a dry ice ethanol bath
and stored at -80°C until thawed, homogenised and plated onto CV-1 monolayers (Fawl et
a l, 1996). Cd is a toxic heavy metal which strongly induces metallothionins and heat
shock proteins. When administered to mice, Cd ions rapidly accumulate in the mouse
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peripheral nervous system and remain at high levels in these tissues for at least 1 week. 
Daily administration of Cd to latently infected CBA mice leads to reactivation o f HSV from 
TG within 2 to 4 days o f treatment (Fawl and Roizman, 1993). They also showed that Cd 
treatment induced reactivation of HSV-1 strain F from strain CBA, but not from BALB/c 
mice (Fawl et al., 1996).
1.7. Genes Located in the Rl Regions
Beyond the 3’ terminal of the LATs and within the L/STs there are two additional 
ORFs within the R l region on the same strand which have been shown to express 
polypeptides ORF O and P. Two other genes within the R l sequences on the opposite 
strand, RL1 and RL2, have been demonstrated to express polypeptides, ICP34.5 and ICPO, 
respectively (Fig. 8 ). The most recently published information on these proteins is detailed 
below.
1.7.1. ICPO
The gene which encodes ICPO (also called VmwllO) is RL2 (McGeoch et al., 
1988). One of the interesting features o f RL2 is that it is one o f only four HSV-1 genes that 
contain introns (Fig. 8 ). RL2 lacking the first, second or both introns were constructed by 
site directed mutagenesis (Everett, 1991). Viruses lacking the RL2 introns were 
indistinguishable from the parent virus in terms o f growth, particle to pfu ratio or viral 
polypeptide expression in a variety of cell types. The lack of introns did not affect the time 
course or efficiency of expression of ICPO either during normal infection or in 
cyclohexamide reversal experiments. However, in transfection assays, the loss of both 
introns resulted in the elimination of the ability of a plasmid encoding RL2 to activate gene 
expression. Everett's results imply that in certain situations the introns in RL2 may 
contribute to the efficient expression of ICPO but such an effect is not apparent in 
recombinant viruses. The role of the RL2 introns remains obscure. Since sequences 
upstream of the RL2 region are involved in pathogenicity (Taha et al., 1989; Thompson et 
al., 1989) and a transcript containing these sequences continues throughout the RL2 region 
(Chou and Roizman, 1986; Dolan et al., 1992), it seemed possible that information within 
the RL2 introns might also be involved in pathogenicity. However, data reported by Everett
(1991) indicate that recombinant viruses with RL2 deletions do not have an altered 
phenotype in vitro or in vivo.
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Figure 8 . A schem atic diagram  of the HSV-1, strain 17+, genome (not draw n to scale).
a. The HSV-1 genome, b. The IRL, IRS and a ’ sequence is expanded to show the relevant 
restriction enzyme sites within this sequence. The BamHl ik > fragment is highlighted in blue.
c. The genes within this sequence which encode functional proteins are, RS2, RL1 and RL2.
d. The putative transcripts that contain the a sequence are called the L/ST for 
long/short transcripts (L /S T ).
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Viruses which express inactive forms of ICPO have a defect in the onset of the lytic 
cycle that is dependent on the multiplicity of infection and cell type. After low m.o.i. of 
human foetal lung (HFL) fibroblast cells, ICPO mutant viruses preferentially attain a 
quiescent state of repressed genome expression, from which they can be reactivated by 
provision of exogenous ICPO (Stow and Stow, 1986; Preston and Nicholl, 1997; Samaniego 
et a l,  1998).
An extensively studied property of ICPO is its ability to localise to and then disrupt 
specific nuclear structures named nuclear domain 10 (ND10), promyelocytic leukaemia 
(PML) bodies or PML oncogenic domains (PODs) (Maul et al., 1992; Everett and Maul, 
1994; Maul and Everett, 1994). Everett et al (1998) showed that ICPO binds to a member of 
the ubiquitin specific protease family o f enzymes and that ICPO induces the proteasome 
dependent loss o f a number of high molecular weight isoforms of PML. Everett et al (1998) 
showed the first example of a regulator of viral gene expression functioning via the 
ubiquitin-proteasome pathway, suggesting a mechanism by which reactivation of latent 
virus might be inhibited.
A mutant HSV-1 strain KOS virus with a 350 bp deletion from -420 to -70  relative 
to the transcriptional start site of ICPO was named ATfi (Davido and Leib, 1996). KOS, 
ATfi, and ATfiR replication in murine corneas and TG were comparable when assayed on a 
complementing cell line, but ATfi titres appeared 15- to 50- fold lower when measured on 
Vero cells. ATfi was correspondingly less virulent than wild type or marker rescued viruses 
in both immunocompetent and SCID mice. ATfi established and reactivated from latency 
with efficiencies comparable to wild type and marker rescued viruses. These results 
demonstrate that although the deletion in ATfi results in lower levels of ICPO in vitro and 
decreased virulence in vivo, the establishment of and reactivation from latency are 
unaffected (Davido and Lieb, 1996).
The reduced expression o f ICPO RNA, protein and transactivation capability at 
early times pi most likely results from reduced VP 16 activation due to deletion of the 
TAATGARAT and octamer/TAATGARAT motifs (Davido and Leib, 1996). It is possible 
that other cis-acting elements have been brought closer to the mRNA start site of ICPO and 
that these can substitute for the deleted promoter elements during reactivation. The nearest 
defined viral promoter is aX  (Bohenzky et al., 1993; Lagunoff and Roizman, 1994; Yeh 
and Schaffer, 1993) which is intact in ATfi and has been shown to drive transcription 
antisense to ICP34.5, particularly in the absence of ICP4. Another region from -550 to -
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129 relative to the transcriptional start site of ICPO, has transcriptional activity in transient 
assays following release of cells from growth arrest and has been proposed to play a role in 
reactivation (Ralph et al., 1994). A concern regarding the reduced virulence of ATfi is 
whether ICP34.5 and ORF P have been adversely affected by the mutation (Davido and 
Leib, 1996).
In contrast to the above data, several studies have reported ICPO mutants grow 
inefficiently in vivo and are impaired in their ability to reactivate from latency (Cai et al., 
1993; Clements and Stow, 1989; Leib et a l , 1989).
ICPO is a 775 amino acid nuclear phosphoprotein which transactivates a variety of 
HSV-1 promoters either alone or synergistically with ICP4 (Cai and Schaffer, 1989; Everett, 
1984; Gelman and Silverstein, 1986; Quinlan and Rnipe, 1985). The mechanism of 
transactivation by ICPO is unknown although ICPO has been shown to interact with a 135 
kDa cellular protein (Meredith et al., 1994) and with ICP4 and ICP27 (Zhu et al., 1994).
1.7.2. ORF O
The unspliced 8.3 kbp LAT has been shown to contain at least 16 open reading 
frames (ORFs) greater than 50 amino acids in length (Lagunoff and Roizman, 1996). These 
ORFs have been designated by the letters A through P (Chou et a l, 1994). ORF O and P 
are almost entirely antisense to the ICP34.5 transcript. Both ORF O and P are well 
conserved between HSV-1 strains (Chou et a l, 1994). In strains KOS, F, MH10, and 
CVG2, a single base pair substitution terminates ORF O after approximately 160 codons 
(Lee and Schaffer, 1998).
The role o f ORF O and ORF P proteins in the establishment of latency is uncertain. 
The ORF O protein binds ICP4, the major regulatory protein, and prevents it from binding 
to DNA (Roizman, 1999).
ORF O overlaps in part with ORF P but in a different reading frame. The first and 
only proposed methionine codon o f ORF O is located in the TATA box of ORF P (Randall 
et al., 1997). Analysis of cells infected with a de-repressed ORF P failed to detect an RNA 
corresponding to ORF O. In-frame insertional mutagenesis revealed that translation of ORF 
O initiates at the ORF P initiator methionine and that at a point between the first and 35th 
codon of ORF P translation switches to the ORF O reading frame. The mechanism of the 
frame shift is unclear, but within the interval between the initiator and 35th codon there are 
no obvious splice donor or acceptor sites. The ORF O protein was found to bind ICP4 and
to preclude it from binding to its response elements on DNA.
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1.7.3. ORF P
A protein product has been identified from ORF P and shown not to be expressed 
from LAT but from the L/S transcript (Bohenzky et a l, 1993), whose promoter contains a 
high affinity binding site for ICP4 (Lagunoff and Roizman, 1995). Thus studies published 
to date show ORF P is expressed only in the absence of a functional ICP4 or if  the ICP4 
binding site is mutagenized (Lagunoff and Roizman, 1994). ORF P contains 240 amino 
acids in strain F (Bruni and Roizman, 1996). For sequence alignment between HSV-1 
strains see Figure 9.
Lagunoff et al (1996) constructed an ORF P mutant virus named ORF P++ in 
which the ICP4 binding site in the promoter sequence is mutagenized and allows expression 
o f ORF P gene throughout the lytic cycle. This virus is highly attenuated upon inoculation 
into mice by the intracerebral or ocular route, and the virus cannot be recovered following 
explantation from the TG. It is believed that either ORF P overproduction blocks the 
expression o f some herpesvirus genes such as ICP34.5 or de-repression o f the transcription 
o f ORF P has a negative effect on the transcription o f the antisense ICP34.5 RNA 
(Lagunoff et al., 1996).
Randall and Roizman (1997) constructed a recombinant virus, R7546(P++)- which 
had the ICP4 binding site mutagenised to de-repress ORF P transcription and the initiation 
methionine codon replaced with an isoleucine codon to prevent the synthesis o f ORF P 
protein. This mutant had reduced virulence and attenuation. It also had reduced synthesis 
o f ICPO and ICP22 and it was implied that ORF P expression was required for their 
synthesis (Randall and Roizman, 1997). Randall and Roizman (1997) indicated that 
ICP34.5 suppression was due to antisense transcription and not the expressed ORF P 
protein.
Bruni and Roizman (1996) demonstrated that the ORF P protein co-localises with 
splicing factors in the nuclei o f infected cells which led to the hypothesis that it is a 
component o f spliceosomes. ORF P protein co-localises and binds to p34 which is a 
component of the SF2/ASF splicing factor. In cells infected with viruses carrying a de­
repressed ORF P, it is rapidly post-translationally modified. However, within a few hours 
after initial infection, the accumulation of ICP22 and of ICPO the products o f spliced mRNA 
are grossly reduced whereas the accumulation o f ICP4 and ICP27 are unaffected (Roizman, 
1999).
ORF O and P block the synthesis or function of three key immediate early proteins,
ICPO, ICP22 and ICP4. Viral replication cannot ensue in the absence o f these proteins.
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Figure 9. ORF P consensus sequence.
The ORF P consensus sequence from three well studied HSV-1 strains 17+, F and KOS. 
Periods represent gaps. The only major strain specific variable lies in the number o f AGV 
repeats (adapted from Lee and Schaffer, 1998)
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Inasmuch as ORF O and P are antisense to RL1, ablation o f the coding domains of these 
genes would also result in the deletion of the RL1 gene. Since the latter is required for viral 
replication in neuronal cells, the experiment would be meaningless (Roizman, 1999). 
Substitution of the initiator methionine of ORF O and P does not block the establishment of 
latency.
Lee and Schaffer constructed two mutant viruses in HSV-1 strain KOS to study the 
interdependent phenotypes of ORF O/P and ICP34.5. The first mutant constructed 
contained a nonsense mutation that terminates ORF P translation at amino acid 38 but does 
not alter the sequence o f ICP34.5 encoded by the complementary DNA strand (Lee and 
Schaffer, 1998). This mutant expressed a truncated ORF P protein and had no observable 
phenotype relative to wild type virus in vitro or in vivo. The second mutant contained a 
mutation in the L/ST promoter that de-repressed L/ST expression by abrogating ICP4 
binding to its cognate binding site near the transcription initiation site of the L/STs. This 
mutant over-expresses the L/STs and ORF P, and is highly attenuated following intracranial 
inoculation of juvenile mice. However, replication of this mutant was efficient in the mouse 
eye and TG without eliciting an adverse host response. It induced a cell type specific 
expression of both ICP34.5 transcripts and LATs since both types of transcripts were 
abundant in Vero cells but barely detectable in mouse neuroblastoma cells (NB41A3) (Lee 
and Schaffer, 1998). Table 4 gives an overview of the ORF P mutant viruses described 
above.
1.7.4. ICP34.5
The existence of a neurovirulence locus in the long repeat region of the HSV-1 
genome was first identified by Thompson et al (1983). Following intracranial inoculation, 
mutants in this region are 100,000 less virulent than wild type viruses (Taha et a l, 1989; 
Chou et a l, 1990; MacLean et a l, 1991). Previous work showed that the terminal 500 bp a 
sequence acts as a yi HSV promoter which led to the discovery of the protein ICP34.5. In 
strain F the gene was named yi34.5 by Chou and Roizman (1986) and the same gene in 
strain 17+ named RL1 (Dolan et al., 1992).
The RL1 promoter is partially located in the a sequence and lacks a canonical
TATAA box. Two common strains of HSV-1, F and 17+, show homology in ICP34.5 with
the exception of a peptide repeat PAT present 10 times in strain F but only 5 times in strain
17+ (Fig. 10a; Dolan et a l , 1992). Deletion mutants of RL1 include 1716 and R3616.
Several other RL1 mutations have been made which place stop codons downstream of the
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Table 4. ORF P mutant viruses.
Virus name Mutation Parental strain
ORF P++ ICP4 binding site mutated F
R7546(P++)- ICP4 binding site mutated & initiating Met 
replaced with lie
F
L/ST-4BS 4 bp substitution in the ICP4 binding 
site in the L/ST promoter
KOS
L/ST-n38 a single bp transition mutation in ORF P 
at codon 38
KOS
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Figure 10. HSV RL1 m utant viruses.
a. Three intensely studied HSV-1 strains and their RL1 genes represented diagrammatically.
Strain F has 10 copies of PAT, strain 17+ has 5 PAT copies, and strain KOS has 3 copies.
R3616 is a RL1 negative mutant in strain F. 1716 is a RL1 negative mutant in strain 17+. 1771
contains a stop codon (9 bp) downstream of the initiating methionine. 17termA contains a
stop codon inserted at the Zfo/EII site (28 amino acids) downstream of the ATG in strain 17+.
R4009 contains the same mutation as 17termA, but in strain F. b. The HSV-2 strain HG52
depicting the RL1 gene which contains an intron. 2616 is a RL1 deletion mutant in HG52.
2624 is a RL1 mutant virus which does not have the intron. The conserved 63 amino acid carboxy
37terminus is depicted by a blue box.
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initiating methionine. In strain 17+, two mutant viruses with a stop codon include 1771 
which has a stop codon inserted immediately downstream of the Ncol site at the initiating 
methionine and 17termA which has a stop codon inserted at the RsdEII site 90 base pairs 
downstream of the initiating methionine (Fig. 10a). In strain F, the RL1 stop codon 
insertion mutant, R4009, has a mutation at the BstEll site, similar to the strain 17+ mutant 
17termA (Fig. 10a).
At some sites o f primary infection (e.g. footpad, vagina) the replication of ICP34.5- 
mutants is much less than that of wild type virus, whereas in others (e.g. eye) replication 
appears to be almost completely inhibited (Spivack et a l, 1995). ICP34.5- mutants
establish latency inefficiently and have been reported to reactivate far less efficiently than 
wild type virus, as measured by explant in vitro reactivation from mouse ganglia (Pemg et 
al., 1995). The impairment in 1716 during latency is more marked in the TG rather than in 
the dorsal root ganglia (DRG) which may be due to replication at the site of inoculation 
(Spivack et al., 1995).
Replication of ICP34.5 mutants in tissue culture is normal in several cell types, but 
is restricted in SK-N-SH neuroblastoma cells due to premature host shut-off (Chou and 
Roizman, 1992), murine 10T1/2 cells, stationary phase primary mouse embryo cells 
(Bolovan et al., 1994) and 3T6 cells (Brown et al., 1994a). The in vitro phenotype of 
mutant viruses will be described in more detail in Sections 1.11. and 1.12.
Dick and Rosenthal (1995) identified a tissue culture phenotype which 
distinguished clinical isolates from the KOS laboratory strain and mapped around the RL1 
locus. The clinical isolates produced small plaques on Vero cells, were cell associated and 
viral glycoprotein processing appeared to be restricted to the endoplasmic reticulum (small 
plaque phenotype). In 1999, Bower et al reported that a HSV strain isolated from the brain 
o f a neonate possessed a small plaque phenotype. The large plaque virus was isolated from 
the lungs and the gastro-intestinal tract. The major sequence difference between the small 
plaque, large plaque and KOS virus isolates was in the number of repeats of CCCGCGACC, 
encoding PAT. The large plaque isolate had 22 repeats the small plaque isolate had 18, 
while KOS has 3 repeats of the PAT domain (Bower et al., 1999). Another difference 
between the large and small plaque isolates was a deletion o f a sequence preceding the nine 
nucleotide repeats, causing the loss of glycine-glutamic acid glycine-alanine (GEGA). 
Other differences between the small, the large, and the KOS strains included a deletion of 
arginine near the N terminus, two conservative mutation, and two non-conservative 
mutations (Bower et al., 1999).
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Several mutant viruses have been studied to examine the RL1 phenotype in vitro 
and in vivo from HSV-2 strain HG52. A HG52 mutant, 2616, was isolated and determined 
to have a 786 bp deletion (Harland and Brown, 1991). A splice donor and splice acceptor 
site within the RL1 sequence was identified and by RT-PCR experiments demonstrated to 
be functional by Harland et al (1996). Ravi (1998) made a deletion mutant lacking the 
intron, 2624, and found that it maintained virulence upon intracranial inoculation in vivo. 
For a description o f all the recombinant viruses see Figure 10b.
1.8. ICP34.5 Homologous Viral Proteins
A small number of genes to date have been shown to have homology with HSV-1 
RL1. Among the herpesviridae only HSV-2 has a homologous gene which is also named 
RL1. The other RL1 homologous gene comes from the African Swine Fever Virus (ASFV), 
LMW23-NL (Sussman et al., 1992).
ASFV is a large icosahedral arbovirus which contains a linear dsDNA genome of 
170 to 190 kbp and replicates in the cytoplasm of infected cells (Costa, 1990). It is the sole 
member o f an unnamed family of animal viruses. Cells of the mononuclear phagocytic 
system are major targets for ASFV replication in vivo. Viral infections with extensive 
necrosis o f fixed macrophages of the spleen, lymph nodes, lung, and liver as well as specific 
lineages of reticular cells are evident following infection with highly virulent isolates 
(Konno et al., 1971; Mebus, 1987, 1988; Moulten and Coggins, 1968). Strains of ASFV 
exhibiting moderate virulence also infect these cell types, but the degree of tissue 
involvement and the resulting damage are much less severe (Mebus, 1987, 1988). The 
nature o f the virus-cell host interactions responsible for the differing outcomes of infection 
with highly virulent, moderately virulent, or avirulent ASFV strains is unknown.
1.8.1. LMW23-NL
The ASFV gene LMW23-NL is predicted to express a highly basic protein of 184
amino acids with an estimated molecular mass of 21.3 kDa (LMW23-NL). Sussman et al
(1992) carried out a search using two protein data bases, PIR (release 7.0) and BLAST
which revealed a striking similarity between LMW23-NL, MyD116 and ICP34.5 (Sussman
et al., 1992). All three proteins contain a centrally located acidic region with a highly
conserved hydrophilic 56 amino acid domain located at the carboxy terminus. ICP34.5 and
LMW23-NL both contain a highly basic terminus composed o f 8 to 10 lysine and arginine
residues (Sussman et al., 1992; Zsak et al., 1996). In the conserved domain o f LMW23-NL,
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comparison o f this to HSV-1 ICP34.5 reveals 55% overall conservation and 30% identity 
(Sussman et a l , 1992). In the same region, comparison to the cellular gene MyD116 (see 
below) revealed 25 exact matches and 19 conservative matches, which correspond to 78% 
overall conservation with 44% identity (based on the Dayhoff Pam-250 symbol comparison 
table with a 0.5 cutoff (Schwartz and Dayoff, 1979).
Zsak et al (1996) determined that LMW23-NL is highly conserved among ASFV 
isolates and that it exists in either of two forms: 23-NL, or a shorter form, NL-S which is 
found in the European and African pathogenic isolates. Although highly conserved, the 
NL-S gene is nonessential for growth in pig macrophages or Vero cells in vitro.
1.9. ICP34.5 Homologues Cellular Proteins
1.9.1. GADD34/MyD116
Two cellular genes GADD34 and its murine homologue, MyD116, have been 
shown to contain a centrally located highly acidic region with a highly conserved 
hydrophilic 63 amino acid domain located at the carboxy terminus homologous with 
ICP34.5. Growth arrest and DNA damage inducible (GADD) genes were first sequenced 
by Fomace et al (1989).
Five GADD genes have been sequenced and named, GADD 153, GADD45, 
GADD34, GADD33 and GADD7. In general, GADDs are often co-ordinately expressed 
genes that are induced by genotoxic stress and certain other growth arrest signals (Zhan et 
a l, 1994). GADD34 was shown to have homology with ICP34.5, specifically in the C- 
terminal o f GADD34. The domain of ICP34.5 which binds protein phosphatase 1-a (PP1- 
a ) is highly homologous to, and in fact replaceable by, the corresponding domain of the 
GADD34 gene (Chou and Roizman, 1992; He et al., 1996). The function of this is 
discussed in Section 1.11.
Another cellular protein which shows homology with ICP34.5 is the murine 
myeloid differentiation primary response gene (MyDl 16) (Lord et a l, 1990; McGeoch and 
Barnett, 1991). Like ICP34.5, MyDl 16 is predicted to consist o f a large amino terminal 
domain, a 38 amino acid sequence repeated 4.5 times and a carboxyl terminus containing 
sequences partially homologous to a 52 amino acid stretch in ICP34.5.
The precise function of MyDl 16 is currently unknown. However, it is expressed 
early in cellular differentiation and in terminally differentiated cells and may be involved in 
regulating the differentiation process or in maintaining the differentiated state in myeloid
cells (Lord et a l, 1990; Sussman et a l, 1992).
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Khodarev et al (1999) used DNA arrays containing a limited number of probes to 
test the accumulation o f cellular transcripts in three different human cell lines. The human 
embryonic lung human fibroblasts were the closest to susceptible “normal” human cells in 
vitro (Khodarev et al., 1999). They also used two isogenic cancer cell lines differing in the 
absence or presence o f p53 and found that there was a significant accumulation of a small 
subset o f cellular transcripts. The transcripts encode regulatory proteins and transcriptional 
factors and one stress response protein (GADD45) (Khodarev et al., 1999).
M yDl 16, GADD45, MyDl 18, and GADD 153 encode acidic proteins with similar 
charge characteristics, and have previously been shown to be regulated by the tumour 
suppressor, p53 (Zhan et a l, 1994). It is thought that the function of GADD34 or MyDl 16 
alone or in association with GADD45 is to preclude stress responses which could result in 
cell death. He et al (1996) demonstrated that the carboxyl terminus of ICP34.5 is essential 
in precluding premature shut-off of protein synthesis in both neuroblastoma cells and in 
human foreskin fibroblasts following HSV infection. M yDl 16 is one o f several genes 
cloned as cDNA from myeloid leukaemia cells induced to differentiate by IL-6 and is an 
immediate response gene; its expression peaks 1 h after exposure of cells to IL-6. Steady 
state levels o f M yDl 16 mRNA have been detected in the terminally differentiated cells. 
One of the functions of the genes expressed after differentiation of the myeloid leukaemia 
cells is to preclude terminally differentiated cells from undergoing apoptosis.
The pathway in which RL1 may act, or the stress it precludes, appears to be 
different from that described to date for other virus proteins as exemplified by the 
involvement o f bell. B e ll has been shown to protect cells from apoptosis in stress or during 
development. However, bcl2 does not preclude apoptosis resulting from depravation of IL- 
6 or the ciliary neurotrophic factor, and leukaemia inhibiting factor that share common 
receptors and signal transduction pathways. Chou and Roizman (1994) predict that RL1, 
and in particular the carboxyl domain shared with M yDl 16 and GADD34, may play a role 
in blocking apoptosis in terminally differentiated cells and that RL1 acquired this domain 
for its own use.
1.10. ICP34.5 Cellular Interactions
In 1997, Brown et al reported that ICP34.5 and the conserved 63 amino acid
domain of the cellular protein MyDl 16 specifically complex with proliferating cell nuclear
antigen (PCNA). The function o f PCNA includes acting as a processivity factor for DNA
polymerase gamma (Bravo et a l, 1987; Prelich et a l,  1987) and the recruitment of
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replication factors to DNA replication initiation sites (Kill et al., 1991). GADD45 and p21 
both directly complex and interact with PCNA in competition with each other (Chen et al.,
1995). The site of interaction between p21 and PCNA has been defined by using small 
peptides to inhibit DNA replication (Warbrick et al., 1995). The projected three- 
dimensional model of PCNA is illustrated in Figure 11.
It was proposed by Brown et al (1997) that after HSV infection ICP34.5 complexes 
with PCNA either directly or indirectly, and this complex allows cellular DNA replication 
to continue. When ICP34.5 is not present, PCNA complexing does not occur and the cell 
goes into a growth arrest state and does not provide an alternative mechanism for the virus 
to go through the replication cycle. It is thought that in certain cell types and cell states 
ICP34.5 is not required.
1.11. ICP34.5 in vitro Function
Viruses have evolved a variety of mechanisms to block the shut-off o f protein 
synthesis. Poliovirus degrades double-stranded RNA protein kinase R (PKR), the influenza 
virus synthesises the NS1 protein which blocks the binding of double-stranded RNA to 
PKR. Adenovirus produces a short double-stranded RNA called VarRNA, which binds but 
fails to activate PKR. Vaccinia virus has protein K3L, which blocks the phosphorylation of 
eIF-2a. HSV-1 differs from other viruses in that its main defence to counter host response 
to infection was to capture a fragment of a cellular gene, GADD34, to dephosphorylate elF- 
2 a  rather than to evolve mechanisms to prevent the activation o f PKR or the 
phosphorylation of eIF-2a.
In cells infected with the HSV-1 ICP34.5- virus R3616, the double stranded PKR is 
activated, eIF-2a is phosphorylated, and protein synthesis is shut-off. Although PKR is 
activated in cells infected with the wild type virus, ICP34.5 binds protein P P l-aan d  
redirects it to dephosphorylate eIF-2a, thus enabling sustained protein synthesis (Fig. 12; 
Roizman, 1999).
He et al (1997) showed that the carboxyl terminus o f M yDl 16 interacts with PP1- 
a  in yeast, and both MyDl 16 and ICP34.5 interact with P P l-a  in vitro. Fractions 
containing the ICP34.5 and PP1 complex specifically dephosphorylate eIF-2a. Both 
ICP34.5 and GADD34 proteins contain the amino acid sequence m otif common to subunits
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Figure 11. Coiled 3-D structure of PCNA.
This is a predicted 3-D structure of human proliferating cell nuclear 
antigen (PCNA) by X-ray diffraction PDBid number 1AXC.
The resolution is 2.6A (Gulbis et a l 1996)
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Figure 12. PKR pathway with ICP34.5.
One role of ICP34.5 in vitro is to preclude shut-off of host cell and virus protein 
synthesis in human neuroblastoma cells (SK-N-SH). HSV infection activates the double 
stranded protein kinase PKR. PKR phosphorylates the eukaryotic translation initiation 
factor eIF-2a. If ICP34.5 is not present, phosphorylated eIF-2adoes not promote protein 
synthesis and leads to protein shut-off in SK-N-SH cells. If ICP34.5 is present it binds to 
protein phsophatase 1 (PP1) and potentially another factor (X) to dephosphorylate eIF-2a 
and maintain viral and host protein synthesis. Forced mutations of an ICP34.5 null mutant 
revealed expression of US11 immediately upon infection does not allow accumulation 
of PKR (Concept from B. Roizman and I. Mohr).
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of PP1 that is required for binding to the PP1 catalytic subunit (He et al., 1998). He et al 
(1998) showed that amino acids 190-203 of ICP34.5 fused to GST strongly bound and 
pulled down PPL Moreover, a peptide containing amino acids 185-211 of ICP34.5 
competed with intact ICP34.5 for binding PP1 and substitution o f Val193 and Phe195 with 
Glu and Leu, respectively, abolished the activity of ICP34.5 (He et al., 1998).
To summarise, PKR is activated in cells infected with both wild type and mutant 
viruses (Roizman, 1999). However, in wild type virus infected cells ICP34.5 acts as an 
accessory P P l-a  factor. Specifically, it binds to PP1 through a short sequence common to 
all PP1 accessory factors and redirects PP1 to specifically dephosphorylate eIF-2a at the 
expense o f other substrates of PP1.
He et al (1996) constructed several mutant viruses to clearly define the domain(s) 
responsible for blocking the host response to infection. Studies on those mutants show that 
the domain o f ICP34.5 necessary to preclude the total shut-off o f protein synthesis 
corresponds to the carboxyl terminal domain of ICP34.5 homologous to MyDl 16 and 
GADD34. Although, the carboxyl terminus of GADD34 can substitute for ICP34.5 in 
precluding the shut-off o f protein synthesis, the virus carrying the chimeric gene is avirulent 
(Roizman and Sears, 1987).
Serial passage in human cells of a mutant virus lacking RL1 yields second site, 
compensatory mutations in the US11-US12 region (Mohr and Gluzman, 1996; Mulvey et 
al., 1999). The locus where these mutations occurred have been termed SUP (Mohr and 
Gluzman, 1996). Analysis of the compensatory mutation revealed that a deletion in the 
US 12 domain brought the US 12 promoter 5’ to the coding sequence o f the US 11 gene 
converting the latter to an immediate-early gene and reducing the accumulation of active 
PKR kinase (Fig. 12; Mohr and Gluzman, 1996; He et al., 1997; Cassady et al., 1998a; 
Mulvey et al., 1999).
U S11 is not essential for growth of HSV-1 in cultured cells and is not required for 
neurovirulence in animals (Brown and Harland, 1987; Longnecker and Roizman, 1986; 
Nishiyama et al., 1993; Umene, 1986). The loss o f US 11 function is tolerated only in the 
presence of a GADD related function (i.e. ICP34.5). Both viral proteins/functions and their 
respective cellular counterparts may contribute to whether a given cell type is permissive for 
the growth of ICP34.5 mutants (Mulvey et al., 1999).
Cassady et al (1998a) constructed a recombinant virus lacking RL1 and US8-12,
R5103. The recombinant virus R5104 was derived from R5103 but contains the US 10 gene
and the US 12 promoter fused to the coding domain of the US 11 gene (Cassady et al.,
45
Introduction: 1
1998b). R5104 had a protein profile similar to that of wild type virus, whereas protein 
synthesis was shut-off in cells infected with R5103. Lysates of R3616, R5103 and R5104 
virus infected cells lacked the phosphatase activity specific for eIF-2a characteristic of wild 
type virus infected cells. Lysates of R3616 and R5103 which lacked the second site 
compensatory mutation contained an activity which phosphorylated eIF-2a in vitro whereas 
lysates o f mock infected cells or cells infected with wild type HSV-1 strain F or R5104 did 
not phosphorylate eIF-2a (Cassady et al., 1998b).
1.11.1. PKR
The double-stranded RNA dependent protein kinase PKR is an interferon (IFN) 
inducible protein (Clemens and Elia, 1997). PKR, a polypeptide of 68 kDa in humans and 
65 kDa in mice, is a serine/threonine kinase, which is activated by autophsophorylation 
upon binding to dsRNA (Clemens and Elia, 1997). Activated PKR then phosphorylates the 
a  subunit o f the translation initiation factor eIF-2a, a modification that causes inhibition of 
protein synthesis. PKR exhibits antiviral and antiproliferative activities. Consistent with an 
antiproliferative action, PKR has been shown to induce cell death by apoptosis. The 
mechanisms by which PKR regulates cell growth are not fully understood. Proteins capable 
o f regulating cell growth, PKR and p53, exhibit some similar properties. Induction of both 
proteins results in inhibition o f cell growth in mammalian or yeast cells. Mutant forms of 
both PKR and p53 can transform cells in culture. P53 is predominately a nuclear protein 
whereas PKR exhibits nuclear localisation. PKR is required for antiviral responses but p53 
is not and p53 is essential for inducing cell cycle arrest upon DNA damage but it is not 
known whether PKR is implicated in this process. Depletion of p53 in mice induced 
spontaneous tumours whereas depletion of PKR is not tumorogenic (Abraham et al., 1999; 
Yang et al., 1994). Cuddihy et al (1999) reported that they have shown PKR to physically 
associate with p53 and modulate phosphorylation of human p53 on Ser in vitro. They 
showed that PKR modulates p53 transcriptional function by participating in signalling 
pathways leading to p53 activation (Cuddihy et al., 1999).
PKR activity is dependent on dsRNA and manifests two distinct kinase activities: 
one for autophosphorylation and the other for phosphorylation of eIF-2a. The 
phosphorylation o f eIF-2a blocks the exchange of GDP for GTP and consequently the 
inhibition o f formation o f the eIF-2.GTP.Met.tRNA heterotrimeric complex. PKR plays an 
important role during viral infection in cell growth control and differentiation. Several
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reports suggest that PKR is involved in programmed cell death after viral infection and in 
tumour necrosis factor induced apoptosis. Donze et al (1999) showed that expression of 
wild type PKR causes apoptosis and correlates with increased mRNA levels for the Fas 
receptor, a member o f the tumour necrosis family of proteins. Expression of an inactive 
form o f PKR (K296R) or the vector alone did not induce apoptosis or elevate Fas mRNA 
levels. Functional studies o f PKR have been hampered by the toxicity of the protein in 
tissue culture cells (Koromilas et al., 1992). Epstein-Barr virus and influenza which cause 
apoptosis also lead to increased expression of Fas antigen. Fas belongs to the tumour 
necrosis factor (TNF) and nerve growth factor (NGF) receptor family (Steller, 1995).
1.12. In vitro Plaque Morphology
Isolated mutants in initial HSV studies were important tools in studying virus 
replication, latency and oncogenic properties (Stow, 1978). In addition to temperature 
sensitive (ts) mutants, a number of specialised mutants with alterations or defects in 
individual genes which affect plaque morphology have been described. The usual 
morphology o f HSV plaques is characterised by the occurrence o f numerous rounded cells 
(syn+ plaques). Variants have been described which induce cell fusion and result in the 
production o f giant multinucleate cells (syn plaques) (Ejercito et al., 1968; Brown et al., 
1973; Timbury et al., 1974). Incubation of cells infected with certain syn mutants in the 
presence o f 2-deoxy-D-glucose results in phenotypic but not genetic reversion from syn to 
syn+ (Gallacher et al., 1973) and inhibition of the glycosylation o f virus specified 
glycopeptides (Knowles and Person, 1976; Keller, 1976b) suggesting that one or more fully 
glycosylated viral proteins are required for cell fusion. In double infected cells syn+ 
dominates syn (Keller, 1976a). The syn mutant described by Brown et al (1973) reverts to 
syn+ at a low frequency and has been used as an unselected marker in three-factor crosses. 
Mixed plaques containing discrete sectors of both morphologies have been interpreted as 
having heterozygous molecules during genetic recombination (Brown and Ritchie, 1975 a; 
Ritchie et al., 1977).
Brown et al (1994a) studied the plaque phenotype properties o f 17+ and 1716 in
different cell types. In BHK cells, 17+produced plaques of average size with non-syncitial
(syn+) morphology with 1716 plaque size described as slightly smaller but with the same
morphology (Brown et al., 1994a). In mouse embryo fibroblast 3T6 cells, 17+ produced
characteristic plaques while 1716 produced very small "abortive" plaques which failed to
spread and regressed with time (Brown et al., 1994a). In 1716 infected 3T6 cells, there was
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a forty-fold increase in the particle:pfu with most o f the virus confined to the nucleus 
(Brown et al., 1994a). The RL1 mutant, 1771 demonstrates similar phenotype properties in 
3T6 cells (Brown et al., 1994b; MacLean, personal communication).
Brown et al (1994a) developed a method for maintaining 3T6 cells in a "stationary 
state". The stationary state o f 3T6 cells was achieved when the serum concentration was 
reduced from 10% to 0.5% and the cells left undisturbed for 5 to 6 days before infection 
(Brown et al., 1994a). Although 1716 did not replicate when 3T6 cells were in a stationary 
state, 17+displayed normal replication (Brown et al., 1994a). Hence, it was considered that 
BHK cells were permissive for ICP34.5 negative viruses but 3T6 were “semi-permissive” 
when growing exponentially and “non-permissive” when in a stationary state. No other 
HSV-1 RL1 mutant viruses have been reported to have similar plaque phenotype properties 
to date.
1.13. HSV-1 and HSV-2 Virulence and Pathogenicity
The overall pathogenicity of HSV has been described above in three major stages, 
lytic replication, latency, and reactivation. The ability of HSV-1 and HSV-2 to replicate 
beyond the lytic stage successfully in vivo comes under the broad heading of pathogenicity 
and virulence.
The key difference between the pathogenicity of HSV-1 and HSV-2 is the initial 
site of infection. The HSV-1 portal of infection and colonisation is usually the 
oropharyngeal mucosa and TG. HSV-2 replication is in the genital region with colonisation 
at the sacral DRG (Aurelian et al., 1989). Once HSV-1 and HSV-2 lytically replicate, they 
travel by anterograde motion to the TG and DRG, respectively, where they both establish a 
latent infection. The molecular mechanisms for latency and reactivation are currently 
thought to be the same for HSV-1 and HSV-2. Pathogenicity of both HSV-1 and HSV-2 in 
experimental animals is often measured by intracerebral inoculation and replication in the 
CNS.
Certain HSV mutants with lesions in genes that encode viral DNA replication 
enzymes (e.g. ribonucleotide reductase and thymidine kinase) replicate to near wild type 
levels in dividing cells, but do not replicate in neurones (Nichol et a l, 1996). This is likely 
due to the low levels of deoxyribonucleoside triphosphates in neurones. Several mutants 
have been characterised as pathogenic. Genes which have been deleted in a mutant virus 
and grow normally in vitro and by L D 5 0  in vivo have been characterised as non-essential.
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One non-essential locus in the HSV-1 genome, UL43/43.5, that is important to this study is 
described below. Few HSV-2 genes have been studied in vivo to date.
1.13.1. UL43/UL43.5
The UL43 gene is conserved among all of the sequenced Alphaherpesviridae 
subfamily. MacLean, C. et al (1991) showed that the UL43 open reading frame was 
dispensable for growth in cell culture, but attempts to demonstrate the presence of a protein 
were not successful. Ward et al (1996) demonstrated that there is an open reading frame 
antisense to the UL43 gene, named UL43.5. In 1996, Carter et al reported that the UL43 
open reading frame is expressed and showed the first pair o f antisense genes expressed 
during productive infection by wild type HSV-1 strain F (Carter et al., 1996). Due the non- 
essential phenotype, the UL43 gene has been selected as a good candidate for inserting 
foreign genes.
1.14. Viral Vectors
Gene therapy and cancer therapy are among recent approaches to treat as yet, 
incurable genetic diseases and cancer, respectively. These therapies include the use and 
development o f non-viral and viral vectors. Non-viral gene delivery systems currently 
include liposomes and “naked-DNA”. These methods have the advantage of not causing 
disease. However, a disadvantage includes inefficiency of gene transfer. Different viruses 
including retroviruses, adenoviruses (AdV), adeno-associated viruses (AAV) and HSV are 
currently being studied as potential viral vectors for gene and cancer therapy. A mixture of 
the viral and non-viral therapies is also being studied using HSV with plasmids/cosmids 
(amplicons). Individual viral vectors are described in brief below. A selection of key 
advantages and disadvantages o f the different viral and non-viral approaches is summarised 
in Table 5.
One o f the most commonly studied methods of viral gene transfer is the use of 
retroviral vectors. Effective retroviral vectors, created by deleting essential genes, are 
propagated in producer cells lines. A foreign gene and a selectable marker are inserted into 
the vector which when packaged remains capable o f entering the nucleus and recombining 
into the chromosome of dividing cells in culture (Miller and Miller, 1992). Retroviruses 
have the limitation of only being able to be purified at low titres and lack the availability of 
transducible cells for transplantation. The inability of these vectors to infect non-dividing
cells makes them inappropriate for postmitotic gene transfer into neuronal tissue in vivo.
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Table 5. Vectors under criticism.
(concept from Freidmann, 1997)
l.
Liposomes ’’Naked" DNA
Advantages
H ave no 
viral 
gene to 
cause 
disease
Sam e as liposom e; 
expected to be useful 
for vaccination
Disadvantages
L ess effective  
than viruses 
at transferring 
gen es to cells
Inefficient at gene  
transfer; unstable in m ost 
tissues
ii.
Retroviruses Herpes simplex viruses Adenoviruses Adeno-associated viruses Amplicons
Advantages
Integrate genes  
into host chrom o  
som es; chance 
for long term  
stability
Latently infects neurones 
norm ally; does not stimulate 
the imm une system ; 
natural neurotropic infection
M ost do not cause 
serious disease; 
large capacity for 
foreign genes
Integrate genes  
into host chrom o­
som es; cause no known  
human disease
D o not have 
viral proteins; 
causing no 
disease
Disadvantages
G enes integrate 
randomly 
possib ly  
disrupting host 
genes; many 
infect on ly  
divid ing cells
Reactivation m echanism  
is as yet not known; 
superinfection may cause  
reactivation
G enes may 
function
transiently ow ing  
to lack o f  
integration or to 
attack from  
immune svstem
Sm all capacity for foreign  
genes
L ess effective  
than viruses 
at transferring 
genes to cells; 
unknown
i = viral vectors
ii = non-viral vectors
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Adenoviruses have been studied for potential use in gene therapy due to its large 
DNA genome (approx. 38 kbp) and a capacity of maintaining large foreign DNA inserts (up 
to 10 kbp). Deletion o f essential early genes such as E la-E lb  leads to defective viruses that 
can be propagated in producer cells lines. The major limitation in the development of AdV 
vectors is that despite deletion of E la-E lb  genes, there is a “leaky” expression of late viral 
genes leading to cytopathic effects and an immune response (Yang et al., 1994).
Adeno-associated virus is a naturally defective small DNA virus known to be non- 
pathogenic (Fink et al., 1996). AAV is difficult to propagate to high titres but is capable of 
gene delivery and expression in non-dividing cells including neurones (Kaplitt et al., 1994). 
The long term persistence and expression of AAV has not yet been fully examined (Fink et 
al., 1996), but its main limitation includes small packaging potential for foreign DNA.
The HSV-1 life cycle and its ability to establish a life long latent infection in neural 
tissue has gained attention as a potential genetic vehicle by which to deliver and express 
therapeutic genes to the CNS. At present two major classes o f HSV-1 vectors have been 
developed: (1) replication defective mutants and (2) neuroattentuated mutants. The ability 
of HSV and these mutants to establish a life long latent infection, however, raises a critical 
issue in contemplating the use of these vectors in humans, especially in individuals who 
have already been latently infected with HSV. To exploit HSV as a vector it must be 
disabled to minimise the deleterious effects on the target cell. Strategies include the 
deletion o f essential genes, allowing virus growth only in a complimenting cell line and the 
deletion o f genes which specifically prevent growth in target cells but still allow growth in 
culture.
The selection of proper animal models upon which to conduct vector studies is 
critical, as the use o f an animal system such as the rat which is non permissive to HSV 
replication yields inaccurate conclusions (Andreansky et a l, 1996). Neuronal cells are 
postmitotic and cannot be removed for transduction for gene therapy which is why further 
studies are being carried out on HSV gene delivery vectors (Fink et a l, 1996). In vivo 
studies by Starr et al (1996) demonstrated the recessive nature of mutations used in 
constructing the mutant viruses and the demonstration that the latent HSV-1 immediate 
early promoter in the rat brain can be reactivated by superinfection with replication 
defective HSV-1 mutants (Starr et a l , 1996). All currently available HSV-1 recombinants 
could potentially trigger or enhance outbreaks of productive viral infections in latently 
infected individuals.
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1.14.1. Gene Therapy using HSV Vectors
Based on studies using neuronal cell cultures in vitro, HSV-1 has been proposed as 
a vector to deliver genes to mammalian neurones in vivo (Geller and Breakfield, 1988). A 
recombinant HSV capable of inhibiting its own replication as well as the replication of wild 
type virus would have increased safety as a general purpose vector for in vivo gene transfer, 
anti-tumour therapy, and viral vaccination against HSV infection. Preliminary studies show 
ICP34.5- viruses will express trans-genes in neuronal cells (Roizman, 1996).
1.14.1.1. Promoter/Enhancer Elements and Foreign Gene Expression
There are critical considerations when constructing HSV viral vectors for use in 
gene therapy. Two important aspects o f selection include (1) the right locus in which the
foreign gene is inserted and (2) an appropriate promoter and enhancer element for
expression of the desired gene.
Lachmann et al (1996) examined the potential of a murine RNA polymerase (pol.l) 
promoter driving the reporter gene neomycin phosphotransferase (neoR) with 
encephalomyocarditis virus internal entry site (EMCV-IRES) inserted into two independent 
loci (US5 or LAT) of HSV-1. Lachmann et al (1996) demonstrated that RNA pol.l 
promoter can be utilised to drive trans gene expression during lytic, but not latent infection 
in two independent loci. Lachmann and Efstathiou (1997) examined the LAT promoter 
driving the lacZ  and lacZI neoR reporter genes inserted with an IRES in the LAT locus. 0- 
galactosidase expression was seen during lytic and latent phases of infection using B ALB/c 
mice in vivo.
Coen et al (1989) described tk- mutants that do not replicate in ganglia, yet express 
LAT efficiently and stably in mouse neurones in vivo. Coen et al suggests that tk- mutants 
modified to place the gene of interest under the control of LAT or neurone specific gene 
expression signals may offer advantages (Coen et al., 1989).
1.14.1.2. “Pro-drug” Gene Therapy using HSV tk
Elshami et al (1996) compared pairs of tumour cell lines transfected with connexin
genes that differed only in their degree of gap junctional communication. Elshami et al
(1996) transduced tumour cells with an AdV vector containing the HSY tk  gene and
performed in vitro studies in which varying ratios of HSVtk+ to HSVtk- cells were mixed
and subjected to a fixed concentration o f GCV. Using this they compared the strength of
the bystander effect. More efficient cell killing was uniformly seen in connexin
52
Introduction: 1
transfectants compared with the less coupled cell lines (Elshami et al., 1996). These results 
provide direct evidence that gap junctional communication plays an important role in 
mediating the bystander effect of the HSV/GCV system in vitro.
Cool et al (1996) showed that long term survival of rats with 9L gliosarcoma 
tumours was observed only in animals with tumours transduced in vivo with HSVtk and 
GCV treatment. The results demonstrated that 9LTk subcutaneous tumours are treated 
more efficiently than brain tumours which might be related to the generation of more 
effective antitumoral immune responses when the tumours were subcutaneous (Cool et al.,
1996). The long term efficacy of in vivo gene transfer of HSV-tk, followed by GCV 
administration has recently been confirmed in another model, the C6 rat glioblastoma, with 
some of the treated animals still in remission at 8 months (Izquierdo et al., 1995). The 
efficacy of this approach was questioned by Tapscott et al (1994) when they found that 
tumour formation was decreased in rats injected subcutaneousy or intracerebrally with cells 
modified to express an intracellular selectable marker alone or with the HSV-tk, even in the 
absence o f GCV. The vector they used carried a chimeric hygromycin phophotransferase-tk 
fusion gene (Tapscott et al., 1994). Culver et al (1992) first reported the ability to eliminate 
small brain 9L gliosarcomas in synegeneic Fischer 344 rats by sterotactically injecting in 
these tumours a mouse packaging cell line producing HSV-tk retroviral particles, and by 
administering GCV later (Culver et al., 1992).
1.14.1.3. Amplicon-based Vectors
An amplicon contains a copy o f an HSV replication origin (oriS) and a packaging 
signal sequence located in a sequence of the HSV genome (Vlazny and Frenkel, 1981; 
Stow, 1982; Kwong and Frenkel, 1984). The amplicon is transfected into suitable cells with 
helper virus which provides the required genes in trans for amplification and packaging of 
the amplicon genome. The amplicon-containing viral particles are in effect defective 
virions, containing multiple copies of the amplicon sequences in a concatameric form, and 
are able to infect mammalian cells (Zhang et al., 1998).
Zhang et al (1998) reported using HSV tk inserted into an amplicon with a tk- and 
gH- mutant as a helper virus. Zhang et al (1998) used a BHK tk-/gH+ cell line in the 
presence o f selection medium containing methotrexate to prepare amplicon stocks of high 
titres.
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Studies with HSV-1 amplicons have been reported using a helper virus with a 
mutation in the essential IE3 gene. More recently a packaging defective vector 5dll.2 with 
a deletion in the IE2 gene, resulted in higher vector titres (Starr et al., 1996).
Fraefel et al (1996) reported using helper-virus free amplicon stocks generated 
from the whole HSV genome fragmented and cloned into cosmids. An amplicon plasmid 
was co-transfected with the HSV containing cosmids to generate a stock of helper free 
amplicons (Fraefel et al., 1996).
1.14.1.4. Replication Restricted HSV Vectors
An HSV-1 strain 17+mutant /«1312, defective for expression of VP 16, ICPO, and 
ICP4 containing the lacZ gene controlled by the LAT promoter proceeded by an IRES 
demonstrated an ability to establish latency in DRG and latent phase expression of p-gal 
(Marshall et al., 2000).
1.14.1.5. RL1 Mutant Vectors
Most replication defective HSV-1 vectors contain a deletion to remove one or more 
immediate early genes in order to prevent virus replication at the earliest time after 
infection. These genes must be complemented in trans for growth in culture. An 
inactivating mutation in the gene encoding ICP27 which activates immediate early gene 
expression after infection can be used to produce a non-pathogenic virus. Alternatively, a 
mutation in genes necessary for replication in particular target cells prevents replication in 
some fully differentiated cells (including neurones) but which still allows virus growth in 
actively dividing fibroblasts in culture.
For attenuated HSV growth in neurones mutations have been made in genes such 
as ICP6, tk, and ICP34.5. Myocardium cells are fully differentiated and cannot support a 
productive infection by these mutants, and thus lack o f transgene expression in this cell type 
might suggest that apoptosis is occurring in this case. An HSV mutant, 27-lacZ, in which 
the essential immediate early gene Vmw65aTIF was deleted, gave high efficiency gene 
transfer to the cardiac myocytes in vitro and the rat heart in vivo. Viruses in which ICP34.5 
(1716/lacZ) or ICP34.5 and IE63 (1764/lacZ) were inactive gave a much lower efficiency of 
gene transfer, mirroring the degree of cytopathic effect observed in the beating myocytes 
cultures (Coffin et al., 1996a). In these viruses, the lacZ marker gene was inserted in the 
nonessential UL43 gene.
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Enteric neurones represent a system for transplantation into the brain of patients 
lacking specific neurological functions, since they survive transplantation into the CNS and 
extend axons into surrounding brain tissue (Tew et al., 1992, 1994). Viruses lacking 
ICP34.5 either alone (1716) or in combination with the virion transactivator Vmw65 (1764) 
were used to efficiently deliver a reporter gene to the enteric neurones even though it has 
been shown such viruses can deliver the same reporter gene to PNS and CNS neurones in 
vivo (Howard et al., 1997). A virus lacking both ICP27 and ICP34.5 was shown to produce 
less cellular damage than one lacking only ICP27, and it was as efficient in gene transfer, 
where inactivation of Vmw65 reduced toxicity further (Howard et al., 1997).
1.14.2. Cancer Therapy using HSV Vectors
To generate neuroattenuated mutants that will replicate only in tumour cells, HSV 
has been modified by either deletions in viral genes encoding enzymes for viral DNA 
synthesis (tk or ribonucleotide reductase) and/or deletions in RL1 (Chou and Roizman, 
1990; MacLean, A., et al., 1991; Martuza et al., 1991, Mineta et al., 1994a,b; Chambers et 
al., 1995; McKie et al., 1996; McKie et al., 1998).
Methods currently used to treat malignant gliomas include surgery, radiation and 
chemotherapy. These approaches have not significantly enhanced the life span o f patients 
(Mahaley et a l, 1989). Recent studies have used HSV-1 ICP34.5- mutants to treat glioma 
tumours because these viruses retain the ability to replicate in dividing tumour cells but do 
not replicate in the surrounding terminally differentiated cells o f the CNS (Andreansky et 
a l, 1996).
1.14.2.1. “Pro-drug” Cancer Therapy using HSV tk
One approach of gene therapy for cancer purposes is the transfer of “suicide”
genes into tumour cells to sensitise them selectively to drugs that are normally non-toxic.
Most of these genes encode viral or bacterial enzymes converting inactive forms of the drug,
designated “pro-drug” into toxic antimetabolites that inhibit nucleic acid synthesis
(Moolton, 1994). One such gene from HSV-1 encodes a tk that phosphorylates antiviral
nucleosides, such as GCV and acyclovir (ACV) normally metabolised at very low levels by
mammalian enzymes. These drugs are transformed by viral thymidine kinase into
monophosphate forms that are subsequently converted by normal endogenous cellular
kinases to triphosphates. These molecules are potent inhibitors o f DNA polymerases. As
analogs of the natural deoxyguanosine triphosphate, they inhibit DNA synthesis and as a
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consequence kill the cell (Moolten, 1994). Although untransduced cells are not sensitive to 
GCV at concentrations able to kill HSV tk gene modified cells, it has been found both in 
vitro and in vivo that HSV-tk-negative cells can in fact be killed by proximity to HSV-tk- 
positive tumour cells treated by GCV. This phenomenon first observed by Moolten has 
been designated the “bystander effect” (Moolten, 1986; Culver et al., 1992).
1.14.2.2. RL1 Mutant Vectors
There are several RL1 mutant viruses and three RL1 deleted viruses (RE6, R3616, 
and 1716) that are actively being studied for their potential use as cancer therapies in the 
CNS and PNS.
The RE6 HSV-1/2 intertypic recombinant was first described in 1983 (Thompson 
and Stevens, 1983). Subsequently, RE6 was shown to be avirulent due to a defect in the 
RL1 gene which resulted in severely reduced replication in neuronal tissues (Thompson and 
Stevens, 1983; Thompson et al., 1989). Brandt et al (1997) injected lxlO6 pfu/mouse of the 
neuroattenuated RE6 into the vitreous humour into LH(3-Tag transgenic mice (mice 
containing the SV40 large T-antigen (Tag) driven by the murine P-leutinizing hormone 
promoter expressing Tag in the retina), a statistically significant reduction in retinoblastoma 
tumour size was observed. This was the first report o f the use of an HSV mutant to treat 
spontaneously arising tumours in an immunocompetent animal and supports the possible 
use of this as a cancer therapy. However, they showed that although intravitreal injection of 
RE6 resulted in a significant difference in retinoblastoma size, the 95% confidence intervals 
overlapped and they could not achieve complete regression of the tumour in any of the 
treated mice. This was in contrast to other reports with melanoma cell implants in which 
elimination of the tumours was achieved at least in a portion of the treated animals 
(Randazzo et al., 1995).
The strain F, ICP34.5- virus, R3616, was used with fractionated ionising radiation 
and results suggest a synergistic action. This treatment reduced tumour volumes and gave 
longer survivals when compared with either treatment alone. Ionizing radiation in addition 
to its own cytocidal properties interacts with R3616, resulting in enhanced viral replication,
n
improved distribution and tumour volume reduction. The viral dose was 1x10 pfu/tumour 
(one dose in total) and the total dose of 40Gy (over the course of two weeks). R3616 has 
been reported to cause a limited distribution of tissue damage along the injection site 
(Martuza et al., 1991; Markovitz et al., 1997).
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Epithelial ovarian cancer (EOC) remains localised within the peritoneal cavity in a 
large number of patients, lending itself to intraperitoneal approaches o f therapy. This cancer 
has been studied with a number of viral vector systems. Preclinical results have been 
obtained as a preliminary to carrying out Phase I trials (Link et al., 1996; Alverez et al.,
1997). Coukos et al (1999) investigated the effect of 1716 used as an oncolytic agent 
against EOC and the use of human teratocarcinoma PA-1 as carrier cells for intraperitoneal 
therapy. 1716 caused a direct dose dependent oncolytic effect on EOC cells in vitro. A 
single intraperitoneal administration of 5xl06 pfu/mouse resulted in a significant reduction 
o f tumour volume and spread and an increase in survival in a mouse xenograft model 
(Coukos et al., 1999). In comparison with the administration of 1716 alone, irradiated PA-1 
cells, infected at two multiplicities of infection with 1716 and injected intraperitoneally at 
5x l06 cells/animal, led to significant tumour reduction in the two models tested and the 
significant prolongation of mean survival in one model (Coukos et al., 1999). 
Administration of 1716 infected PA-1 carrier cells resulted in larger areas of tumour 
infected by the virus (Coukos et al., 1999). Kucharczuk et al (1997) demonstrated the 
efficacy of 1716 in reducing tumour burden and conferring survival advantage in an 
intraperitoneal model of malignant mesothelioma in the SCID mouse. Moreover, these 
studies suggested that extra-CNS administration o f replication restricted HSV-1 might be 
safe.
1716 administered intraperitoneally to SCID mice was found to be completely 
avirulent (Kucharczuk et al., 1997). There was no viral spread outside the tumours as 
determined by immunohistochemistry and PCR analysis of multiple murine tissues, 
including intraperitoneal and retroperitoneal organs as well as distant organs and the brain. 
This was not the result for wild type HSV-1, to which SCID mice were found to be 
extremely sensitive (Kucharczuk et al., 1997). The administration of 1716 to normal human 
skin xenograft model was accompanied by no toxicity, whereas administration o f wild type 
HSV-1 led to rapid destruction of the xenograft (Randazzo et al., 1996). Application of 
replication restricted HSV-1 for extra-CNS malignancies was recently extended to other 
tumours; a ribonucleotide reductase deleted mutant was used in an experimental animal 
model of metastic colorectal carcinoma in the liver (Carroll et al., 1993) and a replication 
restricted ICP34.5- mutant was used to treat experimental metastic and subcutaneous 
melanoma (Randazzo et al., 1995; Randazzo et al., 1997).
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1.15. Aims
There were two aims of this project, firstly, to determine the role o f two antisense 
genes expressing ICP34.5 and ORF P in HSV-1 virulence and secondly, to identify the 
HSV-2 strain HG52 ICP34.5 protein.
To achieve the first aim the following strategy was devised:
(1) Construct recombinant viruses expressing ICP34.5 and ORF P singly 
using 1716.
(2) Characterise recombinant viruses in vitro and in vivo.
To achieve the second aim the following strategy was used:
(1) Construct glutathione S-transferase/HSV-2 RL1 fusion protein.
(2) Purify the fusion protein.
(3) Immunise using fusion protein to generate polyclonal antisera.
(4) Analyse ICP34.5 expression by Western blotting.
(5) Construct intertypic recombinant viruses using 1716 expressing either 
HSV-2 RL1 with or without its intron.
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2. Materials
2.1. Bacteria
The E. coli strain used for cloning was XL2-blue Ultracompetent (Stratagene™). 
For expression o f ICP34.5, BL21 (DE3) [F-ompT-r'bm‘b] were used (Studier and Moffat, 
1986). Bacteria were grown in L-broth (170mM NaCl, 10 g/1 Difco bactotryptone, 5 g/1 
yeast extract) and 2xYT (85mM NaCl, 16 g/1 Difco bactotryptone, 5 g/1 yeast extract). 
Bacteria from glycerol stocks were plated out onto L-broth agar (L-broth containing 1.5% 
(w/v) agar).
2.2. Plasmids
pGEM34.5 was provided by Dr. L. McKie (McKie et al., 1994). The plasmid, p35, 
containing the UL43 gene (n.p. 91610-96751) cloned into pUC19 (MacLean, C. et al., 
1991) was provided by Dr. A. MacLean. An oligonucleotide linker was inserted into p35 
which became p35(PacI), which was provided by Dr. A. MacGregor.
Plasmids containing the HSV-2 RL1 gene, with and without the intron, pSBl and 
pSB2 (Bdour, 1995), respectively, were provided by Dr. J. Harland. 
pGEX-2T(N+l) was generously provided by Dr. R. Everett.
2.3. Cosmids
Cosmids containing the whole HSV-1 strain 17+ genome were generously provided 
by C. Cunningham (Cunningham and Davison, 1993).
2.4. Cells and Tissue Culture Media
2.4.1. ETC10
Baby Hamster kidney 21 clone 13 (BHK) cells (MacPherson and Stoker, 1961) 
were grown in Eagle's medium (Gibco) supplemented with 10% new-born calf serum 
(Gibco), 10% (v/v) tryptose phosphate broth (Busby et al., 1964).
2.4.2. DMEM10
Human neuroblastoma (SK-N-SH) cells, human cervical carcinoma (HeLa) cells, 
African green monkey (Vero) cells and mouse embryo fibroblast 3T6 cells (European 
Tissue Culture Collection) were gown in Dulbecco's modified essential medium (DMEM) 
supplemented with 10% foetal calf serum (DMEM 10). Penicillin/streptomycin were used 
at appropriate concentrations.
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2.4.3. Emet/5C2
When infected cells were radiolabelled, Emet/5C2 (Eagle's medium containing 
one-fifth normal concentration methionine and 2% newborn calf serum) was used.
2.4.4. EMC5
Eagle’s medium containing 1.5% carboxymethylcellulose and 5% calf serum.
2.5. Viruses
2.5.1. HSV-1
2.5.1.2. Strain 17+
The wild type parental virus used in this study was HSV-1 strain 17+ (Brown et a l,
1973).
2.5.1.3. Mutant 1716
Strain 17+ deletion variant 1716 was used extensively for making recombinant 
viruses and as an ICP34.5 negative control in many experiments (MacLean, A. et a l, 
1991).
2.5.1.4. Mutant gD17+
Strain 17+ mutant virus with the gD promoter driving lacZ expression in the UL43 
locus (R. Reid, personal communication). This mutant was used as a control for insertion 
of a gDHacZ cassette in the UL43 locus.
2.5.1.5. Strain F
An additional wild type HSV-1 strain, F, was used to compare phenotypic and 
ICP34.5 properties in vitro with strain 17+ (Ejercito et a l ,  1968).
2.5.2. HSV-2
2.5.2.1. Strain HG52
The wild type parental virus HSV-2 strain HG52 was extensively used in this study 
(Timbury, 1971).
2.5.2.2. Mutant 2616
A HG52 deletion variant in the RL1 gene, 2616, was used for protein expression 
and growth behavior studies (Harland and Brown, 1991).
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2.5.2.3. Mutant 2624
A HG52 mutant virus in which the RL1 intron is deleted. This mutant was used to 
study ICP34.5 protein expression (Ravi et a l , 1998).
2.5.2.4. Other HSV-2 Strains
Additional HSV-2 strains which were used to look for ICP34.5 expression 
included: strain 333 (Seth et a l , 1974), G (Ejercito et a l , 1968), 186 (Esparza et a l,  1974), 
MS (Gudnadottir et al., 1964).
2.6. Antisera
HSV-1 proteins
A peptide antibody to the (PAT)10 repeat in ICP34.5 was provided by Dr. A. 
MacLean (McKay et al., 1993). Two separate antisera to the ORF of RL1, namely, Rabbit 
1 and 137, were provided by Dr. J. Harland (Brown et al., 1997). Antisera specific to ORF 
P were provided by Mr. R. Reid. Dr. A. Cross generously provided monoclonal antibodies 
against UL42 (ZLF11) and gl (3104). Dr. H. Marsden additionally provided rabbit 
polyclonal antisera which recognise gC and gD and P-galactosidase.
Cellular proteins
The commercially generated PCNA antibody was supplied by Sigma.
2.7. Radiochemicals
All radioisotopes were supplied by Amersham International pic. They had the 
following activities:
[35S]-methionine [>1 000 Ci/mmol]
[32P]dCTP [3 000 Ci/mmol]
2.8. Oligonucleotides
Oligonucleotides were synthesised using a model 8600 Biosearch multiple column 
synthesiser at the Institute of Virology.
2.9. Enzymes
Restriction enzymes were purchased from Boehringer Mannheim and New 
England Laboratories. T4 DNA ligase and T4 polynucleotide kinase were purchased from 
Boehringer Mannheim.
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Lysozyme and RNaseA were purchased from Sigma Chemical Co.
2.10. Sequencing
All sequences in this thesis was kindly carried out by Mrs. L. Taylor at the Institute 
o f Virology and performed on an ABI 377 DNA sequencer.
2.11. Phospho-im aging
Several immunoblots were analysed on a BioRad Molecular® Imager Fx machine 
using a BioRad Pentium computer with QuantityOne Phospho and Multi-imager software 
(4.0.3). Instruction was generously provided by Mr. Colin Loney.
2.12. Solutions
2.12.1. Bacterial Culture Reagents
Promega Wizard kit:
Resuspension Solution: 50mM Tris-HCl (pH7.5), lOmM EDTA, and 100 pg/ml
RNaseA
Lysis Solution: 0.2M NaOH, l%(w/v) SDS
Neutralisation Solution: 1.32M KAc (pH4.8), 40%(v/v)propan-2-ol, and 4.2M
guanidine hydrochloride
TE buffer: lOmM Tris-HCl (pH7.5), ImM EDTA
Solution 1: 50mM Glucose, lOmM EDTA, 25mM Tris HC1 (pH8) and 
Lysozyme (4 mg/ml)
Solution 2: 0.2M NaOH and 1% (w/v) SDS
Solution 3: 3M KAc (pH4.8)
2.12.2. Tissue Culture Reagents
HEBS: (pH7.05) 130mM NaCl, 4.9mM KC1, 1.6mM N aH P04,
5.5mM D-glucose, 2 ImM HEPES 
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Lvsis buffer: 0.6% (w/v) SDS, lOmM EDTA, lOmM Tris-HCl (pH7.4) 
and 500pg/ml Proteinase K
NTE buffer: lOmM Tris-HCl (pH7.5), lOmM NaCl, ImM EDTA
PBS-A: 170mM NaCl, 3.4mM KC1, lOmM Na2H P04, 1.8mM 
KH2P 0 4 (pH7.2)
RS buffer: lOmM KC1, 1.5mM MgCl2, lOmM Tris-HCl (pH7.5)
Tris-saline:
Versene
140mM NaCl, 30mM KC1, 280mM Na2H P04, 1 mg/ml 
glucose, 0.0015% (w/v) phenol red, 25mM Tris-HCl 
(pH7.4), lOOU/ml penicillin, 0.1 mg/ml streptomycin.
0.6mM EDTA in PBS-A containing phenol red
2.12.3. Agarose Gel Reagents
TBE: 89mM Tris, 89mM Boric acid, and 2mM EDTA
RE stop: lOOmM EDTA, 10% (w/v) Ficoll 400, 0.25% (w/v)
Bromophenol blue in 5x TBE
2.12.4. Southern blot Reagents
Gel Soak 1: 200mM NaOH and 600mM NaCl
Gel Soak 2: 1M Tris-HCl (pH8) and 0.59M NaCl
20xSSC: 0.3M Na3Citrate and 3M NaCl
Hybridization buffer: 0.5M NaP (pH7.4) and 7% (w/v) SDS
Wash solution: 2x SSC and 0.1% (w/v) SDS
2.12.5. Immunofluorescence Reagents
Permea mix: 0.5% (v/v) NP40, 10% (w/v) sucrose in PBS-A
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Fix solution: 2% (w/v) sucrose, 5% (v/v) formaldehyde in PBS-A
2.12.6. SDS-PAGE and Western blot Reagents
BM: 15 ImM Tris-HCl (pH6.7), 6.28% (w/v) SDS, 0.15 % (v/v) p-
mercaptoethanol, 0.31% (v/v) glycerol, and 0.1% (w/v) bromo- 
phenol blue
RGB: 375mM Tris-HCl (pH8.9) and 0.1% (w/v) SDS
SGB: 0.1M Tris-HCl (pH6.7) and 0.1% (w/v) SDS
Towbin buffer: 20% (v/v) MeOH, 25mM Tris-HCl (pH8.3), 192mM glycine
2.12.6.1. Western blot Denaturation and Renaturation Buffers.
Denaturation buffer: 7M guanidine hydrochloride, 50mM Tris-HCl, pH8.3,
50mM DTT, 2mM EDTA, 0.2% (w/v) nonfat dried milk
Renaturation buffer: 50mM Tris-HCl, pH7.5, lOOmM NaCl, 2mM DTT, 2mM 
EDTA, 0.1% (v/v) Nonidet P-40, 0.25% (w/v) nonfat dried 
milk
2.12.7. Immunoprecipitation Buffers
Buffer A : lOmM HEPES, 50mM NaCl, ImM EDTA, 0.5% (v/v)
Triton, 7mM 2-mercaptoethanol, 0.5M sucrose and added 
immediately before use ImM PMSF
Buffer E: lOOmM Tris-HCl (pH8.0), lOOmM NaCl, 2mM EDTA, 
2mM EGTA, 1% (v/v) NP40, 0.5% (w/v) Na deoxycholate, 
and added immediately before use 0.5mM PMSF
Buffer EB: Buffer E and 2mg/ml BSA
Buffer EN: Buffer E with 500mM NaCl 
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2.12.8. Pull-down Reagents
Buffer C: 50mM Tris-HCl (pH8.0), 0.5mM NaCl, ImM EDTA, 0.5%
(v/v) NP40 and Boehringer Mannheim protease inhibitors
2.12.9. Fractionation Reagents
Hypotonic buffer: 1.6mM MgCl2, 6mM KC1, lOmM Tris-HCl (pH8.0), ImM
dithiothreitol, ImM PMSF, 5mM benzamidine, and 
0.5%(v/v) NP40
2.12.10. Immunohistochemistry Reagents
STWS: 2%(w/v) potassium bicarbonate, 20%(w/v) magnesium
sulphate in dH20
2.13. Chemicals
Chemicals used were analytical grade and mostly supplied from BDH chemicals 
UK or Sigma Chemicals Co.
APS and TEMED were supplied from Bio-Rad Laboratories. Ampicillin 
(Penbritin) was supplied from Beecham Research.
2.14. Other materials
2.14.1. Centrifuges
Volumes >50ml up to 10,000 rpm Beckman Centrifuge
Volumes 1.5 ml - 45 ml up to 3,000 rpm Benchtop Fison’s Coolspin
Centrifuge
Volumes <1.5ml up to 13,000 rpm Micro-centrifuge
2.14.2. Film and computer scanning of autoradiographs
Autoradiograph XS-1 film (Southern, Northern and Western blots) was supplied 
from Kodak.
Film used for immunohistochemical analysis was 1600 speed from Fuji and Zoom 
film from Kodak.
Autoradiographs were scanned using a Studioscanllsi scanner with 600 dpi. 
Autodradiographs were developed in a Kodak X-omat model ME-3.
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2.14.3. Miscellaneous Equipment
DNA was crosslinked to nitrocellulose membrane using a Stratagene UV 
Stratalinker™ 1800.
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3. METHODS
3.1. Bacterial growth
Growth o f plasmids was carried out using E  coli and harvested by either a large 
scale or small scale preparation, Section 3.1.1. or 3.1.2., respectively.
3.1.1. Large Scale Isolation of Plasmid DNA: Promega© Wizard™ Maxi-
prep
A 500 ml E. coli plasmid-containing culture was grown overnight in L-broth 
containing 100 pg/ml ampicillin. Cells were pelleted by centrifugation at 5,000 rpm 
(Sorvall GSA rotor) for 10 min. at RT. The supernatant was discarded and the pellet 
resuspended in 15 ml Resuspension Solution. Fifteen ml Lysis Solution was added to the 
pellet by gently mixing thoroughly and incubating at RT for 20 min. Fifteen ml 
Neutralisation Solution was added and mixed by inverting several times. The samples 
were centrifuged at 2,000 rpm (Fison’s Coolspin) for 20 min. at RT. The clarified 
supernatant was poured into a fresh 50 ml Falcon tube and 0.5x propan-2-ol was added and 
mixed by inversion. Samples were centrifuged at 2,000 rpm (Fison’s Coolspin) for 15 
min. at RT. The supernatant was discarded and the pellet left to dry. Once dry, the pellet 
was resuspended in 2 ml TE buffer. Ten ml Wizard™ resin was added to the pellet. This 
solution was added to a Wizard™ maxi-column. A vacuum was applied to draw the 
solution through the Wizard™ maxi-column. The resin was washed by adding 80% EtOH 
to the Wizard™ maxi-column. The DNA was eluted by adding 1.5 ml of preheated H20  
(65-70°C) and incubating at RT for 1 min. before centrifuging the Wizard™ maxi-column 
at 2,500 rpm (Fison’s Coolspin) for 5 min. at RT. A final step o f purification of DNA was 
done by using a syringe with a Luer-Lok® extension and 0.22 pm filter. Once the solution 
went through the filter the DNA was precipitated by adding 2 volumes EtOH and 0.1 
volume 3M NaAc, vortexing and placed in dry ice for 20 min. and centrifuged at 2,500 
rpm (Fison’s Coolpsin) for 10 min. at RT. The supernatant was discarded and the pellet 
rinsed with 1 ml 70% EtOH and centrifuged as above. The supernatant was discarded and 
the pellet left to dry at RT. The DNA pellet was resuspended in 1.5 ml dH20  (50 pg/pl 
RNase A).
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3.1.2. Small Scale Isolation of Plasmid DNA
A single colony that was grown overnight on an agar plate was picked with an 
autoclaved toothpick and placed in a Universal bottle containing 5 ml L-broth and Amp 
(100 pg/ml). The bottle was placed in a 37°C shaker overnight. One ml of the grown 
culture was centrifuged at 7,000 rpm (microfuge) for 1 min. The cell pellet was 
resuspended in 100 pi o f Solution 1 by a brief vortex and incubated at RT for 5 min. Two- 
hundred pi of Solution 2 was added and mixed by inverting 4 to 6  times, and incubated at 
RT for 5 min. One-hundred-and-fifty pi of cold Solution 3 (3M KAc) was added and 
mixed by inversion and incubated at RT for 5 min. This mixture was centrifuged at 13,000 
rpm (microfuge) for 5 min. and the supernatant-containing plasmid DNA transferred to a 
fresh tube. The 450 pi volume o f supernatant (from solutions 1, 2, and 3) was clarified by 
adding 450 pi phenokchloroform to each tube. Samples were vortexed and centrifuged at
13,000 rpm (microfuge) for 5 min. at RT. The aqueous layer was transferred into a fresh 
tube and phenokchloroform extraction repeated as above. The aqueous layer was mixed 
with 1 ml EtOH and centrifuged at 13,000 rpm (microfuge) for 5 min. at RT. The pellet 
was washed with 70% EtOH and dried in a “speedi-vac”. The pellet was resuspended in 
100 pi dH20  (50 pg/pl RNase A).
3.2. Transformation of Bacterial Cells
XL-2-Blue Ultracompetent E.coli (Strategene) were thawed from -70°C on ice and 
20 pi aliquoted into an Eppendorf tube. One pg of plasmid DNA was added, mixed, and 
the tube placed on ice for 30 min. The DNA and E.coli was heat shocked by placing in a 
42°C water bath for exactly 90 sec. followed by placing on ice for 2 min. Eighty pi 2xYT 
broth was added and the reaction tube incubated for 1 h at 37°C. After 1 h the mixture was 
pipetted and spread onto a L-broth agar plate containing appropriate antibiotics (Amp (100 
pg/ml) and/or X-gal (20 pg/ml)). The 100 pi mixture was absorbed on the agar for 15 
min. before the plates were inverted and placed in a 37°C incubator for 16 h.
3.3. Restriction Endonuclease Digestion
Plasmid and viral DNA was routinely evaluated by different restriction 
endonuclease digestion profiles. The duration and temperature conditions were carried out 
according to the manufacturers’ instructions (Section 2.9). Enzyme activity was stopped
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by placing RE stop solution in the reaction mixture. Digestion was visualized by 
electrophoresis through an agarose gel (Section 3.4).
3.4. Agarose Gel Electrophoresis
Agarose gels (0.6-1.5% (w/v) agarose) were prepared by boiling the appropriate 
quantity of agarose in lx  TBE. Ethidium bromide was added at a concentration of 0.5 
pg/ml, immediately prior to pouring the gel. The solution was poured into a tray (BioRad) 
which held a comb. Once cool, the tray was placed in an electrophoresis kit, the comb 
removed and samples pipetted into individual wells. Electrophoresis o f the samples was 
carried out until the dye front was approximately 1 cm from the end of the gel.
3.5. Elution of Restriction Enzyme Fragments from Agarose Gel
DNA was digested with the appropriate restriction enzyme and electrophoresed 
through an agarose gel containing 0.5 pg/ml EtBr until the fragment to be isolated was 
well resolved. The gel was visualised under a long-wave UV light and the desired 
fragment excised using a sterile scalpel.
The Gene Clean™ system was used to isolate DNA from the agarose gel. Nal was 
added to TBE Modifier and to 1 gel slice. The samples were placed in a water-bath at 
55°C for 10 min. Glass milk beads were resuspended by vortexing and 5 pi was added to 
each sample. The sample containing beads was vortexed briefly and incubated at RT for 5 
min. followed by centrifugation at 13,000 rpm (microfuge) for 1 min. The supernatant was 
discarded and the glass milk beads were washed with 0.5 ml Gene Clean Wash (-20°C) by 
vortexing. The beads were pelleted by centrifugation at 13,000 rpm (microfuge) for 1 min. 
This wash was repeated. Twenty pi dH20 was added to the pellet which was vortexed and 
incubated at 55°C for 5 min followed by vortexing and centrifugation at 13,000 rpm 
(microfuge) for 2 min. The supernatant contained the DNA.
3.6. Phenol Chloroform Extraction and Precipitation of Plasmid DNA
An equal volume o f phenokchloroform was added to the DNA, mixed by vortexing 
and subjected to centrifugation for 2 min. at 13,000 rpm at RT (microfuge). The aqueous 
layer containing DNA was pipetted into a fresh tube. Two volumes of EtOH and 0.1 
volume 3M NaAc was added to the aqueous layer, vortexed, and placed on dry ice for 20 
min. The solution was centrifuged for 20 min. at 13,000 rpm at RT (microfuge). The
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supernatant was discarded and 1 ml 70% EtOH added and centrifugation carried out as 
stated above. The supernatant was discarded and the DNA pellet left to dry. The pellet 
was resuspended in dH20  (RNase A 50pg/ml).
3.7. Ligation of Plasmid DNA
Different molar ratios of plasmid DNA to vector were added to a total volume of 
14 pi. Four pi 5x Ligation Buffer was added, the solution mixed and centrifuged to collect 
at the bottom of tube. Lastly, 2 pi T4 DNA ligase (3U/pl) was added to the solution, 
mixed well and placed in a water bath at 16°C overnight. The following day this was used 
in a transformation reaction (Section 3.2).
3.8. Purification of a Synthetic Oligonucleotide
The oligonucleotide was removed from the column by passing 1.5 ml ammonia 
through the column between two 1.5 ml syringes for approximately 1 h. After this time all 
the solution was pulled back into one syringe and transferred to a screw cap cryo-vial. 
Deprotection o f the oligo was carried out for 5 h at 60°C. The vial was placed on dry ice 
for 15 min. and the cap carefully opened and a layer of parafilm with holes used to seal the 
top. The vial was placed in a vacuum spin overnight. The oligonucleotide was 
resuspended in 100 pi dH20  by vortexing and incubated at 37°C for 30 min. The sample 
was centrifuged for 2 min. at 13,000 rpm (microfuge). The supernatant was placed in a 
fresh Eppendorf tube and OD analysis carried out.
3.9. Tissue Culture
Herpes simplex virus growth was studied in vitro for protein expression and 
replication kinetics.
3.10. Cells
Replication o f HSV-1 strain 17+ and HSV-2 strain HG52 wild types differ from 
RL1 deleted viruses in some (3T6) but not all cell lines (BHK): additional cell lines such 
as Vero, HeLa and rabbit skin cells were used to study ICP34.5 mutant viruses. An in 
vitro function o f ICP34.5 is to preclude protein synthesis in certain cells, such as SK-N-SH 
cells.
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3.10.1. BHK21/C13 Cells
Baby hamster kidney cells 21 (BHK) seeded at a 1 in 10 dilution were grown in 
100 ml ETC 10 in 850cm2 roller bottles in a humidified atmosphere o f 5% C0 2  at 37°C for
3 to 4 days. Confluent cells (3xl08/roller bottle) were harvested as described in Section
3.11.
3.10.2. HeLa, Vero, Rabbit Skin and 3T6 Cells
HeLa, Vero, Rabbit Skin, and 3T6 cells were grown for 3 days in DMEM 10 with 
5% C02. Cells were passed in large flasks (T-175) by seeding at a 1 in 10 dilution in 50 ml
DMEM10. Confluent cells (3xl0 7  cells/T-175 flask) were harvested as described in 
Section 3.11.
3.10.3. SK-N-SH Cells
The human neuroblastoma (SK-N-SH) cells were grown in DMEM 10 with 5% C0 2
for 5 days in a T-175 flask. Cells were split 1 in 4 for passage.
3.11. Passaging Cells
Trypsin solution (0.25% (w/v) in Tris-saline containing phenol red (pH7.5) 
(NaHC03)) was thawed from -20°C and mixed with versene to yield 0.06% (v/v) 
trypsin/EDTA solution.
T-175 flasks or roller bottles with confluent monolayers were opened in a category 
2 hood, the supernatant decanted, and 10 ml or 20 ml, respectively, of a trypsin/EDTA 
solution was poured over the monolayer and decanted. This was repeated before the flask 
or roller bottle was left for 2 to 3 min. The cells were shaken into 10 or 20 ml media for 
further use.
3.12. Cryopreservation of Cells
Confluent cell monolayers of Vero, HeLa, SK-N-SH or 3T6 cells were harvested
from T175 flasks as described above by trypsinizing and resuspending in 15 ml media and
pipetted into Falcon tubes. Cells were centrifuged at 3,000 rpm (Fison’s Coolspin) at 4°C
for 10 min. and resuspend in 5 ml of the appropriate growth medium, with 10% DMSO.
Aliquots o f 1 ml were pipetted into 1.5 ml cryo-vials. These were frozen overnight at -
70°C and moved to a liquid nitrogen freezer for long term storage.
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3.13. Growth of HSV Stocks
o
Roller bottles containing a fresh monolayer o f BHK cells (3x10 cells/bottle) were 
infected with 0.003 pfu/cell o f HSV in 20 ml o f ETC 10. These were incubated at 31°C for 
4 days or until c.p.e. was complete, when the cells were shaken into the medium. The cell 
suspension was poured into a 250 ml plastic Falcon tube and cells pelleted by 
centrifugation at 2,000 rpm (Fison’s Coolspin) for 10 min. at 4°C. The supernatant and 
cell pellet was divided into 2  individual stocks: cell-associated virus and cell-released 
virus.
3.13.1. Cell-associated Virus
The cell pellet was resuspended in 0.5 ml medium/roller bottle, pipetted into a 
sterile Universal bottle, thoroughly sonicated and centrifuged at 2,000 rpm (Fison’s 
Coolspin) for 10 min at 4°C, as described above. The supernatant was kept on ice while
the pellet was treated as described above. Both supernatants were pooled to give the cell-
associated virus stock. This was aliquoted into 1.5 ml sterile cryo-vials and stored at - 
70°C.
3.13.2. Cell-released Virus
The supernatant was poured into 250 ml sterile centrifuge bottle and spun at 12,000 
rpm (Sorvall GSA rotor) for 2 h at 4°C. The supernatant was discarded and the virus pellet 
resuspended in 1 ml ETC 10/roller bottle. The pellet was sonicated until homogeneous, 
and 1 ml aliquots transferred into 1.5 ml sterile cryo-vials and stored at -70°C.
3.14. Virus Titration
Virus stocks were serially diluted 10-fold in PBS-A/10%CS and 0.1 ml aliquots 
added to fresh monolayers of BHK cells on 60mm plates from which the media had been 
removed. The plates were incubated at 37°C with 5% C0 2  for 1 h to allow absorption to 
the cells, before overlaying with 4 ml EMC 10. The plates were incubated at 37°C for 48 
to 72 h. The EMC 10 was poured off each plate and monolayers fixed and stained with 
Giemsa stain at RT for 1 h. After rinsing the plates with tap water and allowing them to 
dry, plaques were counted using a dissection microscope and virus titres calculated as 
pfu/ml.
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3.15. Plaque Purification
Once c.p.e. was complete in transfection plates, cells were scraped into growth 
media, transferred to a bijou bottle and sonicated in a soni-bath until homogeneous. Serial 
10-fold dilutions were made in PBS-A/10%CS. One-hundred pi from the 102  tolO6  
dilutions from each were plated on fresh BHK monolayers in 60mm plates from which the 
media had been removed. After 1 h absorption at 37°C and 5% C02, the plates were rinsed 
once with PBS-A/10%CS and overlaid with 4 ml EMC 10 and incubation continued at 
37°C for a further 48 to 72 h. Using a 200 pi Gilson pipette, the plate with the fewest well 
separated plaques were picked, resuspended in 500 pi PBS-A/10%CS and sonicated in a 
soni-bath until homogeneous. This procedure was either repeated or a Southern blot 
performed to check the purity of the recombinant virus.
3.15.1. X-gal Staining
Recombinant viruses containing the (3-galactosidase gene lacZ were plaque 
purified by staining with X-gal. BHK cells monolayers were infected with virus as 
described in Section 3.14 except the media overlay contained methyl cellulose with 2% 
calf serum and 150 pg/ml X-gal.
3.16. Sterility Checks on Virus Stocks
Brain heart infusion agar (BHI) plates were used to check for fungal contamination 
in viral stocks. A small aliquot of a viral stock was streaked onto BHI plates in duplicate 
which were sealed with parafilm and incubated at RT for 7 days. BHI plates containing 
10% horse blood (BHI blood agar) were used to check for yeast or bacterial contamination 
by plating a small aliquot o f viral stock and incubating at 37°C for 7 days. If there was no 
growth by 7 days stocks were considered sterile.
3.17. Preparation of HSV Virion DNA
Ten roller bottles containing a fresh monolayer of BHK cells (3xl0 8 cells/bottle) 
were infected with 0.003 pfu/cell o f HSV in 20 ml of ETC 10. These were incubated at 
31°C until c.p.e. was complete, then the cells were shaken into the medium. The cell 
suspension was poured into a 250 ml plastic Falcon tube and cells pelleted by 
centrifugation at 2,000 rpm (Fison’s Coolspin) for 10 min. at 4°C. The supernatant was
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kept on ice while nuclei were extracted from the cell pellet by treatment with 0.5% (w/v) 
NP40 in RS buffer (pH7.5) followed by centrifugation at 2,000 rpm (Fison's Coolspin) for 
10 min. at 4°C. The supernatant was kept on ice and the above repeated before pooling the 
supernatants and centrifuging at 12,000 rpm (Sorvall SS34 rotor) for 2 h at 4°C. The 
supernatant was discarded and the virus pellet lysed by resuspension in NTE buffer before 
adding EDTA and SDS to a final concentration of lOmM and 2% (w/v), respectively. 
Viral DNA was extracted 3 times with saturated phenol and once with cholorform, prior to 
precipitating with 2 volumes of EtOH by gentle inversion. The DNA was pelleted by 
centrifugation in a Fison's Coolspin centrifuge at 2,000 rpm for 10 min. at RT. The DNA 
pellet was washed with 2/3 volume 70% (w/v) EtOH by gentle inversion and centrifuged 
as described above. The supernatant was discarded and the pellet air-dried for 15 min. 
before re-dissolving in dH20  containing RNaseA (50 pg/ml). The quantity o f DNA was 
determined by OD at 280nm.
3.18. Infected Cell DNA Preparation
Linbro plates with BHK cell monolayers were infected at a m.o.i. o f 5 pfu/cell at 
31°C. After 48 h the supernatant was removed and cells lysed by incubating with 2 ml 
lysis buffer for 4 h at 37°C. NaCl was added to a final concentration of 200mM and 
infected cell DNA extracted twice with an equal volume o f phenol and once with 
chloroform, precipitated by the addition of 2 volumes of EtOH, and dried in a vacuum 
dessicator. The DNA was dissolved in 400 pi of water containing 50 pg/ml RNaseA. 
Restriction digests were carried out on 5% of the total sample.
3.19. Transfection of Virus DNA by C aP04 and DMSO Boost
Viral HSV DNA and plasmid DNA were diluted to the desired molar ratios and 
placed in an Eppendorf tube. The following were added to the DNA, 400 pi HEBS 
(pH7.5) and calf thymus DNA (10 pg/ml). These were mixed and spun down in a micro­
centrifuge and CaCl2  added to a final concentration of 130mM. The samples were left at 
RT for 30 min. and added to a fresh confluent monolayer of BHK cells in 60mm plates, 
from which the medium had been removed. Following incubation at 37°C for lh, cells 
were overlaid with 4 ml ETC 10 and incubated at 37°C. Four hours later the media was 
removed from plates and the plates washed twice with ETC 10. For exactly 4 min. the cells
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were overlaid with 1 ml 25% (w/v) DMSO in HEBS at RT. Four ml ETC 10 was added 
immediately and subsequently the plates were washed twice with 4ml o f ETC 10, and 
overlaid with 4 ml ETC 10. Plates were incubated at 37°C until c.p.e. was complete. Cells 
were scraped into the medium and pelleted by centrifugation at 2,000 rpm (Fison’s 
Coolspin) for 10 min, resuspended in 1 ml medium, sonicated and stored the virus at -70°C 
until further use (Section 3.15).
3.20. One-cycle Replication Kinetics
Plates (30mm) were seeded with 2x l0 6  cells/plate in 2 ml ETC 10 and grown
overnight at 37°C and 5% C02. Growth media was poured off and 100 pi o f the virus (10 
pfu/cell) added. The plates were returned to 37°C and 5% C 0 2  for 1 h. Plates were 
washed with 2 ml PBS-A/10%CS and overlaid with 2 ml ETC 10. This was time point 0 h. 
Plates were incubated at the appropriate temperature and harvested at the designated time 
points (usually 0,2,4,6,8,12, and 24h) by scraping the cell monolayer into the medium and 
transferring the suspension to a sterile bijou bottle (Harland and Brown, 1997). The 
samples were sonicated and stored at -70°C until the experiment was complete (at most 72 
h post infection). The samples were quickly thawed, diluted and plated as described in 
Section 3.15.
3.21. Multi-cycle Replication Kinetics
Thirty mm plates were seeded with 2x10^ cells/plate in 2 ml ETC 10 and grown 
overnight at 37°C with 5% C02. Growth media was poured off and 100 pi o f the virus 
(0.01 -0.001 pfu/cell) added. The plates were returned to 37°C and 5% C 0 2  for 1 h. After 1 
h the plates were washed with 2 ml PBS-A/10%CS and overlaid with 2 ml ETC 10. This 
was time point 0 h. Plates were incubated at the appropriate temperature and harvested at 
the designated time points (usually 0,4, 8 , 12, 24, 48, 72 and 96h) by scraping the cell 
monolayer into the medium and transferring the suspension to a sterile bijou bottle 
(Harland and Brown, 1997). The samples were sonicated and stored at -70°C until the 
experiment was complete. The samples were quickly thawed and plated as described in 
Section 3.15.
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3.22. Southern Blot and Hybridization
Purified DNA was digested with the appropriate restriction enzyme(s) before 
electrophoresing on a 1% (w/v) agarose gel. The gel was visualised under a short wave 
UV light to confirm DNA digestion then placed in a bath containing Gel Soak I for 1 h at 
RT. After rinsing with dH20  the gel was incubated in Gel Soak II for 1 h at RT and rinsed 
as above. Finally, the gel was incubated in 20xSSC for 1 h at RT.
A pack of 'Hi-Dry' towels was stacked on the bench followed by 3 sheets of dry 
Whatmann 3MM paper. On top were 3 sheets of pre-soaked 3MM paper and 1 sheet of 
nitro-cellulose membrane (Hybond N) in 20xSSC. The gel was placed on top and cling 
film was wrapped around the top. A glass plate and heavy weight were placed atop and 
this was left overnight to transfer DNA. To transfer DNA to two membranes this 
procedure was repeated on top of the gel. A UV crosslinker was used to cross link the 
DNA to the membrane. The membrane was allowed to dry and placed in a glass bottle and 
hybridization buffer added. The membrane was incubated in a BioRad oven at 65°C 
overnight. The membrane was washed twice in wash solution at 65 °C for 30 min. Finally, 
it was dried for 15 min. at 80°C. The membrane was exposed to XS1 film making sure 
that it was 1 0 0 % dry each time it was exposed.
3.22.1. Radiolabelling DNA
Twenty-five ng template DNA in dH20  in a final volume of 11 pi was placed in a 
tube and denatured by heating in a boiling water bath for 1 0  min. followed by chilling 
quickly in an ice bath. The DNA was pulsed in a micro-centrifuge and placed on ice while 
4 pi of High Prime enzyme and buffer was added (Boehringer Mannheim). Five pi 
(50pCi[a32P]dCTP] was added and the tube was incubated for 15 min. at 37°C. The 
reaction was stopped by placing the tube in a boiling water bath for 10 min. After boiling, 
the radiolabelled probe was used with the blot as described in the Southern blot and 
hybridization section (3.22).
3.23. Indirect Immunofluorescence
Linbro wells containing coverslips were seeded at 0.5-5xl0 5 cells/well and grown 
overnight at 37°C with 5% C02. The cells were infected at a low moi (0.1 pfu/cell) for 6  h. 
After infection the cells were fixed by removing the medium and washing three times with
PBS-A and adding 0.5 ml Fix solution for 10 min. at RT. Coverslips were washed 3 times
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with PBS-A and a block was performed with 100 pi PBS-A/1%CS at 4°C overnight. The 
PBS-A/1%CS was removed and 500 pi Permea mix was added for 5 min. at RT. 
Coverslips were washed 3 times with PBS-A. The primary antibody was diluted to the 
desired concentration in PBS-A/1%CS and 20pl placed in the centre of a well on the lid of 
the Linbro dish. After wiping off excess fluid, the coverslips were carefully placed, cells 
facing down, on the antibody. Coverslips were incubated in the primary antibody for 1 h 
at RT. Coverslips were placed back in the wells, cells facing upwards, and washed 6  times 
with PBS-A. The secondary antibody FITC goat anti-rabbit IgG was diluted 1/100 in 
PBS-A/1%CS. Twenty pi drops were placed in the lid as described above, coverslips 
incubated at RT for 30 min. and washed 6  times with PBS-A.
Coverslips were mounted by dipping in H20  and drying on a paper towel at RT 
until dry. A small drop of mounting fluid was placed on a glass slide and the dry 
coverslip, cells facing down, placed on the drop. A longer period o f storage required 
painting clear nail varnish around the edges of the coverslips to prevent drying.
3.24. Protein Expression in Infected Cell Extracts
Virus stocks were used to infect 60mm plates containing 4x l0 6  cells with
20pfu/cell as described in Section 3.21. Plates were incubated for the desired time at 
37°C. Samples were harvested by removing media and washing infected cell monolayers
twice with cold PBS-A. The monolayers were taken off in 300 pi lx  BM.
3.25. SDS-PAGE
Polyacrylamde gel electrophoresis was used to visualise viral and cellular proteins. 
Unless otherwise stated the routine percentage of acrylamide used in this work was 10% 
polyacrylamide using 2.5% (w/v) crosslinker. These are single acrylamide gels, but 
gradient acrylamide gels were also used in this study. In the resolving gel a gradient o f 5 
to 12.5% acrylamide is made using a gradient mixer.
Slab gels were cast vertically in a sandwich consisting o f 2 glass plates separated 
by 1.5 mm perspex spacers. The resolving gel was prepared using RGB with 0.06% (w/v) 
APS and 0.4% (v/v) TEMED. A 1 ml layer of butan-2-ol was poured on top to exclude air 
and enable polymerization of the gel. Prior to adding the stacking gel, the butan-2-ol was 
removed and the surface of the running gel rinsed with dH20 .
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The stacking gel was composed of 5% acrylamide crosslinked with the same ratio 
of NjN’-methylene-bisacrylamide used in the resolving gel. The SGB was mixed with 
0.06% (w/v) APS and 0.04% (v/v) TEMED. This was poured on top o f the resolving gel 
and allowed 30 min. to solidify.
Gels were electrophoresed either for 3 to 4 h at 50mA, or overnight at 10mA 
(Marsden et al, 1978).
Gels were either prepared for Western blot (Section 3.26) or fixed and stained in a 
solution o f Me0 H:C2 H4 0 2 :dH2 0  (50:7:50) with 0.2% (w/v) Coomassie Brilliant Blue 
R250 for 30 min. at RT. Gels were destained for a minimum of 1 h twice in a solution of 
M e0H:C 2H4 0 2 :dH20  (5:7:88). Gels were either dried under a vacuum and exposed to 
Kodak XS-film, or enhanced in 3 volumes of En3Hance (New England Nuclear) for 1 h at 
RT, washed in H20  twice for 30 min., before drying under a vacuum and exposed for 
flurography at -70°C.
3.26. Western blot of ICP34.5
Samples were electrophoresed through a 10% SDS-PAGE gel as described above. 
Nitro-cellulose ECL membrane (Amersham) and two 3MM Whatmann paper was cut to 
the same size as the gel and pre-soaked in Towbin buffer. The proteins in the gel were 
transferred to membrane for either 3 h at 250mA, or overnight at 50mA. After 
transferring, the membrane was blocked in PBS-A/T (PBS-A and 0.05% Tween 20) 
containing 5% (w/v) Marvel milk for 1 h at RT. The membrane was washed in PBS-A/T 
2x 15 min. The primary antibody was diluted to the desired concentration in 25 ml PBS- 
A/T and incubated at either 37°C for 2 h or 4°C overnight. The membrane was washed in 
PBS-A/T 3 times for 15 min. at RT. The membrane was incubated in HRP conjugated 
secondary antibody at RT for lh  followed by 3 washes in PBS-A/T for 10 min. each. A 
detection reagent (ECL) was added to the membrane for lmin. and the membrane was 
exposed to the blot to XS-1 film for the desired amount of time.
3.26.1. Western blot Renaturation of Proteins
Proteins were separated by SDS-PAGE and electrophoretically transferred to a 
nitrocellulose membrane in cold 25mM Tris, 192mM glycine (pH8.3), without MeOH. 
The transfer was carried out in a 4°C room. The filter was blocked by incubation in 30mM 
HEPES, pH 7.5, containing 100 pg/ml phenol extracted salmon sperm DNA as the
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blocking agent. The filter was incubated in 100 ml denaturation buffer for 1 h at RT. The 
filter was washed several times in cold renaturation buffer and incubated in 500 ml 
renaturation buffer for 16 h at 4°C. This denaturation and renaturation procedure was 
adapted from the method of Hager and Burgess (1980).
3.27. Immunoprecipitation of ICP34.5
Cell monolayers, in Linbro well plates, were infected with virus at a moi of 10 and 
treated the same as described in the virus and host cell protein synthesis shutoff section. 
At the desired time(s), cells were scraped into the medium and into a 15 ml Falcon tube, 
centrifuged for 15 min. at 3,000 rpm (Fison's Coolspin) at RT. The supernatant was 
discarded, the pellet resuspended in 1 ml PBS and pipetted into a new Eppendorf tube. 
The tube was centrifuged at 10,000 rpm (microfuge) for 5 min. The supernatant was 
discarded, the pellet resuspended in 800 pi ice cold Buffer E, and placed on ice for 15 min. 
The sample was clarified by centrifugation at 7,000 rpm (microfuge) for 15 min. at 4°C. 
The pellet was kept and stored in 100 pi dH20  at -70°C in case lysis was not complete. 
The supernatant was pipetted into a fresh Eppendorf and either used immediately or stored 
at -70°C. Fifty pi o f the supernatant was added to 150 pi Buffer A and 50 pi antibody in 
an end-to-end mixer at 4°C overnight. After overnight mixture 75 pi protein A sepharose 
50% (v/v) in Buffer E was added and the sample placed back on the mixer for 1 h at 4°C. 
After 1 h the sample was centrifuged at 10,000 rpm (microfuge) at 4°C for 5 min. The 
supernatant was removed and placed in a new Eppendorf tube. The pellet was washed 
twice with Buffer EB and once with Buffer EN. After the final wash the pellet was 
resuspended in 50 pi BM. Samples were analysed on SDS-PAGE.
3.28. Virus and Host Cell Protein Synthesis Shut-off
Replicate cultures were either mock infected or exposed to virus for 1 h at 37°C. 
The inocula were removed, the cells washed twice with 2 ml Emet/5C2, and overlaid with 
Emet/5C2 . At different times after infection the media was poured off and Emet/5C2 
containing 50pCi/ml o f [3 5S]-methionine (specific activity, >1,000 Ci/mM) added to 30
mm plates for 1-2 h. The cells were then harvested, solubilized, subjected to
electrophoresis in denaturing polyacrylamide gels, transferred to nitrocellulose sheet and 
autoradiographed.
79
M ethods: 3
3.29. ICP34.5/GST Fusion Protein, Growth and Purification
Bacterial cultures (NM522) were grown overnight in 5 ml. These cultures were 
diluted 1/10 in 2xYT broth and grown in a shaking 37°C incubator to an OD of 0.5 (3 h). 
Varying concentrations o f IPTG were added (starting with 0.1 mM) and the cultures placed 
back in the incubator for 2 h. After 2 h 10 pi of this culture was retained to visualize on the 
gel later. The remaining culture was centrifuged at 10,000 rpm (microfuge) at 4°C for 10 
min. The supernatant was discarded and the pellet resuspended in 300 pi ice cold PBS-A. 
Cells were lysed using a soniprobe. Samples were centrifuged at 10,000 rpm (microfuge) 
for 5 min. at 4°C. The supernatant was transferred to a fresh Eppendorf and the pellet was 
stored at -70°C to visualize on a gel later. Twenty pi o f 50%(v/v) Glutathione beads were 
added to the supernatant and mixed for 5 min. at RT. Samples were centrifuged at 10,000 
rpm (microfuge) for 5 min. at 4°C. The supernatant was discarded and 100 pi of PBS-A 
added to the pellet, vortexed, and centrifuged for 5 min. at RT. This was repeated twice. 
The fusion protein was eluted by adding 10 pi glutathione elution buffer, vortexing and 
leaving at RT for 5 min. Samples were centrifuged at 10,000 rpm (microfuge) for 5 min. 
at RT. The supernatant was placed in a fresh tube and 30 pi lxBM  (Section 2.12.6.) 
added. BM was also added to the bead pellet, loaded in a well and analysed by SDS- 
PAGE.
3.30. Production of HSV-2 ICP34.5 Antisera
Two New Zealand White rabbits were immunised intramuscularly first with 2 ml 
o f protein containing 1 mg ICP34.5 in Freund's complete adjuvant 100% (v/v) followed by 
6  boosts, each 14 days apart, using the same amount of antigen but in Freund's incomplete 
adjuvant. Animals were bled 10 days after each boost and the antisera tested against HSV- 
1 strain 17+ and HSV-2 strain HG52 infected cell extracts for reaction with ICP34.5 
specific bands.
3.31. Fractionation of ICP34.5
Confluent monolayers in 90mm plates were infected with virus at a m.o.i. of 10 
pfu/cell at 37°C at 5% C0 2  for 6  h and 16 h. Plates were harvested by scraping the 
monolayer into the media. The suspension was poured into a 15 ml Falcon tube and spun 
at 3,000 rpm (Fison’s Coolspin) for 10 min. at 4°C. The cell pellet was rinsed with 1 ml 
PBS-A and put into an Eppendorf tube. Samples were centrifuged at 3,000 rpm
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(microfuge) for 5 min at 4°C. The supernatant was decanted and the pellet resuspended in 
1 ml Hypotonic buffer. This buffer lysed the samples which were left on ice for 5 min. 
After incubation the samples were briefly vortexed and the centrifuged at 10,000 rpm 
(microfuge) for 10 min. at 4°C to pellet the nuclei. The supernatant was left on ice while 
the pellet was rinsed with 1 ml PBS-A and centrifuged as described above. After 
centrifugation the PBS-A was decanted and the pellet resuspended in 100 pi BM. Thirty 
pi of the cell supernatant was pipetted into a fresh Eppendorf tube and 70 pi BM added to 
it. Samples were boiled for 10 min. and electrophoresed on a SDS-PAGE and Western 
blotted.
3.32. Pull-down
Freshly prepared glutathione agarose beads with bound ICP34.5/GST fusion 
protein (50 pi of a 50% (v/v) slurry) were mixed with 300 pi labeled cell protein extract 
and incubated for 1 h at 4°C with continuous mixing. The beads were harvested by brief 
centrifugation and washed 3 times in 1 ml Buffer C. The beads were mixed with 100 pi 
SDS-polyacrylamide gel loading buffer, boiled for 10 min., analysed by SDS-PAGE and 
either fixed, dried and autoradiographed, or used for Western blotting.
3.33. In vivo Studies
ICP34.5 mutant viruses demonstrate an avirulent phentoype in vivo and 
recombinant viruses were examined by the following in vivo methods.
Intracranial (Section 3.34) and footpad (Section 3.35) injections under Prof. 
Brown’s project licence (No. PPL/60/2215) were performed under my personal licence 
(No. PIL/60/6414).
Snout infection (Section 3.36), harvesting snout and trigeminal ganglia for 
replication kinetics (Section 3.36.1), and harvesting trigeminal ganglia for 
immunohistochemistry (Section 3.36.2) were carried out in Dr. Sawtell’s laboratory 
(Children’s Hospital, Cincinnati, USA).
3.34. Intracranial LD50
Three week old BALB/c mice were inoculated intra-cerebrally with single virus
stocks. Mice were anaesthetised by inhalation of halothane and 25 pi of the appropriate
virus dilution in PBS-A/5%CS inoculated into the central region o f the left cerebral
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hemisphere. Four mice were inoculated with each virus dilution (doses were in the range
1 7
of 10 to 10 pfu/mouse). Stocks were always re-titrated on the day of inoculation to 
ensure correct dose administration. Mice were observed daily up to 21 days post 
inoculation for signs o f illness or death, and the LD50 for each virus calculated according to 
the formula of Spearman-Karber (Wardlaw, 1987).
Any mice which died within the first 16 h were assumed to have been killed by the 
anaesthetic/injection protocol and were excluded from the experiment. The formulae used 
to calculate LD 50 was the following:
Log10LD5 0 = m -  A(Zp-0.5)
A = the constant interval between the log 10 dilutions ( = 1). 
m = log 1 0  dilution corresponding to the lowest giving death.
For instance, where there is not 100% death, it is assumed that 100% death would follow 
with a dose which is 1 0 -fold higher than the largest dose, 
p = the mortality fraction at each dilution as a decimal.
For instance, where mice die at the lowest dose given, it is assumed that a dose which is
1 0 -fold lower would produce no deaths.
3.35. Footpad Infection
As described by Clements and Subak-Sharpe (1983,1988), 4 week old female 
BALB/c mice were inoculated in the right rear footpad with different doses of virus diluted 
in PBS-A/5%CS. Twenty-five pi of virus were injected into the right rear footpad. To
study virus replication, at days 0 ,2 ,4,6 ,8 ,and 1 0 , 2  mice per virus were killed by cervical
dislocation, their right rear footpad washed with 70% EtOH, severed, and placed in an 
Eppendorf tube on dry ice.
3.35.1. Co-cultivation/Latency Reactivation
Female 4 week old BALB/c mice were infected in the right rear footpad as 
described above. Following inoculation, the virus stocks were re-titrated to ensure correct 
dosage. The mice were housed for 40 d. All surviving mice were given a lethal dose of 
pentobarbitone intraperitoneally and ex-sanguinated. They were dissected under a 
microscope (Opmid-Zeiss) and 10 ipsilateral DRG dissected and separately placed into 
microtitre plates containing 200 pi ETFClO/well (Fig. 13, 14). The DRG media was 
removed every second day and placed on fresh BHK cell monolayers and fresh 200 pi
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Figure 13. In  vitro reactivation method.
a. BALB/c mice were infected with viruses in the right rear footpad. Latency 
was established in the DRG. Forty-one days pi mice were exsanguinated and 
DRG dissected, b. View of the spinal cord from the side (i.) and from the top (ii.). 
This representation of the spinal cord shows the location of individual ganglia.
One of the thoracic ganglion (T12), 6 lumbar ganglia (L1-L6), and 3 sacral ganglia 
(S I-S3) were dissected (Adapted from Bloom, 1998).
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Figure 14. In  vitro reactivation method.
a. Diagrammatic representation of a cross section from a single DRG. Only the right 
side DRG was dissected, b. An individual dorsal root ganglion was placed into a 
microtitre well containing media (Adapted from Engel, 1997).
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pipetted onto the ganglia. The BHK cells monolayers were examined for the presence of 
plaques or c.p.e. Reactivation frequency was measured by percentage o f total ganglia that 
reactivated per virus dose. Supernatant that contained reactivating virus was used to infect 
a 24 well plate with a fresh BHK monolayer to prepare DNA to confirm the genome 
structure by Southern blotting.
3.36. Snout Infection
Four to 7 week old outbred Swiss Webster mice (Harland Laboratories) were 
intraperitonially injected with 1 0 0  pi pentobarbitol, anesthetized, and bilaterally inoculated 
via snout scarification with l x l 0 5pfu in 1 0  pi per side.
3.36.1. Harvesting Snout and Trigeminal Ganglia for Replication Kinetic
Analysis
On days 1 through 6  pi, animals (n=3 per day for each virus) were sacrificed by a 
lethal dose of sodium pentobarbitol intraperitoneally. Mice were decapitated and snouts 
disinfected by rinsing in 70% EtOH, each side removed snap frozen and stored at -70°C.
Trigeminal ganglia were dissected using sterile razor blades and forceps, snap 
frozen on dry ice and stored at -70°C. Once the experiment was complete, snouts were 
ground in a porcelain pestle and mortar with liquid nitrogen, homogenized in 1 ml glass 
pestle and mortar with 1 ml DMEM10 and debris pelleted by 10 min. centrifugation at
10,000 rpm (microfuge) at 4°C. Trigeminal ganglia were directly placed in a 1 ml glass 
pestle and mortar and homogenized in 1 ml DMEM10. Supernatants were titrated on RSC 
and virus yield obtained as pfu/ml.
3.36.2. Harvesting Trigeminal Ganglia for Immunohistochemistry Analysis
3.36.2.1. Perfusion
Mice were administered a lethal dose of pentobarbitol intraperitoneally. The heart 
rate was carefully monitored and as it slowed down the ventral abdomen was cut open and 
the diaphragm cut and the left atrium pierced with a needle connected to a peristaltic pump 
with 0.5% (v/v) paraformaldehyde. The right heart was bled out with forceps. Once the 
colour of the liver turned yellow, an indicator that perfusion had reached peripheral organs, 
the pump was turned off and the trigeminal ganglia dissected.
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3.36.2.2. Embedding
Trigeminal ganglia from perfused mice were aseptically placed in 1 ml 4% (v/v) 
paraformaldehyde for 1 h at RT with constant mixing. This was followed by 30 min. 
incubation in a graded series of EtOH (90, 95%, and 100%) and two 1 h incubations in 1 
ml xylene. Trigeminal ganglia were placed in a metal tray and melted paraffin was poured 
over the top and allowed to cool. Filling of the tray was carried out by pouring additional 
melted paraffin on top. A plastic tray was gently pushed on top and the unit placed on ice 
for 30 min. to solidify. Five pm thick sections were cut on a microtone. These were stored 
or deparaffinized for immediate use.
3.36.2.3. Immunohistochemistry
Slides were placed in a rack and put into a bath containing xylene for 15 min. The 
rack was moved to a bath containing 100% EtOH for 15 min., 70% EtOH for 15 min. and 
PBS-A for 15 min. The rack was placed in a bath containing H20  to rinse the sections then 
transferred to a bath with MeOH (with 0.5% (v/v) H 20 2) for 10 min. Slides were rinsed in 
PBS-A for 15 min and a blocking PBS-A solution (0.5% (v/v) NP40 and 5% Marvel milk) 
was pipetted directly onto each section and incubated in a humidified cassette for 30 min. 
An additional blocking step was carried out in "normal blocking serum" for 20 min. Slides 
were placed back in a rack and rinsed thoroughly in a PBS-A bath for 15 min. 
Localization o f HSV antigens was performed by using a three-step biotin-avidin 
peroxidase system. The primary rabbit anti-HSV-1 (DAKKO) was diluted to 1/1000 in 
PBS-A, adsorbed with mouse liver acetone powder and pipetted directly onto each section 
as described above and the sections incubated for 1 h at RT. Slides were placed in a rack 
and washed 3 times for 15 min. in a fresh PBS-A bath. Sections were incubated with 
biotinylated goat anti-rabbit IgG (Vector Laboratories), absorbed with normal mouse 
serum diluted 1/100 with PBS-A, for 30 min. as described above. Slides were placed in a 
rack and washed in a fresh PBS-A bath for 15 min. 3 times. Sections were incubated in 
Vector® NovaRED™  peroxidase substrate solution for 5 min. Slides were rinsed in a H20  
bath and observed under a microscope.
Counterstaining o f nuclei was performed in a bath with Mayer's Haematoxylin for 
1 min. followed by rinsing in H20  (Bancroft, 1982). Mounting o f slides (Histomount) was 
done after taking slides through 3 graded EtOH baths (90%, 95% and 100%) for 10 min. 
and 2  xylene bath's for 1 0  min.
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4. HSV-1 RESULTS AND DISCUSSION
4.1. CONSTRUCTION OF HSV-1 RECOMBINANT VIRUSES
4.1.1. Introduction
In 1983, Thompson et al mapped a HSV neurovirulence locus to a region in 
the long repeat sequences using an HSV-l/HSV-2 intertypic recombinant virus, RE6 . In 
1986, Chou and Roizman demonstrated that the a sequence contained the promoter 
regulatory element and transcription initiation site o f a gene named RL1 in HSV-1 strain F. 
RL1 expresses the protein ICP34.5, which was detected using an antiserum directed 
against a synthetic peptide containing a PAT repeat present within ICP34.5 (Ackermann et 
al., 1986). Several groups (see Introduction) identified that viruses which do not express 
ICP34.5 have a reduction in replication in certain cells in vitro and are avirulent upon 
intracranial inoculation in the murine model in vivo.
In 1994, Lagunoff and Roizman identified 16 open reading frames (ORF A-P) 
that are located in the antisense direction to RL1 within the LAT transcript in the long 
repeat sequences in strain F. Two ORFs (O and P) mapped almost entirely antisense to 
RL1 and expression o f the ORF O and P proteins was subsequently demonstrated 
(Lagunoff and Roizman, 1995) by mutagenising the ICP4 binding site which causes 
repression of ORF O and P transcription.
In 1991, MacLean, A. et al., isolated a spontaneous deletion variant (1716) in 
HSV-1 strain 17+ (Fig. 8 ) which has 759 bp of the long repeat region deleted. As the 
mutant 1716 lacks both RL1 and ORF P it became important to identify whether there 
were individual phenotypes associated with each of these genes. We hypothesized that 
recombinant viruses expressing either RL1 or ORF P would elucidate the individual 
phenotypes o f each gene.
4.1.2. Construction of Mutant Viruses: 1622 and 1623
Two new recombinant viruses were constructed in a 1716 background and named 
1622 and 1623. 1622 and 1623 express only ICP34.5. To generate viruses 1622 and 1623 
several plasmids were sub-cloned and are described in detail below.
4.1.3. Construction of pFJ14H
The plasmid pFJ5AHind was altered in order to attain lacZ  as a selection marker
and the HSV-1 gD promoter to transcribe the gene of interest (Fig. 15). pFJ5AHind,
originally constructed by Rixon and McLauchlan (1990), was digested with Sail and
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pF J14
7.80 kbp
Hindi/!
pFJ14H
7.80 kbp
BcimxU
1
P2 fro m  p R E D I2 2
p F J 5 A H in d
HHOLl:AGCTT\G \TCTCCATGGCCCGGGA 
HHOL2: A 1C TAG \GGTACCGGGC < ( IK  (. \
H im  t i l l  /f  .£,'//1 N co\ Snm \ H ind  111
Legend
P I =  S V 4 0  e a r ly  p r o m o t e r
T 1 =  S V 4 0  e a r ly  p o ly a d e n y la t io n  s e q u e n c e s
P 2  =  H S V -1  g D  p r o m o t e r
T 2  =  H S V -2  I E 5  p o ly a d e n y la t io n  s e q u e n c e s
Figure 15. Construction of pFJ14H.
a. pFJ5AHind (Rixon and McLauchlan, 1990) was first digested with Sall/HindlU
to remove the CAT gene. The gD promoter was isolated from pRED122 by digestion 
with HindllVXhol and was ligated into pFJ5AHind generating pFJ14 (see text for full details).
b. An oligonucleotide linker was synthesized whose sequence is shown, c. The oligonucleotide 
was cloned into the HindlU site to generate pFJ14H.
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H indlll to remove the chloramphenicol transferase (CAT) gene (MacLean, A., 
unpublished) (Fig. 15a). pRED122 (Everett^ 985), was digested with Xhol and Hindlll to 
isolate the HSV-1 gD promoter (403 bp) as described in Section 3.5. Ligation of the gD 
promoter into pFJ5AHind generated pFJ14 (MacLean, A., unpublished) (Fig. 15a).
Two complementary oligonucleotides containing multiple restriction enzyme sites 
were synthesized for sub-cloning of different genes into pFJ14. The sequence is shown in 
Figure 15b. The oligonucleotides were ligated into the single Hindlll site of pFJ14, to 
yield pFJ14H (Fig. 15c).
4.1.4. Cloning RL1 under the gD Promoter
The plasmid pGEM34.5 contains a 1.46 kbp AlullRsal fragment (125074 to 126530 
n.p.) containing the RL1 and ORF P sequence. pGEM34.5 was originally cloned by 
McKie (1994). The RL1 sequence was derived from the HSV-1 BamHYk' fragment 
pBAM'k'/pAT153 (Davison, 1981) (Fig. 16). Two different fragment lengths of RL1 were 
obtained by restriction enzyme digestion and isolation by a 1 % (w/v) agarose gel.
First, the 784 bp ORF of RL1 was obtained by a Ncol (n.p. 125859) and BamHl 
(from pGEM34.5) digest of pGEM34.5 (Fig. 17a,e). Second, a larger RL1 fragment 
containing 134 bp upstream of the RL1 ORF sequence, including the 5’ untranslated leader 
and part of promoter (Chou and Roizman, 1986) was obtained by digesting pGEM34.5 
with Dral (125985 n.p.) and BamHl (from pGEM34.5; Fig. 17a). The difference between 
the predicted fragment length from the HSV-1 restriction enzyme n.p. and the actual 
fragment length is due to additional base pairs from pGEM34.5 which were acquired by 
using the BamHl site downstream of Alul.
The two RL1 and ORF P fragments were individually sub-cloned into pFJ14H 
using compatible restriction enzyme sites. In order to successfully clone the 784 bp RL1 
fragment an extra step was needed. Because pFJ14H contains two Ncol sites it was 
partially digested (Fig. 18a, b). Ligation of these genes into pFJ14H positioned the gene 
immediately downstream of the HSV-1 gD promoter and directly upstream of the HSV-2 
immediately early IE5 polyadenylation sequences. pFJ14H contains lacZ under the 
control o f a SV40 promoter with its own SV40 polyadenylated sequence (Fig. 19). The 
lacZ gene is in the opposite orientation as the inserted RL1 genes. pFJ14H derived 
plasmids were digested with Xbal and RL1 or ORF P with lacZ were isolated from pFJ14H 
and gel purified.
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s e c a m  a ’ t p u g v  r w b ’d h o i f c ’ I b s q y n  j z x y q
I 11 I
b. B am H l  f r a g m e n t s  M o le c u la r  s iz e  I k b £ l
a 1 2 4 7 4
b 1 0 1 3 7
c 9 8 3 5
d 9 2 7 3
e 8 9 1 3
f  8 0 5 5
g  7 7 7 4
h 7 5 3 9
i 6 6 4 0
j 6 4 5 7
k 5 9 4 4
I 5 3 7 2
m 5 1 0 5
n 4 8 9 0
o 3 8 6 6
pq  3 5 7 9 /3 4 3 6
r 3 3 6 5
s t 2 9 0 7 /2 8 4 8
u v  2 2 9 4 /2 2 9 1
w 2210
x y z  1 9 5 3 /1 8 4 0 /1 8 4 1
a ’ 1 5 4 4
b ’ 1313
c ’ 9 2 8
d ’ 8 6 3
e ’ 7 9 7
f g ’ 7 6 7 /7 6 4
h ’ 7 1 7
i’ 6 6 2
j ’ 5 1 7
k ’ 2 2 0
1’ 15 6
m ’ 15 6
n ’ 9 0
Figure 16. Schematic representation of the HSV-1 genome Bam H l sites with 
molecular sizes.
a. A schematic representation of the forty BamHl sites within the HSV-1 sequence 
(Davison, 1981). b. A quick reference to the molecular weights of each fragment. 
Several of the fragments are so small they are indistinguishable by regular agarose 
gel methods The fragments d' through n’ ( Q  ) are not represented in part a.
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Figure 17. A schematic representation of RL1 cloning.
a. pGEM34.5 containing RL1 from HSV-1 was digested either with Ncol 
and BamHl yielding a 784 bp fragment as depicted in (b) or with Dral and 
BamHl yielding a 918 bp fragment as depicted in (c). d. The digests were initially 
electrophoresed on a 1% (w/v) agarose gel with a 1 kbp DNA ladder (lane 3) and the desired 
fragments (►)were gel purified. Lane 1 shows the pGEM34.5 BamHl and Dral 
digest profile with 4 fragments. Lane 2 shows the pGEM34.5 BamHl and Ncol digest 
profile with 2 fragments, e. The purified RL1 fragments, lane 1, 918 bp RL1 fragment, 
lane 2, 784 bp fragment and lane 3, 1 kbp DNA ladder for size assessment. These 
fragments were sub-cloned into pFJ14H.
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pFJI4H
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Figure 18. Partial N col digestion of pFJ14H using EtBr.
a. Schematic representation of Ncol sites in pFJ14H. b. The full range of Ncol 
digestion patterns in pFJ14H electrophoresed through a 1% (w/v) agarose EtBr stained gel. 
Lanes 4 through 12 have varying partial digestions from a 1 h incubation with EtBr. Lanes 1-3 
and 12 are complete digestions of pFJ14H. Lanes 6, 8 and 10 are the best isolates of the correct 
7.8 kbp linear pFJ14H. Lane 14 is a 1 kbp DNA ladder giving correct size comparisons,
c. The linear pFJ14H DNA was cut out and purified. Amount of EtBr for partial 
digestion were as follows: lanes 1-3, 0 pg; lane 4, 0.1 pg; lane 6, 0.5 pg; lane 8, 1 pg; 
lane 10, 2 pg; lane 12, 5 pg.
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2  gDo RL1( 9 1 8bp) eo ly A poly  / hcZ SV40p 
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A m p
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Sp*l
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B glll
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N iil
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Amp
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Figure 19. Diagram of pH H l and pHH2.
a. Fragments containing the gene of interest, R L 1 784 bp (1), or R L1 918 bp (2) 
were separately digested from pFJ14H with Xba\ ligated into theSpel site of p35(PacI).
b. Ligation of oligonucleotides which were synthesized for additional cloning sites in the 
UL43 Nsi\ locus in p35 (MacLean, C. et a l 1991) to generate p35(PacI). c. The p35(PacI) 
containing different Xba\ inserts were named pHHl and pHH2.
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4.1.5. Sub-cloning pFJ14H RL1 Fragments into p35(PacI)
In 1991, MacLean C. et a l, cloned a 5.1 kbp (n.p. 91610- n.p. 96751) BamHl- 
EcoBl fragment containing HSV-1 genes UL41 through UL45, into pUC19, to generate 
p35. This plasmid was digested at the Nsil site located within the UL43 gene (n.p. 94911) 
and a double stranded oligonucleotide linker (Fig. 19a) was inserted to generate plasmid 
p35(PacI) (Fig. 19b. (McGregor et al., in press). p35(PacI) was digested with SpeI (in 
linker; compatible with Xbal) allowing the RL1/ lacZ cassettes from pFJ14H to be ligated, 
generating plasmids pHHl andpHH2 (Fig. 19c).
4.1.6. Generation of 1622 and 1623
Plasmids pHHl and pHH2 were digested with Xmnl and co-transfected with 1716 
DNA onto BHK cells, as described in Section 3.19, to generate new recombinant viruses 
1622 and 1623, respectively (Fig. 20). The transfection plates were incubated until cpe 
was complete. The infected cells were centrifuged, virus released by sonication, and 
titrated on BHK cell monolayers. Two days post titration the media was removed and a X- 
gal overlay applied. Detection by X-gal staining allowed several individual recombinant 
virus plaques to be isolated and taken through two to three further rounds of plaque 
purification (Section 3.15). 1622 and 1623 DNA from each plaque isolate was screened by 
digestion with BamHl and Southern blotting (Fig. 21). 1622 has an extra BamHl site from 
the pFJ14H insert in p35(PacI) generating fragments of 7.8 kbp and 4.5 kbp (Fig. 21a, 
lanes 1-4). 1623 contains a BamHl site from the pFJ14H insert in p35(PacI) generating 
fragments of 4.6 kbp and 7.8 kbp (Fig. 21b, lanes 1-8). There is a slight variation in size 
from 4.5 kbp in 1622 to 4.6 kbp in 1623 due to the different lengths o f RL1 (134 bp).
By the third round of plaque purification, recombinant viruses were completely 
pure and a ten roller bottle stock of 1622 and 1623 was grown on BHK cells (Section 
3.13). A Southern blot was carried out to verify purity and DNA integrity was maintained 
after growth of stocks (Fig. 23). Wild type, 17+ and the RL1 deletion virus, 1716, have one 
BamHl fragment of 6 . 6  kbp spanning the UL41 to UL44 sequence, when digested and 
probed with [3 2 P] radiolabelled p35(PacI) (Fig. 22). 1622 and 1623 have a BamHl site 
from pFJ14H within the HSV sequence in p35(PacI) generating two fragments as 
previously described (Fig. 22).
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Nsil/Spel
U L 4  3 /  
U L 4 3 .5
X
1716
1622
1623
Figure 20. Schematic representation of recom binant viruses.
1716 was used as the parental strain for the listed recombinant viruses. 1622 has the 
HSV-1 RL1 open reading frame. 1623 has the RL1 ORF and 134 bp upstream sequence. 
The basic construct depicts that these genes have been inserted downstream of the 
HSV-1 gD promoter and upstream of the HSV-2 IE5 polyadenylation sequence. These 
recombinant viruses also have lacZ in the opposite orientation for selection upon X-gal 
staining. Denotes the RL1 deletion in 1716.]
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Figure 21. Southern blots of 1622 and 1623 plaque purification
a. DNA from four 1622 plaque isolates (lanes 1-4) was digested with BamHl, 
electrophoresed through a 1% (w/v) agarose gel, Southern blotted and probed with 32P 
labelled p35(PacI). The nitrocellulose was exposed to an autoradiograph o/n at -70°C. 
Band sizes are based on the 1 kbp DNA ladder (lane 5). b. DNA from 1623 plaque 
isolates was analysed by BamHl digestion. Eight plaque isolates (lanes 1-8) show the 
presence of the wild type 6.6 kbp band (►) and the two recombinant bands of 
4.6 kbp and 7.8 kbp. The fragment sizes were based on comparison 
with a 1 kbp DNA ladder (lane 9).
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Figure 22. Southern blot of viral DNA digested with BamHl.
a. A linear diagram illustrating the UL43 sequence in wild type and in recombinant viruses 
and sizes of BamHl fragments following digestion.
b. A Southern blot of DNA prepared from recombinant viruses, 17+ and 1716, stocks. This 
Southern blot shows DNA from virus stocks digested with BamHl, probed with [32P]dCTP 
p35(PacI) and exposed to an auto-radiograph for 5 h at -70°C. The single 6.6 kbp band in 
17+ and 1716 is the wild type BamHl fragment from UL41 to UL44. The recombinant 
viruses 1622 and 1623 have RL1 inserts in the UL43 locus which introduces a new BamHl 
site that cuts within the insert generating two bands, 4.6 kbp and 7.8 kbp. A 1 kbp DNA 
ladder is also shown to give accurate size comparisons.
97
Results and Discussion: 4.1
4.1.7. Discussion
Before recombinant viruses could be constructed sub-cloning was carried out. The 
first step required removing the CAT gene from pFJ5AHind and insertion of the HSV-1 gD 
promoter (P2) generating pFJ14. pFJ14 contained all the genetic components needed but 
could not easily be used to clone the RL1 gene because it did not contain compatible 
restriction enzyme sites. Two oligonucleotide linkers with additional restriction enzyme 
sequences was synthesised and inserted into the Hindlll locus o f pFJ14. The linker with 
extra restriction enzymes gave pFJ14 the new name pFJl4H.
Ncol was needed for the 5’ end o f the 784 bp RL1 fragment. This created the 
complexity of having two Ncol sites within the pFJ14H plasmid. As a result a partial 
digest was carried out. The linker also contained a Smal site which leaves blunt ends and 
yielded compatible ends for the 5’ Dral end of the 918 bp RL1 sequence. The plasmid 
pHHl contained the 784 bp RL1 sequence which was co-transfected with 1716 DNA to 
generate the recombinant virus 1622. The plasmid pHH2 contained the 918 bp RL1 
sequence which was co-transfected with 1716 DNA to generate recombinant virus 1623. 
These viruses are characterised in the subsequent sections.
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4.2. CHARACTERIZATION OF 1622
4.2.1. Kinetics of ICP34.5 Expression from 1622 Infection
Although published data states that ICP34.5 is synthesised late during infection, 
this laboratory has demonstrated (Harland, personal communication; this section) that wild 
type HSV-1 17+, expresses ICP34.5 as soon as 2 h pi. Following Southern blot 
confirmation that the structure o f the recombinant virus, 1622, was correct, the kinetics and 
level o f ICP34.5 expression were analysed. Western blot experiments confirm that 17+ and 
1622 express ICP34.5 at detectable levels by 2 h pi in BHK cells (Fig. 23, 24).
The levels o f ICP34.5 are similar between 1622 and 17+ up to 12 h pi (Fig. 23, 24). 
However, by 16 to 24 h pi there is an accumulation of ICP34.5 in 1622 infected BHK cells 
(Fig. 24). These Western blot results were obtained using a polyclonal antiserum, 137, 
which was raised against a GST/ICP34.5 fusion protein (Brown et al., 1997). There was 
no ICP34.5 detected in 1716 infected extracts, however there are two virally induced 
proteins, one o f 70 kDa and a second o f 40 kDa detected by 137. It is not known whether 
these proteins are cellular or viral but they appear by 6  h pi in 17+ and 1716 (Fig. 23) and 
by 12 h in 17+, 1716 and 1622 (Fig. 24). To determine if  137 had a higher affinity for 
ICP34.5 expressed in 1622, different antisera were used as described in the next section.
4.2.2. Western blot Analysis of ICP34.5 from 1622 Infection
Another polyclonal antiserum, R l, generated by the same method as 137 (Brown et 
al., 1997), used in Western blots, showed a higher level o f expression o f ICP34.5 in 1622 
compared with 17+ or strain F (Fig. 25a).
The ICP34.5 sequence analysis between HSV-1 strains has identified that HSV-1 
strain F has 10 copies o f PAT repeat, strain 17+ has 5, and strain KOS has 3. Migration of 
ICP34.5 by SDS-PAGE consequently varies according to the number o f repeats. An 
antiserum raised against a synthetic peptide, PAT10, was also used in Western blots 
(McKay, et al., 1993). This antiserum consistently reacts with and recognises ICP34.5 in 
HSV-1 strain F well because o f the 10 PAT repeats. Anti-(PAT)ioserum does not 
consistently recognise ICP34.5 in 17+ because it only has 5 PAT repeats. Western blots 
using anti-(PAT ) 1 0  serum again revealed that 1622 over-expresses ICP34.5 compared to 
strain F and 17+ (Fig. 25b).
Two-fold serial dilutions were made o f 1622 infected BHK cells 16 h pi to
ascertain a semi-quantitative level o f ICP34.5 expression compared to ICP34.5 expression
from 17+ (Fig. 26). This demonstrated that the level of ICP34.5 at the 1 to 8  dilution of
99
Results and Discussion: 4.2
220k Da
97.4kDa
66k Da
46kDa
30kDa
Time
< + I C P 3 4 . 5
2 h pi 4 h pi 6  h pi
Figure 23. W estern blot of ICP34.5 from infected BHK cells 2 to 6  h pi.
BHK cells were infected with viruses at a m.o.i. of 10 pfu/cell. Analysis of 
ICP34.5 expression was carried out on a 10% SDS-PAGE which was Western 
blotted with 137 antiserum and Protein A-HRP, reacted with ECL and exposed to 
an autoradiograph. A Rainbow™ high molecular weight marker (MWM) is 
shown. 17+ and 1622 show approximately the same level of ICP34.5 accumulation 
at 2 h pi. The level of ICP34.5 increases by 4 h pi in both 17+and 1622 , and 
again by 6 h pi. 137 recognises two proteins induced by 1716 and 17+ which 
migrate at 70 kDa (O ) and 40 kDa
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Figure 24. W estern blot time course of ICP34.5 expression.
BHK cells were infected with viruses at a m.o.i. of 10 pfu/cell. Cell extracts were 
analysed using 10% SDS-PAGE and Western blotting with 137, Protein A-HRP and 
reacted with ECL. The onset of ICP34.5 expression is detectable by Western blot 
between 2 h pi and 4 h pi in 17+ and 1622. Two proteins which have not yet been 
identified and react strongly with 137 and migrate at 70 kDa (o ) and 40 kDa (^ ). There 
are additional bands from the 1622 infection at 24 h pi (++ and +).
101
Results and Discussion: 4.2
a.
220kl)a
97.4kDa
66kDa
ICP34.5
(strain F)
46 kDa
ICP34.5
(strain 17+)
30k Da
21kDa
14kDa
rsC4SO
so b.
-25
-CU N O  
© C4 +5  so t -  r
«  i—i i— u .
220kD a----
97.4kDa----
66kDa
46 kDa
30kDa
*
u
m
21 kDa
ICP34.5
(strain F)
ICP34.5
(strain 17+)
Figure 25. ICP34.5 expression by W estern blot using different antisera.
BHK cells were infected with viruses at m.o.i. of 10 pfu/cell. Whole cell extracts 
were harvested at 16 h pi and analysed using a 10% SDS-PAGE, Western blotted 
and reacted with different ICP34.5 antisera. a. Western blot using Rl antiserum 
against GST/RL1 ORF fusion protein shows over-expression o f ICP34.5 from 1622 
compared with F and 17+. b. Western blot using (PAT)10 polypeptide antiserum 
generated against a synthetic peptide of 10 (PAT) repeats naturally occurring in 
HSV-1 strain F.
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Figure 26. Sem i-quantitative comparison of ICP34.5 from 1622 and 17+ infected 
BHK cells 16 h post infection.
A serial 2-fold dilution was made of 1622 infected BHK cell extracts 16 h pi. 17+ 
and 1622 infections were carried out at a m.o.i. of 10 pfu/cell. Samples were analysed 
using 10% SDS-PAGE Western blotted and reacted with 137. The dilution showing 
the closest level of ICP34.5 to 17+from 1622 is 1 in 8.
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1622 was close to the neat 17+ infected extract. This result yields an estimation that 1622 
expresses approximately 8  times more ICP34.5 than 17+.
As a further test that ICP34.5 expression in 1622 was genuinely more than in 17+ 
and not a reflection o f a better infection, a Western blot was carried out using an antiserum 
to another HSV protein. Expression of the 65 kDa DNA binding protein (UL42) was 
analysed by Western blot (Fig. 27). The infected cell extracts on this gel are the same neat 
extracts that were used in the Western blot o f ICP34.5 in the previous figure (Fig. 27). The 
level o f UL42 expression is slightly higher in 17+ compared to 1716, 1622 and F. This 
suggests that the overexpresssion o f ICP34.5 from 1622 is genuine and not a reflection of a 
better infection. It also shows that the level o f another viral protein is similar between wild 
type 17+, 1716 and 1622.
4.2.3. Detection of Native ICP34.5 Expression
To look at expression of ICP34.5 from 1622 infection in a more native form in 
vitro, two experiments were carried out: 1 ) immunopreciptation and 2 ) blot renaturation.
4.2.3.1. Immunoprecipitation of ICP34.5 from 1622 Infection
To examine the expression level o f ICP34.5 from 1622 an IP was carried out using 
137. Two different cell types, BHK and 3T6, were examined (Fig 28 and 29). A brief 
explanation of the fractions kept during IP will be given here followed by Western blot 
data. Cells were infected with 17+, 1716, 1622 and mock infected in duplicate at a m.o.i. 
o f 10 pfu/cell and harvested at 16 h pi. One set o f infections was exposed to
35[ S]methionine containing media from 14 to 16 h pi. The second set o f infected plates 
was unlabelled. All infected and mock infected cells were harvested and 
immunoprecipitated with 137 as described in Section 3.29. There were five fractions kept 
and visualised on these autoradiographs. First a fraction o f the infected whole cell extract 
(WCE). Second, following lysis of the cells a fraction o f the cellular pellet was kept in 
case ICP34.5 was insoluble and protein was lost in the debris (PELLET). Third, was a 
fraction of the supernatant which did not bind to the Ab (SN). Fourth, an IP was 
performed on a sub-fraction o f the pellet (PELLET BEADS). The fifth fraction was an IP 
performed with the original supernatant (SN beads) (as per protocol; Section 3.29).
BHK infected extracts were immunoprecipitated with 137 (Fig. 28). The samples
35which had been labelled with [ SJmethionine were analysed using a 10% SDS-PAGE. A
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Figure 27. W estern blot of BHK infected whole cell extracts using an 
anti-UL42 serum.
A monoclonal antibody against the UL42 65 kDa DNA binding protein 
was used in a Western blot to confirm that the virus infections were equal and 
accuracy of loading.There was no alteration in the expression of this protein in the 
recombinant viruses. These were the same extracts used in Figure 24.
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Figure 28. Im m unoprecipitation of infected BHK cell extracts using 137.
Samples were electrophoresed through a 10% SDS-PAGE. One set of samples were radiolabelled 
with 3:i[S]methionine until 16 h pi (a), the second set of samples were not radiolabelled (b).
a. The gel containing radioactive samples was dried down and exposed to a phospho-imaging 
screen o/n. b. The gel containing non-radioactive IP samples was Western blotted with 137. A 
fraction of the infected extracts was saved directly after harvest ( w c e ) .  The harvested samples 
were lysed and a fraction o f the cellular pellet kept for analysis ( p e l l e t ) .  A fraction of the 
supernatant which did not bind to beads was kept ( s n ) .  Sepharose beads were added to another 
fraction of the initial pellet ( p e l l e t  b e a d s ) and the lysed supernatant ( s n  b e a d s ) .  Separate infected 
BHK and 3T6 cells were included in this blot.* Indicates the strong recognition of the heavy chain IgG
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Figure 29. Im m unoprecipitation of infected 3T6 cell extracts using 137.
3T6 cells were infected with a m.o.i. of 10 pfu/cell in duplicate and harvested 16 h 
pi for IP. One set of samples were radiolabelled with 33[S]methionine for 14-16 h 
pi and immunoprecipitated with 137 (a). The second set o f samples was not exposed to 
radioactivity but immunoprecipitated and used in a Western blot with 137 (b).
a. The gel containing radioactive samples was dried down and exposed to a phospho- 
imaging screen o/n. ICP34.5 (☆) was identified from 17+ and 1622 infected cells from
the IP, p e l l e t  b e a d s  fraction. A cellular band migrates closely to ICP34.5 in 17+, 1716 and 162
b. The gel containing non-radioactive samples was blotted using 137. A fraction of the 
w c e  was saved directly after harvest. The harvested samples were lysed and a fraction of 
the cellular pellet kept for analysis ( p e l l e t ) .  Sepharose beads were added to another fraction 
of the initial pellet ( p e l l e t  b e a d s )  and the lysed supernatant ( s n  b e a d s ) .  ICP34.5 from 1622 
is detected in the s n  b e a d s  fraction (4).
W W m
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dried gel containing electrophoretically separated radiolabelled samples was exposed to a 
Phospho-imaging screen overnight. Autoradiography of the IP using radiolabelled infected
35BHK cell extracts showed very little incorporation o f [ S]methionine and no specific 
precipitation o f ICP34.5 (Fig. 28a). Samples which were not labelled with [3 5 S]methionine 
were analysed by 10% SDS-PAGE and Western blotted with 137. The Western blot shows 
precipitation o f ICP34.5 in 1622 (SN BEADS) but not in 17+ and 1716 infected cells (Fig. 
28b). Recognition o f ICP34.5 was detected from separate 17+ and 1622 infected BHK and 
3T6 cell extracts (BHK and 3T6, respectively).
3T6 cells were immunoprecipitated as described for BHK cells above. Infected 
3T6 cells were analysed using a 10% SDS-PAGE, the gel was dried and exposed to a
35Phospho-imaging screen o/n. There was little incorporation of [ S]methionine from 
infected 3T6 cells (Fig. 29a). It appears that there may be a small amount of 
[3 5 S]methionine labelled ICP34.5 detected in the 17+ and 1622 (PELLET BEADS), 
samples which were immunoprecipitated. A cellular protein migrates very closely to 
ICP34.5 and is present in 17+, 1716 and 1622 (Fig. 29a).
Samples which were not labelled with [3 5 S]methionine were immunoprecipitated 
and Western blotted with 137. The Western blot shows recognition o f ICP34.5 in 1622 
and 17+ but not in 1716 in the WCE and the PELLET BEADS fraction. A protein migrating 
at 70 kDa is also recognized in 17+, 1716 and 1622 in the WCE, but only from 17+ and 
1622 in the PELLET BEADS fraction (Fig 29b). Expression o f ICP34.5 from 1622 is greater 
than in 17+. 1622 is also recognised in the SN BEADS fraction (Fig. 28b).
4.2.3.2. Immunofluorescence using 137 Antiserum
The polyclonal antiserum 137 was used in immunofluorescence experiments to 
visualise and localise ICP34.5 from 1622 infection in vitro (Fig. 30). However, there was 
no specific identification o f ICP34.5. A distinct punctate nuclear staining is present in 17+ 
and 1622 but also was detected in mock and 1716.
4.2.3.3. Western blot Renaturation of ICP34.5 from 1622 Infection
Western blot renaturation o f ICP34.5 from 1622 infected cells was also performed 
to examine ICP34.5 expression. BHK cells were infected with 17+, 1716 or 1622 at a 
m.o.i. o f 10 pfii/cell and harvested 16 h pi in SDS lysis buffer. Samples were completely 
denatured and analysed using 10% SDS-PAGE. The gel was blotted in specific conditions
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Figure 30. Immunofluorescence of infected BHK cells using 137.
BHK cells were mock (a), 1716 (b) 17+ (c) or 1622 (d, e) infected and fixed at 
5 h pi. There is punctate nuclear staining in all samples.
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to allow renaturation of enzymatic proteins as described in Section 3.28.1. Although no 
apparent changes took place in the level of ICP34.5, detection of the 40 kDa protein was 
lost post-renaturation from 17+ , 1716 and 1622 (Fig. 31).
4.2.4. Host Protein Synthesis from 1622 Infection
Roizman and others (Chou and Roizman, 1992, 1994) have characterised that one 
o f the roles o f HSV-1 ICP34.5 is to maintain host and viral protein synthesis late in 
infection in a human neuroblastoma cell line (SK-N-SH). To determine whether ICP34.5 
expression from 1622 rescued this phenotype, BHK, SK-N-SH and HeLa cells were
35infected at a m.o.i. o f 10 pfu/cell and pulse labelled with [ SJmethionine for 2 h (14 to 16 
h pi). In BHK cells, all viruses gave the same protein synthesis profile (Fig. 32a). 
However, in 1716 infected SK-N-SH cells, as predicted, little protein synthesis occurred 
(Fig. 32b). The protein synthesis profile in 1622 infected cells was identical to that from 
17+ in SK-N-SH cells (Fig. 32b). Interestingly, another human cell line, HeLa cells, also 
showed a decrease in protein synthesis following 1716 infection (Fig. 32c) with protein 
synthesis again the same in 1622 and 17+ infected cells (Fig. 32c).
In BHK cells, 1716 demonstrates no impairment in viral replication, but in 3T6 
cells it is impaired and the in vivo avirulent phenotype is mimicked (Brown et al., 1994a). 
To determine if this phenotype could be attributed to host protein synthesis shut-off the 
following experiment was carried out (Fig. 33). BHK and 3T6 cells were infected at a 
m.o.i. o f 10 pfu/cell and radiolabelled with [3 5 S]methionine for 2 h (14-16 h pi). At 16 h pi 
cells were harvested in SDS lysis buffer. Samples were electrophoresed through a 10% 
SDS-PAGE, the gel dried and exposed to an autoradiograph film for 5 h at -70°C. Viral 
induced proteins were visible indicative of protein expression from all viruses (17+, 1716 
and 1622). There was no overall difference in protein synthesis between wild type 17+, 
1716 or 1622 (Fig. 33), indicating that host protein synthesis shutoff does not play a role in 
the lack of 1716 replication in 3T6 cells.
4.2.5. In vitro Replication Kinetics of 1622
One role of ICP34.5 is the involvement in viral replication. Deletion of the RL1 
gene dramatically reduces the virus's ability to replicate in some, but not all, cell lines.
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Figure 31. Blot renaturation of 17+, 1622 and 1716 infected BHK cells 
16 h pi.
BHK cells were infected at a m.o.i. of 10 pfu/cell and harvested at 16 h pi in 
SDS lysis buffer. Samples were analysed using a 10% SDS-PAGE and 
Western blotted with 137. Samples were loaded in duplicate lanes for regular 
Western blot methods (a) and renaturation in the absence of methanol at 4°C. 
(b). Both blots were reacted with 137 antiserum. The 40 kDa protein is not 
recognised after renaturation, but ICP34.5 is recognised at the same level. The 
appearance of ICP34.5 size difference is due to uneven electrophoresis through 
the gel.
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Figure 32. Host cell protein synthesis shut-off in BHK, SK-N-SH and HeLa 
cells.
BHK, SK-N-SH and HeLa cells were infected with a m.o.i. o f 10 pfu/cell and at 14 
h pi pulse [ 35S]methionine labelled until 16 h pi. The infected cells were harvested 
and analysed by 10% SDS-PAGE and exposure to an autoradiograph o/n at -70°C. 
a. In all BHK cell infections, there is no difference in protein synthesis, b. In SK- 
N-SH cell infections, there is protein synthesis shut-off from 1716, but no shut-off 
in protein synthesis from 1622 and 17+. c. Infection in HeLa cells show protein 
synthesis shut-off from 1716 only.
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3T6 cells BHK cells
Figure 33. Host cell protein synthesis in BHK and 3T6 cells.
Infected BHK and 3T6 cells were radiolabelled with [35S]methionine for 2 h 
(14 to 16 h pi). Samples were analysed using 10% SDS-PAGE.
The gel was dried and exposed to autoradiograph film o/n at -70°C. There is 
no difference in protein synthesis in BHK and 3T6 cells between the different 
virus infections.
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4.2.5.1. Single Cycle Replication Kinetics
To study single cycle replication kinetics, BHK cells were infected at a m.o.i. of 10 
pfu/cell and no difference between the replication kinetics of 17+, 1716 or 1622 was 
observed (Fig. 34a; Table 6 ). These were the results from a single experiment. In non- 
permissive 3T6 cells, infection at a m.o.i. of 10 pfu/cell showed that 1716 does not 
replicate to the same titre as 17+ (Fig. 34b; Table 6 ). 1716 yields a maximum titre at 36 h 
pi which is approximately 70-fold less (1.2xl0 6 pfu/106  cells) than 1622 and 17+ (8xl0 7 
pfu/106  cells and 7x l0 7 pfu/106  cells, respectively).
4.2.5.2. Multi Cycle Replication Kinetics
The first experiment to look at viral replication used primate Vero cells and human 
HeLa cells (Fig. 35; Table 7), two cell lines which had not previously been studied for 
1716 replication. The following was carried out in three independent experiments and 
yielded similar results. Due to the surprising result o f HeLa host cell protein synthesis 
shut-off from 1716, replication kinetics were examined in these cells (Fig. 33c; Section
4.2.4.). Vero and HeLa cells were infected with a m.o.i. of 0.001 pfu/cell.
Infected Vero cells samples were harvested at 0, 56, 72 and 96 h pi. Samples were 
sonicated and titrated in triplicate on BHK cells. 1716 showed a reduction in its ability to 
replicate. The peak titre of 1716 was 5.0xl0 5 pfu/106cells at 72 h pi. 17+, 1622 and gD17+ 
had similar kinetics with peak titres o f l.lx lO 7 pfu/106  cells, 8x l0 6 pfu/106cells and 
l.lx lO 7 pfu/106  cells, respectively at 96 h pi. This is a difference between wild type 17+ 
and 1716 of approximately 15 to 20-fold (Fig. 35a).
HeLa cells were infected and at times 0, 24, 72 and 126 h pi samples were 
harvested, sonicated and titrated in triplicate on BHK cells. 17+ and 1622 had similar 
kinetics reaching a peak titre o f 9x l0 5 pfu/106cells at 126 h pi. 1716 did not replicate in 
these cells (Fig. 35b).
An experiment with additional RL1 mutant viruses including 17termA, 17termAR, 
1771 and 1771R, were added as controls on BHK and rabbit skin cells (Table 8 ). 17termA 
contains a stop codon insertion near the ifofEII site and 17termAR is its rescuant virus. 
1771 contains a stop codon insertion near the Ncol site and 1771R is its rescuant virus. In 
BHK cells, there was no significant replication difference between these viruses (Fig. 36a; 
Table 9).
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Figure 34. Single-cycle replication kinetics in different anim al cells.
BHK and 3T6 cells were infected at a m.o.i. of 10 pfu/cell.
a. At times 0, 2, 4, 10, 12 and 24 pi infected BHK cells were scraped into the medium, 
sonicated and titrated onto BHK cell monlayers. All viruses grow with similar kinetics 
17+( ♦), 1716 ( ■) and 1622 ( ). b. At times 0, 2, 4, 12 and 36 h pi 3T6 cells were
scraped into the medium, sonicated and titrated onto a BHK monolayer. In 3T6 cells, 
1716(B)  does not replicate as well as 17+ ( ♦) and 1622 ( ), which replicate to reach
titres of 7x107 pfu/106 cells and 8xl07 pfu/106 cells, respectively, at 36 h pi.
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Table 6. BHK and 3T6 titres for single cycle growth kinetics.
BHK cells
17+ 1716 1622
0 2.2x104 4.0xl05 1.5x10s
2 1.5xl04 3.5x10s 1.7x10s
4 1.4xl04 1.7xl05 1.5xl05
10 8.7x10s 4.0xl06 4.0x10s
12 1.5xl07 1.5x10* 4.2x107
24 6.9x107 2.3x10* 5.3xl07
3T6 cells
17+ 1716 1622
0 2.0x104 2.0x10s 2.0x10“
2 4.0x10“ 2.0x10s 2.0x10“
4 3.0x10“ 6.0x10“ 6.0x10*
8 5.0x10s 4.0x10s 2.0x10“
12 6.0xl06 l.OxlO6 l.OxlO6
35 4.0xl07 2.0xl06 3.0xl07
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Figure 35. M ulti-cycle replication kinetics in prim ate and hum an cells.
Vero and HeLa cells were infected at a m.o.i. of 0.001 pfu/cell. Infected cells 
were scraped into the medium, sonicated and titrated onto a BHK monolayer, 
a. At 0, 56, 72 and 96 h pi infected cells were harvested. Vero cells show that 1716 
( ■ ) does not replicate with the same kinetics as 17+ ( ♦), 1622 ( ) or gD 17+ (\).
gD17+ (\)  was used as a control for insertion in the UL43 locus, b. At 0, 24, 72 and 
126 h pi samples were harvested from infected HeLa cells.
■+ —  17+
•  -  1716 
1622 
g D 1 7 +
> -1 7 +
* - 1 7 1 6
1622
V ero  cells
25 50 75 100
Tim e (h pi)
HeLa cells
25 5 0  75 100 125 150
Time (h pi)
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Table 7. Vero and HeLa titres for single cycle growth kinetics.
Vero cells
17+ 1716 1622 SD17+
0 l.OxlO2 5.0xl02 3-OxlO3 3.0xl02
60 2.0xl06 1.7xl05 1.5xl06 2.0x106
75 1.5xl07 3.0x105 3.0xl06 1.5xl07
95 3.0xl07 1.3x10s 7.3xl07 l.OxlO7
HeLa cells
17+ 1716 1622 RD17+
0 l.OxlO3 2.0x103 3.0xl03 4.0x102
2 2.0x102 2.0xl03 5.0xl03 4.0x102
26 1.8xl04 l.OxlO2 1.4xl04 8.0x103
75 3.0x10s 1.2x102 3.0x10s 2.0x10s
130 5.0xl04 l.OxlO2 l.OxlO6 5.7x10s
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Table 8 . The names of viruses and a brief description.
V ir u s  n a m e
\ T
D e sc r ip t io n
wild type RL1 and ORF P
1716 759 bp deletion of R L 1 and ORF P 
at both loci.
1716R 1716 rescuant; wild type.
1771 stop codon 9 bp downstream of initiating 
ATG Ncol iocus in RLi.
1771R 1771 rescuant; wild type RLI.
17termA stop codon near the BstEU locus in R L I .
17termAR 17termA rescuant; wild type RLI.
gD17+ gD promoting lacZ 'm UL43 locus of  17+.
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Figure 36. Multi-cycle replication kinetics in different anim al cells.
BHK and rabbit skin cells were infected at a m.o.i. of 0.001 pfu/cell. At regular 
intervals cells were scraped into the medium, sonicated and titrated onto a 
BHK monolayer in triplicate, a. All viruses replicated on BHK cells 
with similar kinetics 17+ ( ♦ ), 1716(B) ,  17termA (x) ,  17termAR (*), 1771 
( •  ) and 1771R ( | ) ,  with a slightly lower replication from 1622 ( )
b. In rabbit skin cells 17+ ( ♦) 1716 ( ^  and 1622 ( ) replicated poorer
than 17termA (\), 17termAR (*), 1771 ( •  ) and 1771R ( | ).
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Table 9. BHK and Rabbit skin cell titres for single cycle growth kinetics.
BHK cells
17+ 1716 1622 17termA 17term AR
0 l.OxlO2 1.3xl02 8.0x10’ 5.0x10’ 5.0x10’
12 2.8x103 6.5x102 4.8X102 7.5x103 2.8x103
50 6.3x107 7 .1 x l0 7 4.3x106 2.3x107 6.7x107
96 8.8x107 2.0x107 7.7x106 4.2x107 4.2x107
Rabbit skin cells
17+ 1716 1622 17term A 17termAR
0 l.OxlO2 1.5xl02 1.7X102 8.0x10’ 9 .8 x l0 2
12 2.8x103 6.5x102 4.8X102 7 .5 x l0 3 2 .8 x l0 3
50 3 .1 x l0 5 3 .3 x l0 5 5.2x105 1 .8x l07 2 .6 x l0 7
96 2.5x106 2.0x106 5.2x106 5 .0 x l0 7 2 .8 x l0 7
121
Results and Discussion: 4.2
Another permissive cell line, rabbit skin cells, showed no difference in replication 
between 17+, 1716 or 1622 or 17termA, 17termAR, 1771 or 1771R (Fig. 36b; Table 9). 
However, there were two distinct groups of replication: group 1, 17+, 1716 and 1622; and 
group 2, 17termA, 17termAR, 1771 and 1771R. This will be discussed in more detail in 
Section 6.2. It is important to note here that 17+, 1716 and 1622 stocks were grown in 
BHK cells whereas group 2 (17termA, 17termAR, 1771 and 1771R) mutant virus stocks 
were generated on rabbit skin cells.
4.2.6. Intracranial LDS0 of 1622 Infection
Intracranial experiments to confirm that the wild type phenotype had been restored 
to 1622 in vivo were carried out by estimation of LD5 0  values in three-week old, female, 
BALB/c mice (Table 10). In the first experiment mice were inoculated intracranially with 
virus stocks o f 17+, 1716R, or 1622 (Section 3.36). 1716 was not included in this
experiment. HSV-1 strain 17+ and 1716R were used as positive controls with a known 
L D S0  value. 17+ and 1716R (the rescuant of 1716) had the same L D 50  o f <3.2 pfu/mouse. 
The 1622 L D 50  was 1.8xl02  pfu/mouse. 1622 showed a significant difference (60-fold) in 
L D 50  value following intracranial inoculation.
In the second experiment, 1716 and an additional control virus, gD17+, were used. 
The mutant virus gD17+ was a control for an insertion in the UL43 locus having the lacZ 
gene inserted in the UL43 Nsil site. 1716 was included as a negative control. The LD5 0  
for 1622 remained 1.8xl02  pfu/mouse. In this experiment, the LDS 0  o f 17+ was 5.6x10’
pfu/mouse and the L D 50  of gD17+ was lxlO 3 pfu/mouse. The L D 50  of 17+ was raised by a 
factor o f 20. The L D 50  of gD17+, lx l0 3 pfu/mouse, was 50-fold higher than 17+ and 5- 
fold higher than 1622. For 1716 no animals died when infected with lxlO 5 pfu/mouse and 
one mouse out o f four died from the 1716 infective dose lx l0 6  pfu/mouse. This is not 
statistically significant and is consistent with the previously published L D 50  for 1716 of 
> 1 x 1 0 6  pfu/mouse.
4.2.7. In vivo Replication Kinetics from 1622 Infection
One o f the main biological properties of HSV-1 infection is that following infection
at a peripheral site the virus replicates and travels by axonal transport to the neuronal cell
bodies in the sensory ganglia where the virus establishes and maintains a latent state. The
snouts o f male Swiss Webster mice aged 4-7 weeks old were abraded and used as the site
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Table 10. Neurovirulence of 1622 following inoculation of BALB/c mice infected with 
varying doses and calculated as LD50.
Experiment 1
LD
501 0 1 1 0 2 1 0 3 1 0 4 1 0 5 1 0 6
17+ 4/4* 4/4 ND ND ND ND <3.2**
1716R 4/4 4/4 ND ND ND ND <3.2
1716 ND ND ND ND ND ND
1622 0/4 1/4 4/4 ND ND ND 1 .8 x l 0 2
Experiment 2
LD
501 0 1 1 0 2 1 0 3 1 0 4 1 0 5 1 0 6
1 7 + 1 / 4 2 / 4 ND ND ND ND 5 . 6 X 1 0 1
g D 1 7 + ND 1 / 4 1 / 4 ND ND ND lxlO 3
1 7 1 6 ND ND ND ND 0 / 4 1 / 4 1 .8 x l 0 6
1 6 2 2 0 / 4 1 / 4 4 / 4 4 / 4 4 / 4 ND 1 .8 x l 0 2
* Number of deaths per number of mice infected.
** pfu/mouse 
ND = Not Done
i
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of initial infection o f 5x l0 5 pfu/ml o f either 17+, 1716 or 1622 (Fig. 37a; Table 11). On the 
day of infection the input virus was serially diluted and titrated in triplicate on rabbit skin 
cell monolayers which confirmed equal input titres (data not shown). On days 2,3 and 4 pi 
three mice per virus were sacrificed, their snouts and TG dissected, homogenized and 
titrated on rabbit skin cell monolayers in triplicate as described in Section 3.42. Maximum 
titres o f 17+, 1622 and 1716 were seen on day 2 pi (Fig. 37a). There was a significant 
decrease in replication in the snout infected with 1622 and to a greater extent 1716 (Fig. 
37a). This difference was more pronounced in the TG where the peak titre on day 3 pi of
17+ was 1.5xl0 4  pfu/ml (Fig. 37b; Table 11). The 1622 TG titre also peaked on day 3 pi
2 • • but with a titre o f 1.2x10 pfu/ml, a difference o f more than 10 times. The peak titre of
1716 infected TG was 9.0x10 1 pfu/ml on day 2 pi (10-fold less than 1622) with no 
evidence o f viral replication.
4.2.8. Immunohistochemistry of 1622 Infected TG
Based on the replication kinetics experiments carried out in snouts and TG 
demonstrating that 1622 does not replicate with the same efficiency as 17+ 
immunohistochemistry was used to confirm and extend this finding. Seven week old male 
Swiss Webster mice were infected with 5x105  pfu/ml o f 17+, 1716 or 1622. Based on the 
peak titres from the in vivo replication experiments we looked at days 3 and 4 pi. At days 
3 and 4 pi, three mice per day per virus were transcardially perfused and TG dissected. TG 
were prepared for IHC as described in Section 3.38.2.1. On day 3 pi there was no staining 
in mock infected (Fig. 38a) or 1716 infected TG (Fig 38b). There were a few positively 
staining isolated neurones in TG infected with 1622 (Fig. 38c). In contrast, several clusters 
of neurones stained positively from TG infected with 17+ (Fig. 38d). A similar pattern of 
viral staining was seen on day 4 pi (Fig. 39). The positive neurones from 1622 and 17+ on 
day 4 pi were magnified lOOx and shown in Figure 40. The number o f positive neurones 
per field was calculated per virus and is presented in Table 12. On day 3 pi the average 
from two separate sections o f TG infected with 17+ was 41%, 1716 was 0%, and 1622 was 
1.9%. By day 4 post infection the average o f two TG sections from 17+ infected animals 
was 56.65%, from 1716 was 0%, and from 1622 was 1.4%
To confirm the identity o f the viruses used in this experiment a Southern blot was 
carried out using DNA extracted from infected TG. The DNA was digested with BamHI 
and analysed using a 1% (w/v) agarose gel and Southern blotted with a radiolabelled
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Figure 37. In vivo replication from Swiss W ebster mice infected with 17' 
1622 or 1716.
Viral replication in snouts and TG was determined by titrating homogenates of 
tissues harvested from three mice from each virus time point. Tissues were 
homogenized in 1 ml of medium and the data are given in pfu/ml of tissue homogenate. 
a. All mice were inoculated with an input dose of 5x105 pfu/ml. All viruses 
replicated in snouts with differing kinetics. 17+ ( ♦) replicated with the highest 
kinetics. 1622 ( ) and 1716 (■) replicated with reduced kinetics, b. In the TG there
was a significant difference in peak titres. 1622 ( ) was slightly lower than
17+ ( ♦) 1.5xl04 pfu/ml with a peak titre of 1.2xl03 pfu/ml. 1716(B)  did not appear to 
replicate in the TG.
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Table 11. In vivo replication titres of snout and trigeminal ganglia.
XT
Snout Dav 2 3 4
M l 7.0x104 1.0x10s 3 .0 x l0 6
M2 4.0x103 6.0x104 l.OxlO6
M3 6 .0 x l0 3 6 .0 x l0 4 l.OxlO6
Mean 2.7X101 7 .3 x l0 4 1 .7 x l0 6
Standard deviation 5.7 1.3 1.9
1716
Snout Dav 2 3 4
M l l.OxlO4 l.lx lO 5 5.0x105
M2 l.OxlO3 8.0x104 3.0x105
M3 9.0x103 6.0X104 l.OxlO5
Mean 6.7x103 8.3X104 3.0x105
Standard deviation 3.9 1.3 56
1622
Snout Dav 2 3 4
M l 1.4X104 2.3x105 l.OxlO5
M2 1.9X104 2.0x105 l.OxlO5
M3 1.8X104 1.8x l05 l.OxlO5
Mean 1.7X104 2.0x105 l.OxlO5
Standard deviation 1.3 1.7 0
XT
Trigeminal ganglia/Dav 2 3 4
M l l.OxlO4 3.0X104 1.3X104
M2 4.0x104 5.0x104 l.OxlO4
M3 4.0x104 2.1X104 l . lx lO 4
Mean 3.0X104 3.4X104 l . lx lO 4
Standard deviation 2.3 23 1.2
1716
Trigeminal ganglia/Dav 2 3 4
M l 0 l.OxlO1 0
M2 2.0x102 5.0x101 l.OxlO1
M3 2.0x102 4.0x101 l.OxlO1
Mean 1.3xl02 3.0x10* 7
Standard deviation 1.6 2.4 1.6
1622
Trigeminal ganglia/Dav 2 3 4
M l 6.0x102 1.2x10s 1.7X102
M2 2.0x102 9.0x102 8.0x10 1
M3 5.0X102 l.OxlO3 l.OxlO2
Mean 4.3X102 l.OxlO3 6.7x102
Standard deviation 1.8 1.2 8.9
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Figure 38. IHC detection of HSV antigen expression in infected Swiss 
W ebster mouse TG 3 days post infection.
Seven week old mice were inoculated with 5x1 CP pfu/ml of 17+, 1716 and 1622.
On day 3 pi the mice were transcardially perfused and sacrificed. TG were sectioned 
on a rotary microtone and stained for the presence of HSV antigen (see Section 3.38). 
a. TG of mouse mock infected, b. TG of mouse infected with 1716. c. TG of 
mouse infected with 1622. d. TG of mouse infected with 17+. These photo­
micrographs were taken at 20x magnification.
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Figure 39. IHC detection of HSV antigen expression in infected Swiss 
W ebster mouse TG 4 days post infection.
Seven week old mice were inoculated with 5x1 (P pfu/ml of 17+, 1716 and 1622.
On day 4 pi the mice were transcardially perfused and sacrificed. TG were sectioned 
on a rotary microtone and stained for the presence of HSV antigen (see Section 3.38). 
a. TG of mouse infected with 1716. b. TG of mouse infected with 1622. c. TG of 
mouse infected with 17+. These photo-micrographs were taken at 20x magnification. 
Photomicrographs were taken by Dr. N. Sawtell.
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Figure 40. Photom icrograph of single cells positively stained for HSV antigen.
A higher magnification from sections in Figure 41. TG were counterstained with cresal 
violet to emphasize the cellular components and NovaRed® HSV antigen. The ganglion 
section is comprised of neurones (large cells) and many small satellite/support cells, 
a. TG infected with 1622 showing one HSV antigen positive neurone, b. TG infected 
with 17+ shows widespread HSV antigen positive neurones. Magnification of the left 
photos are 20x and the right are lOOx. Photomicrographs were taken by Dr. N. Sawtell.
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Figure 41. Southern blot of isolated genomic profiles from TG.
a. Schematic diagram of the BamHl fragment with the RL1 insert spanning the UL43 
region, b. Viral DNA was isolated from TG and digested with BamHl. Samples were 
analysed using a 1% (w/v) agarose gel and Southern blotted using radiolabelled 
p35/PacI probe. The blot was exposed to an autoradiograph for 5 h at -70°C. 17+ and 1716 
show a single band at 6.6 kbp ( O). This is the wild type BamHl fragment spanning 
UL41 through UL44. 1622 contains an extra BamHl site in which R L 1 in the UL43 divides 
this region yielding two bands, 7.8 kbp(0 ) and 4.5 kbp (□  ).
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p35(PacI) probe. The blot was exposed to an autoradiograph for 5 h at -70°C (Fig. 41). In 
the recombinant virus, the insert has an extra BamHl site in UL43 and this digests into two 
fragments (of 4.6 and 7.8 kbp) as previously described (Section 4.1). In 17+ and 1716 
there is a single BamHl fragment o f 6 . 6  kbp.
4.2.9. Latency and Reactivation by Co-cultivation
The ability o f 1622 to reactivate from latency was examined. Groups o f 4 week 
old, female, BALB/c mice were infected with 17+, 1716, 1716R or 1622 via the footpad 
model described by Clements and Subak-Sharpe (1983, 1988). Virus was injected into the 
right rear footpad o f each mouse with different viruses and input doses. Mice were 
monitored twice daily for signs o f illness or death. Forty-one days pi, mice were sacrificed 
and the 10 ipsilateral DRG which innervate the footpad were assayed for the release of 
virus as described in Section 3.37.1.
An input dose o f 5xl0 5 pfu/mouse showed that HSV-1 strain 17+, 1716R and 1622 
were equally efficient at reactivating from latency with a maximum frequency of -75%  
explanted ganglia reactivating by day 18 post explantation (Fig. 42a; Table 13). The 
percentage reactivation o f 1716 was -22%  explanted ganglia by day 18 post explant. In a 
separate experiment, using an increased input dose o f 5xl0 6  pfu/mouse, 1622 was still able 
to reactivate better than 1716 (Fig. 42b; Table 13) but frequency of reactivating virus from 
1716 was better at this higher dose. The maximum reactivation from 1716 infected DRG 
was -52% . The maximum frequency of reactivating virus from 1622 5xl0 6  pfu/mouse 
infected ganglia was -78%  which is slightly better than the frequency o f reactivating virus 
from 1622 input dose o f 5xl0 5  pfu/mouse.
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Table 12. Quantitative analysis of HSV antigen positive neurones per section 
on day 3 and day 4 post infection.
Day 3 post infection
17+
Positive neurones/Tota number o f  neurones Percent postive
Section 1 55/260* 21.00% 1
Section 2 110/180 61.10%
Average 41%
1716
Positive neurones/Tota number o f  neurones
Section 1 0/130 0%
Section 2 0/200 0%
Average 0%
1622
Positive neurones/Tota number o f  neurones
Section 1 3/120 2.50%
Section 2 2/140 1.40%
Average 1.90%
Day 4 post infection
17+
Positive neurones/Tota number o f  neurones Percent postive
Section 1 87/120 72.50%
Section 2 49/180 40.80%
Average 56.65%
1716
Positive neurones/Tota number o f  neurones
Section 1 0/200 0%
Section 2 0/1800 0%
Average 0%
1622
Positive neurones/Tota number o f neurones
Section 1 0/200 0%
Section 2 5/180 2.80%
Average 1.40%
+  Number of ganglia counted.
■  Percent HSV positive ganglia.
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Figure 42. In  vitro reactivation characteristics of 1622.
a. BALB/c mice were inoculated with an input dose of 5x10'' pfu/mouse and mice were 
left for 41 days to establish latency. DRG were dissected, placed into microtitre plates and 
media replated every two days onto fresh BHK monolayers which were examined for cpe. 
The frequency of DRG reactivating at each time point was calculated as a percentage of the 
total number of ganglia explanted, for each virus at each dilution. In general each time point 
represents four mice per group.
b .  BALB/c mice were inoculated with 1622 and 1716 of 5x106 pfu/mouse and left 
for 41 days to establish latency. Each time point represents, on average, four mice 
per group.
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Table 13. Co-cultivation reactivation percentages.
Input dose o f 5x10 5 pfu/mouse
Days post explant 2 4 6 8 1 0 1 2 14 16 18
17+ 0 5 1 0 35 43.3 63.3 66.7 70 73
1716R 0 35 45 65 65 70 72 73 75
1622 0 3.3 6 . 6 23.3 26.7 66.7 70 72 74
1716 0 3.3 1 0 13.3 16.7 16.7 16.7 2 0 23
Input dose of 5x10 5 pfu/mouse
Days post explant 2 4 6 8 1 0 1 2 14 16 18
1622 0 1 0 25 45 50 65 70 75 75
1716 0 3.3 12.5 12.3 30 35 47.5 50 54.3
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4.2.10. Discussion
In this section the recombinant virus 1622 was characterized. 1622 only expresses 
RL1 and not ORF P. Initially ICP34.5 expression was analysed by Western blotting. By 
placing the RL1 ORF under the gD promoter in the UL43 locus ICP34.5 is expressed 
approximately 8  times more than in wild type 17+ by 16 h pi. Immunoprecipitation using 
137 antiserum from 1622 infected BHK and 3T6 cells confirmed that ICP34.5 is 
overexpressed. Western blots o f time course experiments show that ICP34.5 in strain 17+ 
and 1622 is expressed by 2 h pi. Two additional viral induced proteins of 40 kDa and 70 
kDa are recognized by 137 and R1 (Brown et al., 1997). It is not known what these 
protein are but some theories will be described in the final discussion (Section 7).
It was believed since ICP34.5 was expressed in 1622 at least as well as wild type 
levels, that replication in non-permissive cells in vitro would be restored. This was 
confirmed in 3T6, Vero, and HeLa cells. 1716 had not been previously studied in Vero or 
HeLa cells. The reduction from 1716 replication in 3T6 cells has been morphologically 
examined by Brown et al (1997). Using an electron microscope they showed that 1716 is 
kept in the lamellae of 3T6 cells and unable to be released or fully packaged to spread from 
cell to cell. The mechanism for this phenomenon has yet to be determined. 1716 did not 
have wild type kinetics in Vero cells. One explanation for this might be based on the Vero 
cells being a primate cell line. In HeLa cells, 1716 failed to replicate. This was supported 
by the host protein synthesis shutoff experiments that confirmed published data by Chou 
and Roizman (1992) in HSV-1 strain F and the RL1 deleted mutant, R3616. 1622 had 
restored the ICP34.5 function of maintaining host and viral protein synthesis in SK-N-SH 
cells. Infection of 1716 and R3616 in SK-N-SH cells shuts off protein synthesis by a 
mechanism which involves ICP34.5 binding to protein phosphatase l a  to dephosphorylate 
a translation initiation factor eIF-2a.
Interestingly, a cell specificity was found in rabbit skin cells. Viruses generated 
and grown in rabbit skin cells were able to replicate to a higher titre in rabbit skin cells 
than viruses generated and grown in BHK cells, but the reverse was not true for growth in 
BHK cells.
In vivo experiments showed a difference in replication and virulence between 1622
and 17+. 1622 had a slightly lower LD 5 0  upon intracranial inoculation (between 3 and 60
fold). The defect in replication kinetics was even more pronounced following peripheral
inoculation via the snout and replication in the TG. Immunohistochemistry showed vastly
fewer HSV positive antigen in 1622 than in 17+. No HSV antigen staining was seen in TG
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from mice infected with 1716. This indicates that 1622 is able to replicate in vivo in the 
TG but not as well as 17+. One hypothesis for why this may be occurring is due to the 
ICP34.5 level of expression. Overexpression may block an integral function or interaction 
o f ICP34.5 in vivo. A second hypothesis may be that the initial time ICP34.5 is expressed 
differs between wild type 17+ and 1622. Here we give new data showing in vitro ICP34.5 
is expressed early in HSV infection. The expression o f ICP34.5 from 1622 may be 
delayed compared to 17+ because it is promoted by the gD promoter. The ability to detect 
ICP34.5 so far has been dependent upon Western blotting and it is probable that there may 
be a low level o f expression before 2  h pi which may be determined with different 
immunological detection methods. Further studies to look for transcripts at early time than 
analysed here could elucidate this. Additionally, the kinetics and strength of the gD 
promoter may not give the same activity in vivo as the RL1 promoter.
A theory to explain why the reactivation frequency is reduced from 1716 and 
slightly from 1622 infected mice is that the amount o f virus getting to the ganglia to 
establish latency is low. As seen by the immunohistochemistry experiments the very low 
of HSV positive antigen in the ganglia o f 1716 represents a lack o f virus in the ganglia. 
Therefore, an in situ experiment looking at RNA levels o f 1716 and 1622 in ganglia during 
acute replication could elucidate a more quantitative answer to just how little 1622 
replicates in the murine ganglia.
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4.3. CHARACTERIZATION OF 1623
4.3.1. Expression of ICP34.5
The HSV-1 RL1 promoter is located within the a sequence. ICP34.5 was originally 
published to be a late (yi) protein, expressed at 16 h pi from HSV-1 strain F. This 
laboratory has shown expression o f ICP34.5 from HSV-1 strain 17+ as early as 2 h pi by 
Western blotting (Section 4.2). In order to test if  ICP34.5 could be expressed with the RL1 
5' leader sequence and possible transcription initiation site downstream of the HSV-1 gD 
promoter a second recombinant virus, 1623, was constructed. 1623 has the RL1 ORF with 
134 bp o f additional upstream sequences. Chou and Roizman (1986) considered this 134 
bp, which is outside the a sequence, sufficient to promote expression of RL1. This RL1 
fragment is 918 bp and has Dral at the 5’ terminus and BamHl (from pGEM34.5) at the 3’ 
terminus. The 918 bp, DraUBamHl fragment was sub-cloned downstream of the gD 
promoter as described in Section 4.1. 1623 was used to compare the times of ICP34.5 
expression without the anti-sense gene, ORF P. We hypothesised that the two recombinant 
viruses, 1622 and 1623, would express ICP34.5 at the same time with similar levels as 
wild type, 17+. We also hypothesized that ICP34.5 expression from 1623 in vitro would 
restore growth and virulence in vivo o f 1716.
BHK cells were infected at a m.o.i. o f 10 pfu/cell and samples harvested at 
different times post infection (2 to 12 h), and analysed by SDS-PAGE and Western 
blotting using the HSV-1 ICP34.5 antiserum 137. No ICP34.5 expression from 1623 was 
detected up to 12 h pi (data not shown). ICP34.5 expression was detected on a 5-12.5% 
gradient SDS-PAGE by 16 h pi from 1623 infected BHK cell extracts (Fig. 43). The level 
of ICP34.5 detection was considerably less than 17+. There is no ICP34.5 expression from 
1716. The Western blot shown in Figure 43 demonstrates that there is a pre-domeninant 
HSV induced cellular protein migrating close to ICP34.5, at approximately 40 kDa. This 
gives the appearance of a protein in the adjacent lane containing a mock infected extract. 
There is also strong recognition o f two virus induced proteins whose apparent Mr are 25 
kDa and 21 kDa.
A serial 2-fold dilution o f the 17+ infected BHK cell extracts was made to compare 
the level of ICP34.5 with that o f 1623. In Figure 44, a Western blot shows that a 1 in 8  
dilution o f 17+ infected BHK cell extract is closest to the neat 1623 infected BHK extract: 
thus 1623 expresses ICP34.5 at only 12.5% the level o f 17+.
To test if  1623 was expressing wild type levels of other viral protein a Western blot
using an antiserum to the UL42 HSV protein was carried out (Fig. 45). Infected cell
137
Results and Discussion: 4.3
1623 1716 Mock 17+
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Figure 43. W estern blot of 1623 ICP34.5 expression using 137.
Infected BHK cells were harvested at 16 h pi analysed on a 5-12.5% gradient SDS- 
PAGE and Western blotted using 137 antiserum. Recognition of the 25 kDa is so 
strong that it gives the appearance of being present in the mock infected lanes.
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Figure 44. Semi-quantitative comparison of ICP34.5 expression from 1623
A serial 2-fold dilution was made of 17+ extracts in lysis buffer. Infected BHK cells 
16 h pi were analysed by 10% SDS-PAGE,Western blotted using 137 antiserum, Protein 
A-HRP and ECL. The dilution showing the closest level of ICP34.5 from the neat 1623 
extract (N) is the 1 in 8 dilution of 17+ (1/8).
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F \ T  1716 1622 1623
Figure 45. W estern blot of BHK infected whole cell extracts using 
anti-UL42 serum.
A monoclonal antibody against the UL42 65 kDa DNA binding protein 
was used in a Western blot. These were the same neat extracts used in 
Figure 44.
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extracts on this gel are the same extracts that were used in the Western blot of ICP34.5 in 
the previous figures (Fig. 43 and 44). The level o f UL42 expression is slightly higher in 
17+ compared to 1716 and 1622 and strain F, as explained in Section 4.2. The Western 
blot shows that 1623 is capable of synthesising other viral proteins efficiently. It also 
shows that the level o f another viral protein is similar between recombinant viruses.
4.3.2. Host Protein Synthesis from 1623 Infection
An experiment was carried out to determine whether 1623 infected cells expressing 
a reduced level of ICP34.5 could prevent preclusion of protein synthesis. BHK, SK-N-SH 
and HeLa cells were infected with 17+, 1716 and 1623 at a m.o.i. o f 10 pfu/cell. Infected 
cells were pulse labelled with 3 5 [S]methionine for 2 h from 14 to 16 h pi and protein 
synthesis was visualised by autoradiography of a 10% SDS-PAGE gel (Fig. 46). Although 
the expression of ICP34.5 is much less than in 1 7 \ the function of maintaining protein 
synthesis is restored in SK-N-SH cells. 1623 infection was not as good as 17+ and 1622 as 
seen in the high number of mock cellular bands, however, several viral bands are present, 
particularly visible from infected HeLa cell extracts (Fig. 46c). A second protein synthesis 
experiment was carried out using BHK and 3T6 cells (Fig. 47). BHK and 3T6 cells were 
infected at a m.o.i. o f 10 pfu/cell and radiolabelled with [3 5 S]methionine for 2 h (14-16 h 
pi). At 16 h pi cells were harvested in SDS lysis buffer and analysed using 10% SDS- 
PAGE. Viral induced proteins were visible, indicative of productive infection in all 
viruses (17+, 1716, 1622 and 1623; Fig. 47). There was no overall difference in protein 
synthesis between wild type 17+, 1716, 1622, or 1623 (Fig. 47).
4.3.3. In vitro Replication Kinetics from 1623 Infection
We wanted to determine if an 8 -fold reduction in ICP34.5 expression from 1623 
would affect replication in non-permissive cells as the level was sufficient to restore the 
function of maintaining host cell and viral protein synthesis. Single-cycle and multi-cycle 
replication kinetics were examined in vitro.
4.3.4. Single-cycle Replication Kinetics
One step growth experiments using a m.o.i. of 10 pfu/cell were carried out in 
permissive BHK and non-permissive 3T6 cells at 37°C (see Section 3.25.). The virus 
yield, at regular time intervals pi, was determined by titration on BHK monolayers at 37°C.
141
Results and Discussion: 4.3
a. b. c.
BHK cells SK-N-SH cells HeLa cells
o m v©
O f S r j T - i t  ©  N  N  ^  +
*— \o  vo h  ‘ m  \© t"
i ^  ^  ^  i-h
V©
N n +
V© V© r » r -
I - *
m
Figure 46. Host cell protein synthesis shut-off in BHK, SK-N-SH and HeLa cells.
BHK, SK-N-SH and HeLa cells were infected with a m.o.i. of 10 pfu/cell and at 14 h pi pulse 
labelled w ith35[S] methionine until 16 h pi. The infected cells were harvested at 16 h pi and 
analysed by 10% SDS-PAGE. The dried gel was exposed to an autoradiograph o/n at -70°C.
a. In all BHK cell extracts, there was no difference in overall protein synthesis between viral 
and mock infections, b. In SK-N-SH cell infections, there is protein synthesis shut-off from 
1716. But no shut-off in protein synthesis from 1623 and 17+. c. Infection in HeLa cells 
shows protein synthesis shut-off from 1716 only.
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3T6 cells BHK cells
Figure 47. Host cell protein synthesis in BHK and 3T6 cells.
Infected BHK and 3T6 cells were radiolabelled with [35S]methionine for 2 h 
(14 to 16 h pi) and harvested at 16 h pi. Samples were electrophoresed through 
a 10% SDS-PAGE. There is no difference in protein synthesis between BHK 
infected cells and 3T6 infected cells among different viral infections.
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There was a slight difference between 17+, 1716, 1622 and 1623 replication kinetics in 
BHK cells (Fig. 48a; Table 14).
In 3T6 cells, 1716 and 1623 did not replicate as well as 17+ and 1622 (Fig. 48b; 
Table 14). 1716 replicated with reduced kinetics producing a maximum titre at 36 h pi of 
1.2xl0 6  pfu/cell, 50-fold less than 17+ or 1622 (>5xl0 7  pfu/cell). 1623 failed to replicate 
in 3T6 cells having a final titre, which was the same as the input titre of 1.2xl05 pfu/cell, 
10-fold less than 1716. This unexpected result will be discussed at the end of this section.
4.3.5. Multi-cycle Replication Kinetics
Multi-cycle replication kinetics using a m.o.i. o f 0.001 pfu/cell mimicked the one 
step growth kinetics in 3T6 cells in that 1623 and 1716 grew poorly but 1622 grew as well 
as 17+ (data not shown).
Using a m.o.i. o f 0.001 pfu/cell to infect human and primate cells, replication of 
viruses was examined. In Figure 49a, Vero cells infected with 1716 and 1623 showed a 
marked reduction in replication. The titre from both 1716 and 1623 by 75 h pi was 1.2xl05 
pfu/106  cells and 1.0x10s pfu/106  cells, respectively (Table 15). The titre of 17+ at 75 h 
was l.lx lO 7 pfu/cell and from 1622 was 1.5xl06  pfu/106 cells. The maximum titre of 1623 
was approximately 1 log less than 17+ and 1622 at 95 h post infection and 1 log greater 
than 1716.
In HeLa cells (Fig. 49b; Table 15) there was a marked difference between 
replication o f different viruses. 1716 and 1623 did not replicate in this cell line 
demonstrating a classic "death curve". 17+ and 1622 replicated to reach 1.5xl05 pfu/106  
cells at 75 h pi. At 130 h pi there was a difference in kinetics between 17+ and 1622, this 
observed artefact was due to the age o f the cells and not a true depiction of virus 
replication.
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a.
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Figure 48. Single cycle replication kinetics in different anim al cells.
BHK and 3T6 cells were infected at a m.o.i. of 10 pfu/cell. At regular time 
intervals, cells were scraped into the medium, sonicated and titrated onto a 
BHK monolayer. Titre (pfu/106 cells) is plotted on the y-axis and time (h pi) 
is plotted on the x-axis. a. All viruses grow with similar kinetics 1 ), 1716
(■ ) , 1622 ( )andl623 ( \ ) .  b. In 3T6 cells 1716 ( ■ )  does not replicate as 
well as 17g)(^ ) and 1622 ( ), 1623 ( \  ) fails to replicate.
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Table 14. BHK and 3T6 titres for single cycle growth kinetics.
BHK cells
17+ 1716 1622 1623
0 2 .2 x l 0 4 4.0x10s 1.5x10s 2 .7 x 1 0 5
2 1.5xl04 3.5xl0 5 1.7xl0 5 2 .8 x 1 0 s
4 1.4xl04 1.7xl05 1.5x10s 2.3x105
1 0 8.7xl0 5 4.0xl0 6 4.0xl0 5 3.9x10s
1 2 1.5xl0 7 1 .5 x 1 0 * 4.2xl0 7 1.4xl05
24 6.9x107 2.3x10* 5.3xl0 7 2 .0 x 1 0 5
3T6 cells
17+ 1716 1622 1623
0 2 .0 x 1 0 4 2 .0 x 1 0 s 2 .0 x l 0 4 2 .0 x 1 0 s
2 4.0xl0 4 2 .0 x 1 0 s 2 .0 x l 0 4 2 .0 x 1 0 s
4 3.0x10* 6 .0 x 1 0 4 6 .0 x 1 0 3 1 .0 x 1 0 s
8 5.0x10s 4.0x10s 2 .0 x 1 0 * 1 .0 x 1 0 s
1 2 6 .0 x 1 0 s l.OxlO6 1 .0 x 1 0 * 1 .0 x 1 0 s
35 4.0xl0 7 2 .0 x l 0 6 3.0x107 2 .0 x 1 0 s
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Figure 49. M ulti cycle replication kinetics in prim ate and hum an cell lines.
HeLa and Vero cells were infected at a m.o.i. of 10 pfu/cell. At regular time intervals, 
cells were scraped into the medium, sonicated and titrated onto a BHK monolayer, a. 1623 
replication kinetics in Vero cells was similar between 17+ and 1622. b. HeLa cells infected 
with 17+ and 1622 show simliar kinetics but 1716 and 1623 fail to replicate in HeLa cells.
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Table 15. Vero and HeLa titres for single cycle growth kinetics.
Vero cells
17+ 1716 1622 1623
0 l.OxlO2 5.0xl02 3.0xl03 l.OxlO2
60 2 .0x106 1.7x10s 1.5xl06 5.7x105
75 1.5xl07 3.0x10s 3.0x106 2 .0xl05
95 3.0xl07 1.3x10s 7.3x107 5.0xl06
HeLa cells
17+ 1716 1622 1623
0 l.OxlO3 2 .0xl03 3.0x103 2 .0xl03
2 2 .0xl02 2 .0xl03 5.0xl03 1.7xl03
26 1.8xl04 l.OxlO2 1.4xl04 l.OxlO2
75 3.0xl05 1.2xl02 3.0xl05 l.OxlO2
130 5.0x104 l.OxlO2 l.OxlO6 l.OxlO2
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4.3.6. Discussion
The purpose o f constructing the virus 1623 was to ensure RL1 expression from the 
recombinant virus system. 1623 was being constructed at the same time as 1622 (Section 
4.2) and cloning was carried out before protein expression analysis could be made. It was 
believed that the additional 134 bp might help in the expression of the full length ICP34.5 
protein. 1623, like 1622, had the feature o f singly expressing RL1 without the ORF P gene 
expression.
By Western blotting we determined that 1623 expresses approximately eight times 
less ICP34.5 than wild type 17+. This level o f ICP34.5 expression from 1623 is able to 
maintain protein synthesis in neuronal SK-N-SH cells and HeLa cells at late times (16 h) 
post infection. The protein synthesis from 1623 is substantiated by results published by 
Chou and Roizman (1994) showing a mutant virus with lower ICP34.5 expression in HSV- 
1 strain F but which maintains protein synthesis in SK-N-SH cells.
The replication kinetics o f 1623 were slightly poorer than 17+ in BHK cells, but the 
phenotypic similarity between 17+ and 1623 stopped there. In 3T6 cells, the input dose for 
1623, 1716 and 17+ was the same but 1623 replicated more poorly than 1623. This was 
unexpected as the RL1 negative virus 1716 replicates poorly in 3T6 cells. The lack of viral 
replication from 1623 in 3T6 cells and HeLa cells indicates that there may be another 
mutation in 1623.
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4.4. CONSTRUCTION OF 1624
4.4.1. Introduction
In 1994, Lagunoff and Roizman observed 16 potential ORFs which were predicted 
to encode 50 or more codons within the largest reported unspliced 8.3 kbp LAT. They 
examined expression of five o f these ORFs by in-frame insertions o f an epitope reacting 
with a monoclonal antibody against a human cytomegalovirus protein, gB. Lagunoff and 
Roizman (1994) demonstrated expression of two open reading frames, O and P. In HSV-1 
strain KOS, a family o f transcripts spanning the L-S junction have been identified (Yeh 
and Schaffer, 1993). However, these transcripts were only synthesized in cells infected 
with a virus with a mutation in ICP4. This prevented ICP4 from binding to the consensus 
sequence, ATCGTC, upstream of the ORF P transcription initiation site, and hence 
prevented transcription.
More recent studies (Lagunoff and Roizman 1994; Lagunoff et al., 1996) 
demonstrated that ORF P is not expressed during productive infection in Vero cells by 
HSV-1 strain F at the permissive temperature of 37°C. However, ORF P is detectable 
following infection o f F at the non-permissive temperature o f 39.5°C as ICP4 is 
temperature sensitive in this strain (Lagunoff and Roizman, 1995). ORF P has also been 
detected following infection with a variant o f strain F with the ICP4 binding site in the 
ORF P promoter mutagenised.
Here we wanted to examine the role o f ORF P expression in a lytic HSV-1 strain 
17+ infection. Using the ORF P and RL1 deleted virus, 1716, the ORF P gene was re­
introduced under the gD promoter in a novel location in the UL43 locus as described in 
Section 4.1. ORF P should be expressed with the early/late kinetics o f gD since the ICP4 
binding sequence is not present. The purpose of constructing this recombinant virus was 
to examine the effect o f expression of only ORF P and not RL1 or any synergistic effect of 
ORF P and RL1 and elucidate the functional dichotomy of ORF P and RL1.
4.4.2. Isolation of the ORF P Gene
The ORF P gene fragment was first isolated using pGEM34.5 as template DNA in 
a PCR reaction. The oligonucleotide primers consisted of HSV-1 sequences flanking ORF 
P and additional Smal and BamHl restriction enzyme sites at the ends for ease in sub­
cloning into pFJ14H. The primer sequences are shown in Figure 50b. Initial PCR 
reactions consisted o f varying primer and template DNA concentrations (Table 16).
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Figure 50. ORF P gene isolation from plasmid pGEM34.5.
PCR was carried out on pGEM34.5 (a.) using primers ORF P(N) and ORF P(C) whose
sequence is shown b. c. PCR generated a 705 bp fragment containing the entire
ORF P gene depicted in this cartoon, d. There were several controls used in the
PCR reaction (see Table 3 for exact details). Only one condition generated the ORF P
gene (lane 1) which was isolated on a 1% agarose gel and purified for further
cloning into the plasmid pFJ14H. The 1 kbp DNA ladder (lane 13) shows the
705 bp ORF P gene. Lanes 4 through 9 show excess primers. Lane 9 also shows a
partial PCR product which was not used.
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The optimised concentration o f primers (75pM each) and template DNA (0.5 ng) generated 
a large amount o f 705 bp ORF P product which was analysed by electrophoresis through a 
1.0% (w/v) agarose gel (Fig. 50). There was a partial product from conditions of 0.5 ng 
template DNA and lOOpM primer that resulted in smearing (Fig. 50; lane 9).
Unfortunately, this ORF P product continued to be lost during the gel isolation 
experiments and consequently not enough DNA was isolated and successfully ligated into 
pFJ14H. The next strategy used to isolate the ORF P gene alone was to use a plasmid 
cloned by Mr. R. Reid (unpublished). Reid performed PCR on pGEM34.5 using different 
parameters and ligated the ORF P product into a pGEX vector. The plasmid containing 
ORF P was named pGEX/ORF P. This plasmid fused ORF P in frame with GST and the 
protein was used to generate the ORF P antisera used in this study. Using pGEX/ORF P 
the ORF P gene was isolated by Smal and BamHl digestion (data not shown). This 704 bp 
fragment was previously sequenced by Reid (personal communication). Subsequently, it 
was sub-cloned into pFJ14H.
4.4.3. Sub-cloning ORF P under the gD Promoter
The ORF P fragment was sub-cloned into pFJ14H using compatible restriction 
enzyme sites. Ligation o f ORF P into pFJ14H positioned it immediately downstream of 
the HSV-1 gD promoter and directly upstream of the HSV-2 immediately early IE5 
polyadenylation sequences. pFJ14H contains lacZ under the control of a SV40 promoter 
with its own SV40 polyadenylated sequence (Fig. 51). The lacZ  gene is in the opposite 
orientation to the ORF P gene. pFJ14H derived plasmid was digested with Xbal and the 
ORF PHacZ cassette isolated from pFJ14H.
4.4.4. Sub-cloning pFJ14H ORF P Cassette into p35(PacI)
The ORF PHacZ cassette from pFJ14H was sub-cloned into p35(PacI) by methods 
similar to those described in Section 4.1. p35(PacI) was digested with SpeI (cleavage site 
in the linker) which is compatible with Xbal which enabled the ORF PHacZ cassettes to be 
ligated and generated plasmid pHH3 (Fig. 51).
4.4.5. Generation of 1624
Cloning o f the ORF P gene was difficult and subsequently isolation o f the 
recombinant virus 1624 was delayed. Unlike 1622 and 1623,1624 was never plaque
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Table 16. The conditions for obtaining ORF P from PCR reaction.
Lane Number DGEM34.5 DNA Primer DNA
(Corresponds to (ng concentration) (molar concentration
Figure 50) for each primer)
1 * 0.5* 75pM*
2 0.5 200pM
3 5.0 75pM
4 5.0 200nM
5 0.05 lOOpM
6 0.05 50pM
7 0.05 lOpM
8 0.05 5pM
9 0.5 lOOpM
1 0 0.5 50pM
1 1 0.5 lOpM
1 2 0.5 5pM
Overall reaction mix:
Template DNA X
Primer (ORF P (N)) X
Primer (ORF P (C)) X
h 2o up to 100pi
Buffer (lOx) 1 0 . 0
dNTP [25pM/pl] 4.0
Vent DNA polymerase [lU/pl]0.5
* Corresponds to the ORF P PCR product.
153
Results and Discussion: 4.4
a.
pFJ 14H
7.80 kbp
ORF P (705bp )
b
A inp
p H H 3
13.2 kbp
Spe\
Figure 51. Diagram of ORF P sub-cloning.
a. The fragment containing the gene of interest, ORF P 705 bp was digested from 
pFJ 14H with Xbal where it had been placed under the gD promoter with the FISV-2 
IE5 polyadenylation and lacZ under the SV40 promoter in the opposite direction. 
This fragment was gel purified and ligated into the SpeI site of p35(PacI).
b. p35(PacI) containing the Xbal insert was named pHH3.
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purified as described in Section 4.1. A diagrammatic representation of the recombinant 
virus is shown in Figure 52.
4.4.6. Expression of ORF P
Two antisera (129 and 130) against a GST/ORF P fusion protein were previously 
generated in this laboratory (Reid, unpublished data). Initial findings using the 129 
antiserum in Western blot analysis of several viruses grown at different temperatures 
found that 17+ expresses ORF P during wild type infection (McKie and Reid, unpublished 
data). I repeated these findings using 129 in a Western blot with BHK infected cells at 
37°C for 16 h (Fig. 53). Different bands were detected migrating around the size of the 
expected ORF P protein. In 17+, a band o f 32 kDa was detected (Fig 53 and 54), but in 
tsK (ICP4 temperature sensitive at 39.5°C) a band o f 25 kDa was detected. 1621 was the 
only other virus that had detectable ORF P expression. 1621 is a recombinant virus that I 
constructed from 17+ which has the intact RL1 gene with a 34 bp epitope tag at the 
initiating methionine. 1621 shows two ORF P bands at 26 kDa and 33 kDa (Fig. 53 and 
54). It is not known why there are apparent Mr differences in ORF P proteins between 
1621 and tsK, and wild type. In 1716 and other HSV-1 and HSV-2 infected cell extracts 
no ORF P bands were detected. For a complete listing o f the various mutant viruses used 
in Figure 53, see Table 17. In 1716, the ORF P gene has been deleted and hence we do 
not see any ORF P protein expression. There was no ORF P protein detection from any of 
the HSV-2 viruses.
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NsiMSpeX
1716
U L 4 3 /
U L 4 3 . 5
1624
Figure 52. Schematic representation of recom binant virus 1624.
The HSV-1 strain 17+ RL1 mutant virus 1716 was used as the parental strain for 
the recombinant virus. 1624 has the ORF P open reading frame inserted downstream 
of the HSV-1 gD promoter and upstream of the HSV-2 IE5 polyadenylation sequence. 
It also has lacZ  in the opposite orientation for detection of recombinant viruses 
upon X-gal staining. V  Denotes the RL1 deletion in 1716.
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Figure 53. W estern blot of ORF P expression using 129.
Infected BHK cells were harvested 16 h pi and a Western blot of a 10% SDS- 
PAGE with 129 is shown here. In 17+ the 32 kDa ORF P is detected and 
denoted by (M). In tsK (ICP4 null mutant) only the 25 kDa ORF P protein is 
detected. In a recombinant virus 1621 which has RL1 with an epitope tag, two 
bands at 26 kDa (^ )  and 33 kDa (^ )  are detected.
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MWM 17+ 1623 1622 1716 1621 tsk
46kDa
30 kDa
21 kDa
Figure 54. W estern blot of ORF P expression using 129.
A Western blot of a gradient SDS-PAGE using 129 demonstrated a better 
separation of the different ORF P forms. Using a different set of BHK infected 
extracts 16 h pi, the 25 kDa ORF P protein is detected in 17+ ( ^) but not in tsK.
The tsK mutant has a 22 kDa ORF P protein detected (<). 1621 has ORF P proteins 
migrating at 23 kDa and 25 kDa, as above.
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Table 17. Names and brief description of HSV-1 and HSV-2 viruses.
HSV-1
17+
1716
tsK
1621
1622*
1627*
1628*
wild type HSV-1 strain 
RL1 deleted 17+ m utant 
ICP4 tem perature sensitive 17+ m utant 
Epitope tag RL1 17+ m utant 
Recom binant RL1 overexpressed in 1716 
Intertypic HSV-2 RL1 with intron in 1716 
Intertypic HSV-2 RL1 w ithout intron in 1716
HSV-2
HG52 wild type HSV-2 strain
2604 RL1 deleted HG52 m utant
G wild type HSV-2 strain
333 wild type HSV-2 strain
UW286 wild type HSV-2 strain
MS wild type HSV-2 strain
* = C haracterized  in this text.
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4.4.7. Discussion
Isolating the ORF P gene was not straight forward, the first strategy used in 
obtaining ORF P was PCR. Although PCR did generate an ORF P product the frequency 
was very low (1 in 20). The second strategy, using a plasmid containing the ORF P gene 
cloned by Reid, was more successful. The ORF P gene digested from this plasmid was 
sub-cloned into pFJ14H. The ORF PHacZ cassette was then sub-cloned into p35(PacI) 
yielding the new plasmid pHH3. 1716 DNA and pHH3 were co-transfected to generate the 
recombinant virus 1624. The plaque purification of 1624 was not completed since cloning 
difficulties delayed transfection o f this recombinant virus. The aim o f generating 1624 
was to directly compare it with 1622, or another recombinant virus which only expresses 
ICP34.5. The future o f 1624 will hopefully determine the phenotype attributed to ORF P 
in vitro and in vivo in strain 17+.
A novel result found in this study using other mutant viruses and the antisera made 
by Reid is that strain 17+ can express ORF P during a lytic infection at 37°C. This 
contradicts published work using HSV-1 strains F and KOS which demonstrated that ORF 
P was repressed by a strong ICP4 binding site in the promoter. Another mutant virus, 
1621, also showed expression o f different forms of ORF P. 1621 was a mutant virus 
generated to locate at ICP34.5 by immunofluorescence with a 34 bp epitope at the 
initiating methionine. The 11 amino acid tag at the carboxy terminus of ORF P in 1621 
probably contributes to the increased size o f ORF P proteins by SDS-PAGE. HSV-2 
viruses had no detectable ORF P expression by Western blotting.
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5. HSV-2 RESULTS AND DISCUSSION
5.1. CONSTRUCTION OF A HSV-2 ICP34.5 /GST FUSION PROTEIN
5.1.1. Introduction
Due to the inability o f HSV-1 ICP34.5 antisera to recognize HSV-2 ICP34.5, we 
generated antisera against ICP34.5 of HSV-2 strain HG52. In order to do this, a HSV-2 
ICP34.5/GST fusion protein was constructed. The relevance of these findings will be 
discussed in the following sections and in the Final Discussion (Section 7).
5.1.2. Cloning of pGEX-2T(N+l) and HSV-2 RL1
The 782 bp PCR fragment generated from pSB2 (Section 5.2) which contains the 
complete ICP34.5 ORF, including the initiating methionine but lacking the intron was 
digested with Hindlll and ligated in frame to the 3’end o f GST at the Hindlll site of the 
vector pGEX-2T(N+l) (Fig. 55, 56; Merideth et al., 1994). Recombinant colonies were 
isolated and their DNA structure determined (data not shown).
AGA ATT CGG AAG CTT CGC CGA GCC CAG CCG CCC GCC (ATG) 
R I R K L R R A E P  P A ( M )
Figure 55. Amino acids at the junction o f the GST and ICP34.5 fusion protein.
Sequence at the junction between the 3’ end o f GST in pGEX2T(N+l), and the RL1 PCR 
product from pSBl. The encoded amino acids are indicated below the DNA sequence.
The RL1 PCR product, ending in the initiating ATG, is in bold text. The ATG is bracketed 
to indicate it was not in the primer used to generate the PCR product. The Hindlll site 
used for cloning into pGEX-2T(N+l) is underlined.
5.1.3. Protein Purification
To express the GST/ICP34.5 fusion protein, plasmids were transformed into E. coli 
strain BL21. Following induction with IPTG, the 26 kDa GST band seen with pGEX- 
2T(N+1) was replaced by several bands, the largest of which corresponded to the expected 
55 kDa size o f the fusion protein, based on the number o f amino acids of ICP34.5 (261) 
and the apparent Mr o f the HSV-1 ICP34.5/GST fusion protein (Brown et al., 1997).
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pSB2
4 .6 6  kbp
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Amp
G S T
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2T(N+1)
4.90 kbp
P»»c
lac I
G ST/ICP34.5 fusion protein
Figure 56. D iagram m atic representation of cloning HSV-2 ICP34.5/GST fusion.
The HSV-2 RL1 PCR product from pSB2 which contained the RL1 gene was sub-cloned 
into pGEX-2T(N+l). The position of the primers are marked by blocks. This 
generated a fusion between glutathione S-transferase and ICP34.5.
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Despite the presence o f protease inhibitors, there was an abundance of lower Mr products, 
which were believed to be the result o f proteolytic degradation. All of these proteins 
bound efficiently to the glutathione agarose beads and were readily eluted with reduced 
glutathione. These bands were apparent both on Coomassie staining (Fig. 57a) and 
Western blotting with an anti-GST antibody (Fig. 57b).
5.1.4. Screening of Antisera 596 and 597
A sufficient quantity of fusion protein was generated by bulk growth, to immunise 
two New Zealand White rabbits (596 and 597) as described in Section 3.32. Test bleeds 
were taken every seven weeks, and a final bleed taken 2 0  weeks post immunization. 
Antisera were screened against HSV-2 infected cells by Western blotting. Extracts were 
prepared from mock infected cells and cells infected with HSV-2 strain HG52 and the RL1 
deletion mutant 2616. Both antisera (596 and 597) specifically detected ICP34.5 in HG52 
extracts up to a dilution o f 1:800 (Section 5.3).
5.1.5. Interaction of HSV-2 ICP34.5 with PCNA
Previously, Brown et al (1997) demonstrated that ICP34.5 of HSV-1 interacts with 
the 36 kDa proliferating cell nuclear antigen (PCNA) through the 63 amino acid conserved 
domain at the carboxy terminus. To determine if  HSV-2 ICP34.5 had a similar interaction 
a pull-down experiment was performed using the GST/HSV-2 ICP34.5 protein. The 
pulled down proteins were analysed by Western blot using a monoclonal antibody against 
PCNA. This monoclonal antibody specifically recognised a 36 kDa protein present in 
BHK cell extracts (Fig. 58). This protein was pulled down by HSV-2 ICP34.5/GST but 
not by GST alone demonstrating that ICP34.5 of HSV-2 also interacts with PCNA.
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Figure 57. Induction of GST/ICP34.5 fusion protein.
a. Coomassie stained gel of GST and GST/ICP34.5 fusion protein with Markers shown.
b. A Western blot o f GST or GST/ICP34.5, analysed by 10% SDS-PAGE,
Western blotted and reacted with a GST monoclonal antibody. Samples eluted from beads 
(Elute), samples bound to glutathione agarose beads (Beads) whole cell extracts (WC). A 
novel GST/ICP34.5 fusion protein migrates at 55 kDa with predominant degradation products 
at 45 kDa, 40 kDa and 36 kDa . GST is also indicated by an open arrow.
Elute Beads WC
164
Results and Discussion: 5.1
PCNA
Figure 58. W estern blot of a pull-down of PCNA by GST/ICP34.5.
A GST pull-down using the GST/ICP34.5 fusion protein (with GST as a control) 
was performed on BHK cell extracts, analysed by 10% SDS-PAGE,
Western blotted and reacted with a monoclonal antibody to PCNA. The 36 kDa 
PCNA protein is indicated.
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5.2. CONSTRUCTION OF HSV-2 RL1 RECOMBINANT VIRUSES
5.2.1. Introduction
The protein, ICP34.5, encoded by the RL1 gene was first detected in HSV-1 (Chou 
and Roizman, 1986, 1990; McKie et a l , 1994). The RL1 gene has also been demonstrated 
in HSV-2 strain HG52 (McGeoch et al., 1991; Dolan et a l , 1998). The HSV-2 RL1 gene 
has a high level o f homology especially at the carboxy terminus with HSV-1 RL1, 
although there is a 154 nucleotide intron present in the HSV-2 gene which is not present in 
HSV-1 (Harland et al., 1996).
The functional similarities o f HSV-1 and HSV-2 RL1 have been studied through 
deletion mutants in both viruses. Deletion of the RL1 ORF causes replication defects in 
certain cell types and renders the virus non-pathogenic in vivo. In HSV-1, ICP34.5 has 
been detected by Western blots with polyclonal antisera raised against the HSV-1 RL1 
ORF. These antisera do not recognise HSV-2 ICP34.5. In order to identify ICP34.5 in 
HSV-2 a 2-fold strategy was devised. First, recombinant viruses expressing HSV-2 RL1 
under a strong promoter in an HSV-1 RL1 deleted backbone were constructed. Second, 
antisera to a HSV-2 RL1/GST fusion protein were raised (Section 5.1).
Recombinant viruses were studied to determine if  there is a difference in ICP34.5 
expression in the presence or absence o f the intron. Cassettes expressing ICP34.5 were 
inserted into the nonessential UL43 locus in the RL1 deletion mutant 1716. The basic 
cassette was composed o f lacZ downstream of the SV40 promoter in one orientation and 
RL1 in the other orientation downstream of the HSV-1 gD promoter. These cassettes will 
be described briefly since they follow the same experimental procedures as for the mutant 
viruses 1622, 1623 and 1624 described in detail in previous sections (Sections 4.2-4.4).
5.2.2. pSBl and pSB2
The HSV-2 RL1 gene was originally cloned from the BamHl g  fragment (Fig. 59; 
Davison, 1981). pSB l contains the intact RL1 gene from HSV-2. pSB2 was constructed 
by site directed mutagenesis to specifically delete the intron within RL1 (Bdour, 1995) 
(Fig. 60c). PCR was performed on pSBl and pSB2 to isolate RL1 with and without the 
intron (Fig. 60b and d, respectively). PCR products varied in length due to the intron. The 
RL1 PCR product from pSBl which included the intron was 1015 bp and was 
correspondingly 154 bp longer than the PCR product from pSB2 which is 961 bp. The 
oligonucleotide primers were designed to have Hindlll ends for compatibility o f sub-
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Figure 59. Schematic representation of BamHl sites in the HSV-2 genome and 
RL1 diagram m atic location.
a. HSV-2 strain HG52 genome with BamHl sites indicated by a through f . The 
BamHl fragment, g, the L/S junction fragment consists of the v and u sequences.
b. The g  fragment expanded to show the position of the R L1 and RL2 genes
and the a’ sequence, c. The RL 1 gene including n.p. positions o f the IRj copy of the 
gene and intron. The consensus sequence found in Exon 2 is indicated by the yellow 
box.
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Figure 60. pSBl and pSB2 PCR products containing HSV-2 RL1.
a. and c. are maps of the HSV-2 RL1 containing plasmids.
b. and d. 2% agarose gels of PCR products from the pSB 1 or pSB2. b. Lanes
1,3,4,  and 6 contain the correct size PCR product, 1015 bp from RL 1. d. Lanes
1,2, 4, 7, 9, 11, and 12 contain the correct size PCR product,
961 bp from pSB2
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cloning into pFJ14H.
5.2.3. pFJ14H/I+, pFJ14H/I" and p35(PacI)
The HSV-2 RL1 PCR products were sub-cloned into pFJ14H placing the gene 
downstream of the gD promoter (Fig. 61a,b). Thus two new plasmids, pFJ14H/I+ and 
pFJ14H/I', were constructed. The orientation of the PCR product was determined to 
ensure RL1 was in the correct orientation with respect to the gD promoter (data not 
shown). These two plasmids were digested with Xbal to isolate the RL1 and lacZ genes in 
one cassette which was sub-cloned into plasmid p35(PacI) (Fig. 61c,d). These plasmids 
were separately co-transfected with 1716 DNA to construct recombinant viruses.
To confirm the gene structure integrity, the RL1 PCR fragments were sub-cloned 
into the plasmid pGEM3zf(-) and sequenced with forward and reverse primers with an ABI 
370A automated DNA sequencer at the Institute o f Virology, Glasgow. These sequences 
were placed in the GCG program ‘best-fit’ to confirm sequence identity.
5.2.5. Construction of 1627 and 1628
Co-transfections o f recombinant plasmid p35(PacI), containing HSV-2 RL1 with or 
without the intron, with 1716 DNA were carried out on BHK cells to generate new 
recombinant viruses, 1627 and 1628 respectively, as described in Section 3.19 (Fig 62). 
Several individual plaques were isolated and taken through 2 to 3 rounds o f plaque 
purification and detection by X-gal staining (Section 3.15.1.). DNA from each plaque 
isolate was screened by digestion with the restriction enzymes BamHl and Hindlll and 
Southern blotting with radiolabelled p35(PacI) (Fig. 63). 1627 and 1628 contain one extra 
BamHl and two extra Hindlll sites within the UL41-UL44 region due to the inserted 
RL1 HacZ genes. The Hindlll sites flank the HSV-2 RL1 and promoter giving fragments of 
4.1 kbp and 12.3 kbp (Fig 63a,b). There was also a fragment o f 1 kbp containing RL1 
which was not detected by the p35(PacI) probe used. The BamHl site is located between 
the RL1 and lacZ genes giving two fragments of 4.5 kbp and 7.8 kbp (Fig 63a,b).
Once plaque purification o f 1627 and 1628 was complete viral stocks were made 
on BHK cells (Section 3.13). To confirm the DNA structure and purity of the recombinant 
viruses after stock growth, DNA was extracted, purified and digested with BamHl. Wild 
type, 17+, and 1716 were used as controls. 17+ and 1716 have one BamHl fragment of 6 . 6
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Figure 61. Plasmids used to sub-clone HSV-2 RL1 into 1716 UL43.
a. PCR was performed on pSBl and pSB2, the PCR products were 
separated by agarose gel electrophoresis and purified (Fig. 58). b. PCR 
fragments from pSBl and pSB2 were individually sub-cloned into pFJ14H 
using compatible restriction enzyme sites, c. and d. The pFJ14H fragments 
containing FISV-2 RL1 from pSBl or pSB2 were isolated by Xbal digestion,
1% (w/v) agarose gel electrophoresis and purification (not shown). A schematic 
representation of the cassettes isolated from pFJ14H is shown here. The 
cassettes depicted were individually sub-cloned into p35(PacI). The 
individual clones were co-transfected with 1716 DNA by CaP04 method.
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6 .6  kbp
17161 1 .
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111.
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Figure 62. Schematic representation of the recom binant viruses.
i. A diagrammatic representation of the wild type HSV-1 strain 17+ genome with the 
size of BamHl fragment spanning UL43. ii. 1716 which has both copies of RL1 deleted 
which is depicted b y ^ .  iii. and iv. 1627 and 1628 are new intertypic recombinant 
viruses containing the HSV-2 RL1 under the HSV-1 gD promoter and a lacZ gene under 
a SV40 promoter in the UL43 gene of 1716. iii. 1627 has the HSV-2 RL1 gene with the 
intron. iv. 1628 contains the HSV-2 RL1 excluding the intron.
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Figure 63. Southern blots of 1627 and 1628 plaque purification.
a. Schematic diagram of a Hindi 11 and BamHl digestion in the UL43 sequence of 174 
and 1627/1628. b. After each round of plaque purification recombinant, different 
virus plaques were selected for Southern blotting. This Southern blot shows 2 plaques from
1627 (lanes 1-2; 5-6) and 1 from 1628 (lanes 3 and 6). Viral DNA was extracted and 
digested with Hindlll or BamHl and electrophoresed through a 1% (w/v) agarose gel with a 
1 kbp DNA ladder (lane 7) for size comparison and Southern blotted with p35(PacI). The 
Hindlll digest gives bands of 4.1 kbp and 12.3 kbp. BamHl digestion gives bands of 4.5 kbp 
and 7.8 kbp.
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kbp spanning the UL41-UL44 region when digested with BamHl and hybridised with 
radiolabelled p35(PacI) (Fig. 64). The recombinant viruses contain an extra BamHl site in 
the RL1 cassette which divides the fragments into two bands o f 4.5 kbp and 7.8 kbp (Fig. 
64).
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Figure 64. Southern blot of v iral stocks.
HSV DNA was digested with BamHl, analysed on a l%  (w/v) agarose 
gel and Southern blot. The membrane was probed with [32P] labelled 
p35(PacI). There is a single 6.6 kbp band in 17+ and 1716. 1627 and 1628 have 
two bands of 7.8 kbp and 4.5 kbp.
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5.2.5. Discussion
Several queries about HSV-1/2 ICP34.5 and virulence led us to address if  HSV-2 
RL1 could complement HSV-1 RL1. We also wanted to determine if HSV-2 ICP34.5 was 
expressed. Western blots using antisera against HSV-1 ICP34.5 did not detect protein 
from wild type HSV-2 strain HG52, 1627 or 1628. The HSV-2 RL1 gene was placed 
under a strong promoter (HSV-1 gD) which was believed would aid in the detection of 
HSV-2 ICP34.5. Two recombinant viruses were constructed based on the HSV-1 ICP34.5 
negative mutant, 1716. These recombinant viruses contain the HSV-2 RL1 gene with and 
without the 154 bp intron. Detection o f ICP34.5 was assessed in the subsequent sections 
(Sections 5.2 and 5.3).
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5.3. CHARACTERIZATION OF 1627 AND 1628
5.3.1. Introduction
Initial studies using 1627 and 1628 in Western blots using the HSV-1 ICP34.5 
antisera did not lead to the recognition o f HSV-2 ICP34.5. Using the new antisera (596 
and 597) raised against the HSV-2 RL1/GST fusion protein, Western blots were carried 
out.
5.3.2. HSV-2 ICP34.5 Expression
Two bands o f 37 kDa and 27 kDa were specifically detected in HG52 infected 
extracts (Fig. 65a,b). The 37 kDa band corresponds to the size of the HSV-1 protein (Fig. 
6 6 a) which migrates approximately 10 kDa slower than its predicted Mr. The 27 kDa 
protein is close to the predicted size of 27.9 kDa. To help determine which protein 
corresponded to ICP34.5 and to see if  there was a relationship between the two proteins, 
expression was analysed from a number o f different viruses: 2624, a HSV-2 mutant 
lacking the RL1 intron; and the two HSV-1 1716 based recombinants described in Section 
4.6: 1627 (expressing HSV-2 ICP34.5 containing the intron) and 1628 (expressing HSV-2 
ICP34.5 lacking the intron). HG52 and 1627 gave similar profiles with both the 37 kDa 
and 27 kDa proteins present with the 27 kDa protein being the predominant form (Fig. 
65a,b). In contrast, 2624 and 1628 only expressed the 37 kDa protein (Fig. 65a,b).
In order to demonstrate ICP34.5 protein specificity, 17+, HG52, 1627, and 2616 
infected BHK extracts were harvested at 16 h pi. These samples were analysed by 10% 
SDS-PAGE and Western blotting using 137 and 597 (Fig. 6 6 a,b). ICP34.5 from 17+ co­
migrated with ICP34.5 from HG52 by comparison with different antisera. This suggests 
that the protein expressed from the predicted HSV-2 RL1 ORF is the 37 kDa protein. The 
antisera raised against HSV-2 ICP34.5 did not recognize the HSV-1 homologue (Fig. 6 6 b). 
A number o f other virus induced bands were detected by Western blot (especially with 
antiserum 596; Fig. 65a). One particular band to note is a 36 kDa protein migrating faster 
than the 37 kDa ICP34.5. To test other viral protein synthesis and ascertain a Western 
blot using an HSV-1 US 11 antiserum was carried out. Infected cell extracts used in 
Figure 65 were used to look for expression o f the 21 kDa US 11 protein (Fig. 67). This 
confirms that another HSV-1 protein is expressed in 1627 and 1628 with the same kinetics 
as 17+and 1716.
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Figure 65. W estern blots with anti-ICP34.5 sera.
BHK cells were infected with a m.o.i. of 20 pfu/cell for 16 hours. The infected 
cells were harvested, analysed on a 10% SDS-polyacrylamide gel and Western blotted 
with antisera from the GST/HSV-2 ICP34.5 fusion protein, 596 and 597, using a 1:800 
dilution of each a. and b, respectively. Both antisera 596 and 597 recognize two 
proteins of 27 kDa and at 37 kDa, in HG52 and 1627. The antisera recognise only one 
protein of 37 kDa in 2624 and 1628. HSV-1 strain 17+ ICP34.5 is not recognized by 
either 596 or 597. Molecular weight markers are indicated.
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Figure 6 6 . W estern blots with anti-ICP34.5 sera.
BHK cells were infected with a m.o.i. of 20 pfu/cell for 16 hours. The infected 
cells were harvested, analysed on a 10% SDS-PAGE and Western blotted with 137, 
a GST/HSV-1 ICP34.5 fusion protein, or with antiserum 597 against GST/HSV-2 ICP34.5 
fusion protein, a. As previously observed antiserum 137 recognizes the 37 kDa ICP34.5 
in HSV-1 strain 17+ infected cell extracts, but fails to recognise any specific bands in 
HSV-2 strain HG52 extracts, b. A Western blot with antiserum 597 shows specific 
recognition of two proteins 37 kDa and 27 kDa in HG52 and 1627, but only 37kDa in 2624 
and 1628. Molecular weight markers are given by the side of gel.
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Figure 67. W estern blot of US11 protein.
BHK cells were infected with a mulitplicity of 20 pfu/cell. Infected cells were 
harvested 16 h pi and analysed by 10% SDS-PAGE and Western blotted with anti-US 11 
monoclonal serum. US11 is expressed in 1627 and 1628 at the same level as wild 
type 17+ and 1716.
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5.3.3. Fractionation of ICP34.5 in HSV-2
Cell fractionation experiments were performed to determine the location of the two 
ICP34.5 proteins. Cells infected with HG52, 2624 and the RL1 negative virus 2616 were 
harvested at 16 h pi (Fig. 6 8 ). Samples were separated into nuclear and cytoplasmic 
fractions by hypotonic buffer at 4°C, analysed by 10% SDS-PAGE and Western blotted 
using antiserum 596. The 27 kDa and 37 kDa proteins were distributed similarly, 
predominantly present in the cytoplasm (Fig. 6 8 ). This HSV-2 ICP34.5 protein 
compartmentalization parallels the HSV-1 ICP34.5 cellular distribution.
5.3.4. Immunoprecipitation of HSV-2 ICP34.5
Immunoprecipitation (IP) experiments using both antisera, 596 and 597, were
35
earned out on [ S]methionine labelled extracts prepared from HG52, 2624, 2616, 1627, 
1628, and mock infected cells harvested 6  and 16 h pi. There are only 2 methionines in
35
HSV-2 ICP34.5, and incorporation of [ SJmethionine is poor. Upon autoradiography no 
specific bands could be detected (data not shown). The IP samples were Western blotted 
using 597. When BHK cells were infected at 10 pfu/cell and harvested at 6  h, 
immunoprecipitated and Western blotted with 597 no ICP34.5 proteins were detected (Fig. 
69, lanes 1-6). Infected cells harvested at 16 h pi which were immunoprecipitated and 
Western blotted with 597 showed an unusual ICP34.5 protein profile (Fig. 69, lanes 7-12). 
The ICP34.5 protein with an apparent Mr of 37 kDa was barely detected in HG52 (lane 7). 
The ICP34.5 protein of Mr 37 kDa fluctuated by 1-2 kDa between 2624 (lane 9), 1628 
(lane 12) and 1627 (lane 11). The faster migrating protein named ICP34.5A with an
apparent Mr o f 27 kDa was detected in HG52 (lane 7) and 1627 (lane 11). ICP34.5A of 27
kDa from 1627 was detected better than from HG52. There was an additional strong band 
in 1627 with a Mr o f 23 kDa (lane 11). Two additional bands less strongly recognised in 
1627 were 30 kDa and 20 kDa (lane 11).
The HG52 and 1627 ICP34.5A protein of 27 kDa was detected at 6  h pi using 596 
antiserum in an IP migrating slightly faster in 1627 (Fig. 69, lane 13,17). No other 
proteins were detected from other infections by 596 IP at 6  h pi (lanes 14-15,18). At 16 h 
pi the HG52 IP using 596 shows several bands surrounding the major protein ICP34.5 of 
37 kDa (Fig. 69, lane 19). To clarify that these were individual bands a lighter exposure of 
the autoradiograph was taken and shown in Figure 69b. An unidentified protein migrating
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Figure 6 8 . Localisation of ICP34.5 in BHK cells.
BHK cells were infected at a m.o.i. o f 20 pfu/cell with HG52, 2616 or 2624 and 
harvested at 16 hours post infection. A fraction of the whole cell extract (WC) was kept 
for analysis and the remainder separated into nuclear and cytoplasmic fractions. The 
samples were analysed by 10% SDS-PAGE and Western blotted with 597 antiserum.
The 37 kDa ICP34.5 and 27 kDa ICP34.5A bands are present in the whole cell 
extract and predominantly the cytoplasmic fraction. Molecular weight markers are shown.
Results and Discussion: 5.3
597 A b  596 A b
>7kDa|
>7kDa
1 2 3 4 5 6  7 8  9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Figure 69. W estern blot of HSV-2 ICP34.5 IP.
a. BHK cells infected at a m.o.i. of 10 pfu/cell. Samples were harvested either at 6 h pi (lanes 1-
6; 13-18) or 16 h pi (lanes 7-12; 19-24) The * denotes the reacting 50 kDa IgG heavy chain. 
HG52 (lanes 1,7,13,19), mock infected (2,8,14,20), 2624 (3,9,15,21), 2616 (4,10,16,22), 1627 
(5,11,17,23), and 1628 (6,12,18,24).
b. To clarify individual bands seen in HG52 migrating around 37 kDa (lane 19), a lighter 
exposure was made. There are at least 4 distinct bands.
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at 23 kDa was detected from HG52 (lane 19) and 1627 migrating apparently slightly faster 
(lane 23). This protein of 23 kDa was also detected from 1627 IP using 597 (Fig. 69, lane 
11). The 37 kDa ICP34.5 is detected from 2624 (lane 21) and 1627 (lane 23) but not 
detected from 1628 (lane 24).
The experiment was repeated to examine more closely the ICP34.5 and ICP34.5A 
migration patterns from infected cell extracts. Infected BHK cells were harvested at 16 h 
pi (Fig. 70). Only the 27 kDa ICP34.5A protein was detected from HG52 (Fig. 70, lane 5) 
and 1627 (Fig. 70, lane 3) while 2624 and 1628 showed only detection of the 37 kDa 
ICP34.5 protein. A faint cellular band migrating at 36 kDa could be detected in all viruses 
(Fig. 70, lanes 2-6) and mock (Fig 70, lane 1) infected extracts.
Samples were immunoprecipitated and subjected to 10% SDS-PAGE. A Western 
blot using 597 was performed and shown in Figure 70. The 50 kDa IgG heavy chain is 
detected in the Western blot due to the interaction with Protein A-HRP.
From the Western blot and IP experiments it appears that the 37 kDa protein is the 
same size in all four viruses analysed, but from 1627 infection the 27 kDa ICP34.5A 
protein migrates slightly (1-2 kDa) faster than that from HG52.
5.3.5. In  vitro Replication from  1627 and 1628 Infected Cells
To determine if  expression of HSV-2 ICP34.5 could compensate for loss of HSV-1 
ICP34.5 in an HSV-1 background and if the 27 kDa protein performs an essential in vitro 
function, we analysed the growth o f several different HSV-1 and HSV-2 viruses in 
different cells.
In replication experiments, all viruses grew like their wild type parent in BHK 
cells. 17+, 1716, 1627 and 1628 grew similarly as did HG52, 2624 and 2616 (data not 
shown) in the permissive BHK cells (Fig. 71; Table 18).
In additional experiments using 3T6 cells, a cell line that is non-permissive for RL1 
deleted viruses, 1627 returned to the wild type growth of HSV-1 strain 17+ (Fig 72; Table 
18). The input titre of 1628 was approximately 1 log lower than 17+ and 1627, 
consequently the replication of this virus appears slightly impaired. Alternatively, this 
might be a consequence of the lower level expression of HSV-2 ICP34.5.
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Figure 70. W estern blot of im m unoprecipitated HSV-2 ICP34.5.
BHK cells were infected at a m.o.i. of 20 pfu/cell with mock (lane 1), 1628 (lane 2), 1627 (lane 3), 
2624 (lane 4), 2616 (lane 5), and HG52 (lane 6). Samples were harvested at 16 h pi, 
immunoprecipitated with antiserum 597, electrophoresed through 10% SDS-PAGE and Western 
blotted with 597. Infected cell extracts before IP shows detection of the 27 kDa ICP34.5A from 
1627 (lane 3) and HG52 (lane (6). The 37 kDa ICP34.5 protein is detected from 1628 (lane 2) 
and 2624 (lane 4). A cellular protein of apparent Mr 36 kDa is detected in all virus infections.
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Figure 71. In vitro growth of 1627 and 1628 in BHK cells.
BHK cells were infected at a m.o.i. of 0.1 pfu/cell. Infected cells were harvested 
at 0, 12 and 72 h pi. Infected cells were harvested, sonicated and titrated on 
BHK cell monolayers.
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Figure 72. In  vitro growth of 1627 and 1628 in 3T6 cells.
3T6 cells were infected at a m.o.i. of 0.1 pfu/cell and
harvested at 0, 2, 6, 8, 12 and 36 h pi. Infected cells were harvested, sonicated 
and titrated on BHK cell monolayers.
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Table 18. BHK and 3T6 titres for single cycle growth kinetics.
BHK cells
17+ 1716 1627 1628
0 4.0x104 1.0x10s 1.0x10s 5.0xl04
13 4.8x105 3.0xl06 1.0x10s 1.0x10®
75 3.0x10s 3.0x10® 3.0x10® 1.0x10®
3T6 cells
17- 1716 1627 1628
0 2 .0x104 2 .0x10s 3.0x10® 4.0x10®
2 4.0x104 2 .0x10® 3.0x10® 4.0x10®
4 3.0xl04 6.0x104 3.0x10® 2 .0x10®
8 5.0x10s 4.0x10® 7.0x10® 4.0x10®
12 6.0x10® 1.0x10® 2 .0x10® 1.0x10®
35 4.0x107 2 .0x10® 8.0x10® 1.0x10®
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5.3.6. Host and Viral Protein Synthesis from 1627 and 1628 Infected Cells
The inability o f HSV-1 ICP34.5 deleted viruses to prevent host and viral protein 
synthesis shut-off in SK-N-SH cells has been extensively characterized. However, this 
effect has been less well studied in HSV-2. To look at the phenotype of HSV-2 ICP34.5 
and to determine if  the intron plays a role in this function, host protein synthesis shut-off 
experiments were performed in SK-N-SH neuroblastoma, 3T6, HeLa and BHK cells.
The intertypic recombinants 1627 and 1628 were used in an initial experiment to 
determine if  HSV-2 RL1 could restore protein synthesis in HSV infected SK-N-SH and 
HeLa cells (Fig. 73). No protein shut-off was observed by any virus infected BHK cell 
extracts. 1627 and 1628 prevented the preclusion of host shut-off seen with 1716 in SK-N- 
SH cells. In HeLa cells, the ICP34.5 negative HSV-1 virus 1716 and 1628 had reduced 
protein synthesis compared to wild type 17+ and 1627 (Fig. 73). Additional experiments 
were carried out to analyse HSV-2 RL1 deleted viruses since this had not previously been 
studied (Fig. 74). 2616 did not shut-off protein synthesis in BHK cells which mimics the 
HSV-1 RL1 deleted virus, 1716 data (Fig. 73).
There was no observable difference between wild type and the intron containing 
recombinant virus, 1627 (Fig. 73 and 74). The intronless recombinant virus, 1628, 
appeared to give a partial shut-off o f protein synthesis in SK-N-SH cells (Fig. 73 and 74). 
In SK-N-SH cells, viruses fell into two groups: 1) those which continued protein synthesis: 
17+, HG52, 2624, 1627 and 1628; and 2) those where protein synthesis was severely 
reduced: 1716 and 2616 (Fig. 74). 3T6 cells were also examined and show that protein 
synthesis, as predicted, was maintained in all viruses studied (Fig. 75).
Similarly to the growth kinetics, we can conclude that HSV-2 ICP34.5 
complements the function o f the HSV-1 homologue in HSV-1 RL1 deleted viruses with 
this protein conferring the full function o f preventing the cessation o f protein synthesis in 
SK-N-SH neuroblastoma cells.
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Figure 73. V iral and host protein synthesis in hum an neuroblastom a cells.
BHK, HeLa, and SK-N-SH cells were infected with a m.o.i. of 20 pfu/cell for 14 h and 
pulse labelled with [35S]methionine for 2 h. Infected cells were harvested 16 h pi and 
analysed by 10%SDS-PAGE. HSV-1 viruses, 17+, 1716 and recombinant viruses, 1627 
and 1628, synthesized proteins equally well in BHK cells. In SK-N-SH cells 1716 
displayed shut-off of protein synthesis. In HeLa cells 1716 and 1628 gave a partial 
shutoff of protein synthesis.
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Figure 74. V iral and host protein synthesis in human neuroblastom a cells.
BHK and SK-N-SH cells were infected with a m.o.i. of 20 pfu/cell for 14 h and pulse 
labelled with [33S]methionine for 2 h. Infected cells were harvested 16 h pi and 
analysed by 10% SDS-PAGE. HG52, 2616, 2624, and 1716 recombinant viruses, 
1627 and 1628, synthesized proteins equally well in BHK cells. In SK-N-SH cells 
2616 and 1628 displayed shut-off of protein synthesis.
190
Results and Discussion: 5.3
B H K
■BW"
Figure 75. V iral and host protein synthesis in 3T6 cells.
BHK and 3T6 cells were infected with a m.o.i. of 20 pfu/cell for 14 h and pulse 
labelled with [35]Smethionine for 2 h (14 to 16 h pi). Infected cells were harvested 
16 h pi and analysed by 10% SDS-PAGE. All viruses in both cell lines maintained 
protein synthesis.
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5.3.7. Discussion
This work provides the first demonstration that the RL1 gene in HSV-2 strain 
HG52 expresses a homologue of HSV-1 ICP34.5. This is not surprising as deletion of RL1 
in both HSV-1 and 2 produces a similar avirulent phenotype (Taha et a l, 1989, MacLean, 
A., et a l, 1991). Antisera raised against the HSV-1 homologue do not cross-react with the 
putative HSV-2 gene (Brown et al., 1997). Therefore, we constructed a GST fusion 
protein containing the whole o f the HSV-2 RL1 ORF. This was used to raise two rabbit 
polyclonal antisera. These new antisera specifically recognize two proteins o f 27 kDa and 
37 kDa from wild type HSV-2 infected cells. Interestingly, infection with viruses 
expressing RL1 without the intron exclusively express the 37 kDa protein. This implies 
that the 37 kDa protein is the product o f the predicted spliced RL1 gene and that the 27 
kDa protein contains sequences from the intron. To indicate its close relationship to 
ICP34.5, we have named this 27 kDa protein ICP34.5A. The origin of the 27 kDa protein 
requires further investigation. One possible explanation is translation of a non-spliced 
transcript, or one terminating before the intron acceptor site, to the first in frame stop 
codon in the intron. This would produce a 185 amino acid protein containing the first exon 
o f ICP34.5 plus additional 21 amino acids from the intron (Fig. 76), approximately two- 
thirds of the 261 amino acid length and the Mr of ICP34.5. The theoretical Mr would be 
19 kDa compared to that o f ICP34.5 o f 27.9 kDa (McGeoch et al., 1991). However, like 
the HSV-1 protein (McKay et a l, 1993) the apparent Mr o f HSV-2 ICP34.5 by SDS- 
PAGE is 37 kDa, larger than the predicted Mr of ICP34.5A of 26-27 kDa. The increased 
apparent Mr o f ICP34.5 is a feature in common with many other HSV polypeptides 
(McGeoch et a l, 1988).
192
R esults and Discussion: 5.3
125830 +---------- +--------- +---------+---------+----------125899
e  * V A R R G P G
125900 +---------- +--------- +---------+---------+----------125959
e  A A A S S G R A A A A A E E E E A P G G
125960 +--------- +--------- +--------- +--------- +----------126019
e  D E H A R A R A R A R A V A R R G P G A
126020 + ------- ~ + ~ ~ + ---------- --------+ -_ -------126079
e A A s S G R  A A A A A E E E E A P G G D
126080 + --------- - - + ---------- - + - --------+ _ _ -------126139
e E H A R  A R  A L R  A A T  E W  A V  L H R  V
126140 + --------- ~ + ---------- --------+ . . -------126199
d  A R A A L L V G A P P S V R P D S P R *
e Q V R P S F C V Q P R P S V P T P P A D
f  C A R R S A C R R A P L C P P R L P T L
126200 +---------- +--------- +---------+---------- +---------126259
d P T P P A D P P R L P T L P D S P R * P
e P P R L P T L P D S P R * P T P P A D P
f  P D S P R * P T P P A D P P R L P T L P
126260 +---------- +--------- +---------+---------- +---------126319
d T P P A D P P R L P T L P D S P L R V  K
e  P R L P T L P D S P R * P T P P S A Y R
f  D S P R * P T P P A D P P R L P P T G E
126320 +--------- +--------- +-------- -+— -----+----------126379
d  G R P A D A P P S A P P R R R R L S L R
126380 +---------- +--------- +---------+---------- +---------126439
d  A L Y E T T T R L R L A L H P P L P R Q
126440 +---------- +--------- +---------+---------- +---------126499
d  P G R E K R P P P P P C A A A P A A H P
126500 +---------- +--------- +---------+---------- +---------126559
d  A E P A K G G G E S P P S N A W E A D D
126560 +---------- +--------- +---------+---------- +---------126619
d  N G A Y D A D D S D D A Q P V L L W R R
126620 +---------- +--------- +---------+---------- +---------126679
d  L L S S A A P A S E V A T G S D Y A P V
126680 +---------- +--------- +---------+---------- +---------126739
d  M Q S D A T P L A G P R P V A P A G P R
126740 +---------- +--------- +---------+---------- +---------126799
d  P V A P A G P R P R R R P G R R R P G R
126800 +---------- +--------- +---------+---------- +---------126859
d  R  R  S M
Figure 76. Amino acid sequence o f ICP34.5 with the three forward reading frames in the 
intron. The I R l  ICP34.5 sequence from the initiating methionine is shown at the bottom of 
this figure. The amino acid sequence if  the mRNA is not spliced and thus translation 
continues in the same frame (d) is underlined in the intron until reaching a stop codon at 
n.p. 126256.
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There is no evidence o f a polyA site in the intron (McGeoch et a l, 1991) to suggest 
expression o f a truncated RL1 RNA.
An alternative possibility for the origin of ICP34.5A is expression o f a protein, from 
a 5’ truncated transcript, initiating in the intron and containing exon 2. Although this is 
less likely because there is no in-frame ATG in the intron to initiate translation, another 
HSV-2 gene, UL16, initiates with a Leu instead o f the usual Met (Dolan et al., 1998). 
Determination o f the nature o f ICP34.5A will require analysis of viruses with mutations 
either in exon 1, 2 or the intron. RNA mapping would also help determine the origin of 
ICP34.5A.
The generated antisera recognize ICP34.5 and ICP34.5A by Western blotting and 
immunoprecipitation indicating recognition of both denatured and native epitopes. Due to 
poor labelling with 3 5 [S]methionine, detection o f immunoprecipitated ICP34.5 required 
Western blotting.
Similarly to the anti HSV-1 ICP34.5 sera, the anti-HSV-2 sera do not cross react 
with HSV-1 ICP34.5. This is probably because although the part of the protein with the 
highest homology is at the carboxy terminus most of the antibodies in both the HSV-1/2 
antisera will be directed against the amino terminus (Brown et al., 1997).
By constructing recombinant HSV-1 RL1 deleted viruses expressing the HSV-2 
gene under a strong HSV-1 promoter (gD) of similar kinetic class to ICP34.5, we have also 
demonstrated that the HSV-2 gene can, at least in vitro, functionally complement the loss 
o f the HSV-1 gene in a HSV-1 background. Future experiments will assess whether this 
complementation also applies in vivo regarding pathogenicity and latency.
The functional importance (if any) o f ICP34.5A has yet to be determined. In all 
assays carried out both in vitro and in vivo, viruses with the RL1 intron deleted (1628 and 
2624) and hence only expressing the 37 kDa ICP34.5 behave like wild type. However, in 
viruses containing the wild type gene (ie. including the intron) only low levels of ICP34.5 
are detected by the antisera and the predominant protein detected is ICP34.5A. In contrast, 
viruses lacking the intron express ICP34.5 at much higher levels close to those of 
ICP34.5A in intron containing viruses (Fig. 76). It seems unlikely that a protein expressed 
at such high levels will not have some function in addition to that o f ICP34.5 in the virus 
lifecycle.
The ability o f the HSV-2 ICP34.5 to interact with PCNA as illustrated by GST 
pull-downs indicates at least one function in common with HSV-1 ICP34.5. This
194
____________________________________________________________________ Results and Discussion: 5.3
interaction is likely to be mediated by the highly conserved 63 amino acid carboxy 
terminal region.
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6. MUTANT VIRUSES RESULTS AND DISCUSSION
6.1. ORIENTATION OF INSERTED GENES IN HSV-1 UL43
6.1.1. Orientation Effect on Expression
One o f the major aims of this investigation was to singly express a gene of interest,
either RL1 or the antisense gene ORF P, in a novel site. This was achieved by insertion of 
a gene into the unique Nsil site in the UL43 gene (Fig. 77). In 1996, an open reading 
frame antisense to UL43 was identified and named UL43.5. UL43.5 was shown to encode 
a protein with an apparent Mr o f 38 kDa (Ward et al., 1996). The UL43.5 gene is regulated 
as a late (7 2 ) gene. Deletion of UL43 also deletes UL43.5 and does not alter replication in 
vitro or virulence in vivo and consequently they have been termed non-essential (MacLean, 
C. et al., 1991). For this reason we thought this locus was a good candidate for insertion of 
expression cassettes.
In Section 4.2 and 4.3, 1622 and 1623 were described and characterised. To 
recapitulate, 1622 expresses the RL1 ORF and 1623 expresses the RL1 ORF and an 
additional 134 bp upstream sequence. These RL1 fragments were individually inserted in 
the UL43 Nsil locus. Due to the considerable variation in ICP34.5 expression between
1622 and 1623 (64-fold), the orientation of the inserted RL1 sequence was examined. The 
restriction enzyme BamHl was used to digest pHHl and pHH2, the plasmids co-tranfected 
with 1716 to generate 1622 and 1623, respectively (Fig. 78a). There is one BamHl site in 
the RL1 HSV-1 sequence located in the insert and a second BamHl site at the end of the 
HSV-1 sequence in p35(PacI). The DNA digests were electrophoresed through a 1% (w/v) 
agarose gel (Fig. 78b). pHHl gives two bands of 7.4 kbp and 5.8 kbp (lane 2), but pHH2 
gives two bands o f 8.5 kbp and 4.7 kbp (lane 3). These sizes were determined by 
comparison to a 1 kbp DNA ladder. This gel demonstrates that 1622 (pHHl) has the RL1 
gene is in the same transcriptional orientation as UL43.5. However, the RL1 sequence in
1623 (pHH2) is in the opposite orientation (i.e. same transcriptional orientation as UL43).
Two additional recombinant viruses, 1627 and 1628, were constructed in the same 
manner as 1622 and 1623. The major difference is that the RL1 sequences in 1627 and 
1628 are derived from HSV-2. However, the RL1 gene was inserted similarly in the UL43 
locus. Orientation o f these inserts was determined by Ncol digestion and Southern blotting 
o f recombinant viral DNA (Fig. 79). 1627 and 1628 DNA could be directly examined 
since there is a single Ncol site within the insert (Fig. 78a,b). The Southern blot was 
probed with radiolabelled p35(PacI). The Southern blot revealed that the RL1 insert 1627
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UL43
UL43.5
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Figure 77. Schematic representation of genes inserted in the UL43 N sil site.
a. A diagram of the HSV-1 1716 genome. The)f indicates that RL1/ORF P have been 
deleted in 1716. b. The position and transcriptional orientation of the UL43 ORF. c. 
The transcriptional orientation and ORF of UL43.5. d. The Nsil location and example 
of the RL1 gene in the UL43.5 transcriptional orientation while the (3-galactosidase gene, 
lacZ, is in the UL43 transcriptional orientation.
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Figure 78. Schematic representation of BamW\ sites in HSV-1 and plasmid DNA.
p35(PacI) containing the UL41-UL44 HSV-1 sequences, b. The plasmids used to generate 
recombinant viruses 1622 (pHHl) and 1623 (pHH2) were digested with BamW\ and 
analysed by a 1% (w/v) agarose gel. Lane 1 contains a 1 kbp ladder. pHHl (lane 2) 
gave a band of 7.4 kbp and 5.8 kbp. pHH2 (lane 3) gave two fragments o f 8.5 kbp and 4.7 kbp.
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Figure 79. Southern blot of 1627 and 1628 DNA digested with Ncol.
a. Schematic representation of viral DNA within the p35(PacI) HSV-1 sequence 
UL41-UL44.
b. Viral DNA digested with Ncol was electrophoresed through a 1% (w/v) 
agarorse gel. The gel was Southern blotted and probed with radiolabelled p35(PacI). 
1627 has one DNA fragment of 11.1 kbp recognised (the 2.1 kbp fragment is not 
shown). 1628 has two DNA fragments of 7.3 kbp and 6.0 kbp recognised.
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was in the same transcriptional orientation as UL43.5 while the RL1 insert in 1628 was in 
the same orientation as UL43. 1627 has one visible band at 11.1 kbp one band 2.1 kbp, not 
seen. 1628 has two bands at 6.0 kbp and 7.3 kbp (Fig. 79b).
To clarify the orientation o f RL1 and the opposing lacZ genes in each recombinant 
virus, a summary is given in Table 19.
There are currently no UL43 antisera available. However, Ward et al (1996) raised 
an antiserum against a MBP fusion protein from UL43.5 ORF. This antiserum was made 
available by Prof. B. Roizman for use in a Western blot (Fig. 80). Infected BHK cells 
were harvested at 6  and 16 h pi in SDS lysis buffer and samples were analysed by a 10% 
SDS-PAGE. As predicted, the UL43.5 antiserum detected UL43.5 in 17+ only at 16 h pi, 
with an apparent Mr o f 38 kDa (Fig 80). However, UL43.5 was not detected in any of the 
recombinant viruses. UL43.5 expression was also examined in 1716 but was not detected 
(data not shown). The UL43.5 antiserum is weak and does not readily detect UL43.5 
expression from wild type by Western blotting.
All recombinant viruses described above contain an identical SV40 promoter 
driving the p-galactosodase gene. To determine if there was an orientation effect on 
expression levels o f inserted genes, a Western blot was performed to examine the level of 
expression o f P-galactosidase using an anti-p-galactosidase serum (Fig. 81). 17+ and 1716 
were included in this experiment as negative controls (Fig. 81). Three different cell lines 
were used (BHK, HeLa, and SK-N-SH) to eliminate the possibility that any observed 
orientation effect on expression was not cell type specific. All cells were infected at a 
m.o.i. o f 20 p.f.u./cell. In BHK cells, 1623 and 1628, containing lacZ in the UL43.5 
transcriptional orientation, show higher levels of p-galactosidase expression (Fig. 81a). In 
contrast, 1622 and 1627 have lacZ in the UL43 transcriptional orientation, express P- 
galactosidase at low levels, barely detectable by Western blot (Fig. 81). A similar 
expression pattern was also seen in HeLa cells (Fig 81b). Although lower cell density of 
SK-N-SH cells caused fewer cells to be loaded, the same lacZ expression profile among 
recombinant viruses as in BHK and HeLa cells was observed (Fig. 81c).
The above data suggests that orientation is one factor causing different expression 
levels from an inserted gene in the Nsil UL43 locus. However, the difference in p- 
galactosidase expression may also have been a result o f the overall length or sequence of 
the inserted gene. Although the inserts contained an identical p-galactosidase gene the
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Figure 80. W estern blot of UL43.5 using anti-UL43.5 sera.
BHK cells were infected at a m.o.i. of 20 pfu/cell and harvested in 
SDS lysis buffer at 6 h pi and 16 h pi. Samples were analysed by 10% 
SDS-PAGE and Western blotted with UL43.5 antiserum (Ward et al., 1996).
The positive control of 17+ shows the UL43.5 expression at 16 h pi with a 
Mr of 38 kDa. Two unidentified bands are recognised from 17+ infection 6 h and 
16 h pi with apparent Mr 64 kDa and 98 kDa (lane 12;^)
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Table 19. Orientation of RL1 and lacZ  genes in recombinant viruses.
lacZ RL1
1622 UL43 UL43.5
1623 UL43.5 UL43
1627 UL43 UL43.5
1628 UL43.5 UL43
202
a . b. c .
BHK cells HeLa cells SK-N-SH cells
Figure 81. W estern blot of [3-galactosidase expression in different cell lines.
Cells were infected with different viruses at a m.o.i. of 20 p.f.u./cell. Infected cells 
were harvested into loading buffer 16 h pi. Samples were analysed using 
10% SDS-PAGE and Western blotted with p-galactosidase antiserum,
a. In BHK cells, the p-galactosidase expression is predominant from 1628 
and 1623 virus infection, b. In HeLa cells, the p-galactosidase expression predominant 
from 1628 and 1623 infections, c. In SK-N-SH cells, there is p-galactosidase 
expression from 1628 and 1623. 1622 has a non-specific band which migrates slower 
than p-galactosidase (^).
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RL1 gene in all four recombinant viruses varied in length by 100 to 150 bp. 1623 has a 
134 bp larger RL1 insert than 1622 but 1627 has 154 bp more than 1628 due to the intron 
sequence.
6.1.2. Direct Comparison of Orientation and Expression of Genes Inserted
into the Nsil UL43 Locus
In order to confirm if  the orientation of a gene inserted in the UL43 locus has an 
affect on expression o f that gene, two new viruses were constructed using the original RL1 
cassette from 1622 (Fig. 82a). pHHl was digested with P a d  to separate the Xbal 
BAAIlacZ cassette. This cassette was re-cloned into the UL43 P a d  site in p35(PacI). Two 
new plasmids pHH4 and pHH5 (Fig 82b,c), were digested with BamRl to determine the 
RL1 orientation. Digested DNA was separated by electrophoresis through a 1% (w/v) 
agarose gel (Fig. 83) and showed that pHH4 has one band of 7.4 kbp and another of 5.8 
kbp determining that RL1 is in the same transcriptional orientation as UL43.5. pHH5 
shows two bands o f 8.5 kbp and 4.7 kbp determining that the RL1 gene is in the same 
transcriptional orientation as UL43.
pHH4 and pHH5 were separately co-transfected with 1716 DNA generating two 
new viruses 16(UL43.5)22 and 16(UL43)22, respectively. These viruses were purified 
once on BHK cells and their genomic structure analysed by Southern blotting (data not 
shown). BHK cells were infected at a m.o.i. o f 10 pfu/cell and harvested 18 h pi. Extracts 
were analysed by 10% SDS-PAGE and Western blotted with 137 (Fig. 84). 16(UL43.5)22 
and 17+ express ICP34.5. The appearance that ICP34.5 from 16(UL43.5)22 is 1-2 kDa 
heavier than from 17+, is probably due to uneven migration of the samples through the gel. 
The 70 kDa protein induced by 17+ infection is not recognised from the recombinant 
viruses. Instead, in 16(UL43)22 and 16(UL43.5)22 a 98 kDa protein is detected. 
16(UL43)22 shows no apparent ICP34.5 expression. This is expected since the RL1 gene 
is in the same transcriptional orientation as UL43. We conclude that there is a direct 
correlation between orientation and expression of an inserted gene in the UL43 Nsil locus. 
However, caution must be taken when exerting the importance o f orientation expression as 
this could not be quantitated due to time constraints and virus impurity.
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Figure 82. Schematic representation of cloning pHH4 and pHH5.
a. pHHl was digested with Pacl to isolate the RL1 llacZ  cassette from the 
plasmid backbone, b. and c. The RL1/ lacZ cassette was sub-cloned in opposite 
orientations into the UL43 P ad  site in UL43 in p35(PacI) generating 
pHH4 and pHH5.
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Figure 83. Agarose gel of 16(UL43)22 and 16(UL43.5)22.
A 1% (w/v) agarose gel of pHH4 and pHH5 which were used to generate 
recombinant viruses 16(UL43.5)22 and 16(UL43)22, respectively. BamHl digests 
pHH4 into two bands, 7.4 kbp and 5.8 kbp. pHH5 digests into two bands 8.5 kbp 
and 4.7 kbp. Sizes were determined by comparison to a 1 kbp DNA ladder. 
Undigested plasmid DNA is also visible (*-).
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Figure 84. 16(UL43)22 and 16(UL43.5)22 recom binant viruses ICP34.5 
expression by W estern blotting.
A 10% SDS-polyacrylamide gel was Western blotted with 137 to analyse BHK cells 
infected with new recombinant viruses, 17+, and mock, 18 h pi. 16(UL43.5)22 
express ICP34.5 with an apparent 1-2 kDa more than 17+ of 37 kDa. The 70 kDa 
virus induced protein is present from 17+ infection. A 98 kDa protein is recognised 
from recombinant virus extracts.
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6.1.3. Discussion
Before this study, it was not known that the orientation of an inserted gene in 
UL43/UL43.5 might have an effect on expression. Looking more closely at the Nsil site in 
UL43/UL43.5 we see that by inserting a gene in the Nsil locus the gene is placed at the 
immediate 5’ terminus o f UL43. Inserting a gene in this locus stops translation of UL43, 
however, it might allow translation o f a truncated UL43.5. UL43.5 expression was
analysed by a UL43.5 antiserum (Ward et al., 1996) and although there was no apparent 
expression o f UL43.5 by Western blot analysis we cannot conclude that a truncated protein 
not recognised by this antiserum may be expressed. A potential experiment for further 
investigation would be to look for possible recognition of a truncated UL43.5 transcript.
This finding has significant implications for HSV vectors. Several investigators are 
looking at nonessential genes such as UL43 within the HSV genome as sites to insert genes 
o f interest to target different disorders for cancer and/or gene therapy. If the level of the 
desired gene expression is critical then this study suggests that the gene should be inserted 
in the same transcriptional orientation as UL43.5. Transcriptional studies of RNA could be 
carried out to assess this phenomenon. This orientation dependent effect might apply to 
other sites in the HSV genome.
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6.2. RECOMBINANT VIRUSES AND PLAQUE MORPHOLOGY
6.2.1. Introduction
HSV induces cellular changes upon infection in vitro which include ballooning of 
the cells, the appearance of condensed nuclear chromatin and ultimately degeneration of 
the host cell nuclei. Throughout this study recombinant viruses were constructed using the 
RL1 deleted mutant 1716 as their parental strain. A striking feature of these recombinant 
viruses as well as 1716 itself is their plaque morphology in all cell types. Both permissive 
and non-permissive cells revealed mutant virus plaque sizes smaller than the wild type 
HSV-1 17+. Although plaque size is somewhat arbitrary, dependent on time of infection 
and state of cell cycle, the plaque phenotype in these mutant viruses was so marked it is 
described and investigated below.
6.2.2. Plaque Phenotype in Different Cells
3T6 cells are non-permissive for ICP34.5 negative viruses whereas BHK cells are 
permissive. Cell monolayers (BHK and 3T6) were infected with serial 10-fold dilutions of 
1622, 1716 and 17+. After 1 h absorption the monolayers were washed twice with PBS 
and a methylcellulose/media overlay applied (Section 3.14). Infected cell monolayers 
were kept at 37°C 5 %C0 2  for 72 h. After incubation the methylcellulose overlay was 
removed and the cells were fixed and stained with Giemsa. Plaques were visualised under 
a microscope at 4x magnification and photomicrographs were taken (Fig. 85). Small 
plaques from 1716 and 1622 were seen on 3T6 cells (Fig. 85) and on permissive BHK cells 
(Fig. 85). The small plaque morphology from 1716 on 3T6 cells has been documented 
previously (Brown et al., 1994a,b). However, it was predicted that 1622 plaques would 
return to wild type size. The small plaque phenotype of 1716 and 1622 was observed in all 
cell lines examined in this study. The average plaque size for each virus on 3T6 cells was 
quantified
by measuring plaque size from 60mm plates and is shown in Table 20. Photomicrographs 
of plaques were precisely cut out and weighed. Average weights are given in grams and 
confirm that there is a distinct difference between 1716/1622 and 17+.
Virus stocks were analysed to determine particle to p.f.u. ratios. It is important to 
note that stocks were not grown simultaneously (i.e. different passage number of BHK 
cells). The results in Table 21 show particle:p.f.u. ratios of all viruses were similar. This 
is in agreement with the observation that despite the apparently poor plaque formation,
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BHK cells
(x4 magnification)
3T6 cells
(x4 magnification)
1716 1622 \T
Figure 85. Plaque sizes between 17+, 1716 and 1622 on BHK and 3T6.
Plaque size variation between 1716, 1622 and 17+ is evident in BHK and 3T6 cells. 
Photomicrographs were taken at 4x magnification.
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Table 20. Plaque size quantification in 3T6 cells.
Virus
Number of 
Dlaaues tested Ave. wtfg'l
% of wt 
olaaue weight
1622 26 0.3101 19%
1716 26 0.0926 6%
17+ 22 1.5975 100%
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cos56
cos48
cos6
cos28
cosl4
Figure 8 6 . D iagram m atic representation of the “set c” cosmids.
The entire HSV-1 strain 17+ genome fragments inserted into separate cosmids. 
(Cunningham and Davison, 1993). For exact map location and n.p. see Table 22.
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mutant viruses were able to replicate normally in single-cycle growth experiments in BHK 
cells (Sections 4.2, 4.3 and 5.3).
6.2.3. Rescue of Plaque Size Phenotype using Cosmids
To ascertain whether the small plaque phenotype was the result o f a second 
mutation elsewhere in the 1716 genome rescuants were constructed using cosmids 
spanning the entire HSV-1 17+ genome (Cunningham and Davison, 1993). Cosmid set C 
was used in this study which contains the following cosmids: cos6 , cos28, cos 14, cos56 
and cos48 (Fig. 8 6 ; Table 22). Individual cosmids were co-transfected with 1716 DNA 
and harvested transfectants were given a unique number: 1, 2, 3, 4, and 5 (Table 22). 
Positive and negative transfection controls were carried out using 1716 or 17+ DNA alone, 
named 6  and 7, respectively.
Two cosmids co-transfected on BHK cells with 1716 DNA (1 and 5) and the 
positive control o f 17+ DNA alone (7) rescued large, wild type 17+ plaques (data not 
shown). To test whether this was cell type specific the transfectants 1 and 5 along with 
control transfectants 6  and 7 were titrated on rabbit skin cells (data not shown). Similar to 
BHK cells only transfectants 1 and 5 along with 17+ (7) produced interspersed wild type 
plaques. Cosmid tranfections were serially diluted and plated on 3T6 cell monolayers. 
The only tranfectants producing plaques were 1 and 5 and the positive control 17+ (7) (Fig 
87). Holes in the monolayers appeared from transfectants 2 and 3 at the periphery of the 
plate which were due to detached cells and not virus plaque formation (Fig. 87).
A semi-quantitative analysis was performed by taking photomicrographs o f plaques 
at 4x magnification as described above (Section 6.2.2.). Individual transfectants were 
examined on BHK and 3T6 cells. The only tranfectants to produce plaques on 3T6 cells 
were 1 and 5 and the positive control 17+, 7 (Table 23). In BHK cells, all tranfectants 
produced plaques but of varying sizes. The averages and percent comparison of weight 
between tranfectants are given in Table 22. The frequency with which wild type large 
plaques occurred from 1 and 5 was low due to the mixed population of the transfection 
plate containing ‘wild type’ and ‘1716’ plaques.
6.2.4. Rescued Plaque Size Phenotype using pBAM'k’
The cosmid experiments determined that no other mutation outside TRL and IRL 
regions was causing a genuine small plaque phenotype. However, other mutant viruses,
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Table 21. Plaque forming efficiencies of 17% 1716 and 
recombinant viruses on BHK cells.
Virus Yield of 
Particles
Titre
(p.f.u.)
Particle to p.f.u. ratios
17+ 2.295 x l O 11 1 x 1010 23 (1)
1716 2.4 x l O 10 l x l O 9 24(1.0)
1622 3.3 x l O 10 1 x lO9 33 (1.3)
1623 4.87 x l O 10 1 x 108 48.7 (2.4)
1627 6.0 x 109 1 x 108 60 (2.8)
1628 2.55 x 1010 3 x 109 8.5 (0.37)
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Table 22. Cosmids with n.p. and new transfectant names.
Cosmid n jh 1716/cosmid tranfectant name
cos6 141221-29733 1
cos28 24699-64405 2
cosl4 54445-90477 3
cos56 79442-115152 4
cos48 107496-144681 5
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l a  2a 3a
lb  2b 3b
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4b 5b 6 b 7a
Figure 87. Transfectants titrated  on 3T6 cells.
Each transfection was plated on 3T6 cells at (a) lxlO'  p.f.u./well or (b)l 
pfu/well. Numbers refer to the cosmid 1716 combination (Table 22).
1, 5 and 7 (positive control) were the only transfections to forms plaques 
on 3T6 cell monolayers.
216
Results and Discussion: 6.2
Table 23. Plaque sizes from cosmid and 1716 tranfectants on 3T6 and BHK cells.
3T6 cells
Transfectant
number
1
Number of 
Dlaaues tested 
9
Ave. weightfg) 
0.995
%  of wt 
olaaue weight 
48%
5 8 1.20 58%
7 10 2.06 100%
BHK cells
Transfectant Number of % of wt
number Dlaaues tested Ave. weight(g) Dlaaue weight
1 3 0.400 22%
2 3 0.208 24%
3 3 0.516 28%
4 3 0.358 19%
5 3 0.535 29%
6 3 0.360 19%
7 4 1.86 100%
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which contain stop codons in the RL1 gene do not cause small plaque phenotypes. 1771 
and 1771R and 17termA and 17termAR were included in a single direct comparison 
experiment with 1716 and 17+ to observe plaque size phenotype (data not shown). The 
1716 rescuant virus 1716R, was originally generated using plasmid pBam’k ’ and produced 
a wild type 17+ plaque phenotype.
6.2.5. HSV Glycoprotein Expression
Glycoproteins play an integral role in the viruses ability to spread from cell to cell 
causing syncitia and plaque formation. The glycoproteins gB, gD and gl have been 
heavily studied to demonstrate their role in HSV-1 infection. Western blots were 
performed to determine the expression of some of these glycoproteins during infection in 
BHK cells.
BHK cells were infected at 20 pfu/cell and harvested in SDS lysis buffer 16 h pi. 
Samples were visualised by SDS-PAGE. Glycoprotein D protein was expressed from all 
recombinant viral infections (Fig 88). A Western blot using gD antiserum showed 
expression of gD from all viruses (Fig. 88). Due to the poor quality of the lane, the 17+ 
sample appears skewed. Different extracts were analysed on a second gel and the blot was 
exposed to autoradiograph film. A short exposure of the blot demonstrated that gD 
expression is better in 17+ and 1628. However, a longer exposure showed that all 
recombinant viruses express gD (Fig. 89).
Infected BHK cells were harvested 16 h pi, analysed on a 10% SDS-PAGE, and 
Western blotted with gC antiserum (Fig. 90a) 17+ and 1716 showed expression of gC but 
there was no detectable expression from 1622 (Fig. 90). The experiment was repeated 
using two time points of 6 h and 16 h pi (Fig 90b). 17+ and 1716 show expression of gC at 
6 h. By 16 h pi. 17+ and 1716 express gC, however no recombinant viruses are expressing 
any detectable gC.
Viruses were assayed by Western blot to examine gl expression using a 
monoclonal antibody against gl (Fig 91). BHK cells were infected with 17+, 1716 and 
1622 at a m.o.i. o f 20 pfu/cell and harvested at 16 h pi. All viruses show gl expression at 
similar levels (Fig. 91).
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Figure 88. W estern blotting with gD antiserum .
Infected BHK cells were analysed by SDS-PAGE and Western blotted with a gD 
antiserum.
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Figure 89. W estern blot with gD antiserum .
Infected BHK cells visualised by SDS-PAGE which was Western blot with gD antiserum 
shows clearly gD expression in 17+ and 1623.
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Figure 90. W estern blotting with gC antiserum .
a. BHK cells were infected and harvested 16 h pi in SDS lysis buffer, analysed 
by 10% SDS-PAGE and Western blotted with gC antiserum. Glycoprotein C is detectable 
from 17+ and 1716 infected extracts, b. BHK cells were infected at a m.o.i. of 20 p.f.u./cell 
and harvested at either 6 h pi or 16 h pi.
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Figure 91. W estern blotting with anti-gl serum.
BHK cells were infected at a m.o.i. of 20 pfu/cell and harvested 16 h pi. 
Samples were analysed by 10% SDS-PAGE, and Western blotted 
with gl mAb, 3104.
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6.2.6. Discussion
HSV-1 mutations in several genes with a small plaque phenotype have been 
described. Brown et al (1994a) first reported a small plaque phenotype in BHK cells from 
the RL1 deleted virus 1716. Another mutant producing small plaques is the Vmw65 
insertion mutant, m l814 (Ace et al., 1989), which has a high particle to pfu ratio and is 
avirulent, but can establish latency and reactivate. A UL39 deleted mutant yields 4 to 5 
fold less virus, has small plaque morphology and is avirulent (Goldstein and Weller, 1988).
Additionally, polykaryocyte formation caused by herpes simplex virus infection 
in a given cell line has been suggested to be due to alteration in at least 6 syn loci: Sy«l to 
6 (Tognon et al., 1988).
Romanelli et al (1989) characterized a mutant virus with different syncytial genes 
deleted. Syn\ maps to the BamHl ‘1* fragment affecting gK (Romanelli et al., 1991). The 
syn3 mutation affects the 3' end of gB (DeLuca et al., 1982; Kousoulas et al., 1984). Syn5 
is located within the BamHl ‘q* fragment affecting the UL24 gene. In 1991, Romanelli et 
al studied the syn6 and found that it lies in the junction fragment BamHl k. Only Syn6 was 
able to induce syncitium formation in Hep-2, Vero, BHK and HEL cells. Romanelli et al 
(1991) mapped the syn6 mutation to a BamHUSacl C (-1.6 kbp) fragment. This fragment 
includes the 5' end of RL2 and the putative polyadenylation signal o f RL1. They 
concluded that the gene responsible for the syn6 mutation might be ICPO or ICP34.5. They 
also suggest that the syn6 locus may be an unidentified gene which overlaps with the RL2 
gene or lies on the 1 kbp region between the 5* end of RL2 and the Sacl site, the product of 
which is involved in fusion. Another attractive candidate is ORF P.
The lack o f rescued plaque size in 1622 which overexpresses ICP34.5 indicates 
that small plaque formation is not due to level o f ICP34.5 expression. It is also important 
to note that when ICP34.5 is not expressed in 1771 or 17termA, two RL1 stop codon 
mutants, plaque formation is identical to wild type 17+ in all permissive cell types 
examined in this study. This implies that some sequence other than RL1 may be missing 
or mutated in 1716 and its 'rescuants' 1622, 1623, 1624, 1627, and 1628.
DNA sequence analysis experiments spanning the BamHl k region could be 
carried out to determine if  there may, in fact, be an additional mutation in these viruses.
Certain glycoproteins associated with virus maturation and egress were examined 
in this study. Glycoprotein C was not expressed from all 1716 recombinant viruses, but 
expressed in 1716 and 17+. This may be attributed to cloning in this region, as gC is
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expressed from UL44. Recombinant viruses manipulated in UL43 may have resulted in a 
mutation stopping the expression of gC. However, other mutant viruses with mutation in 
UL43/UL43.5 do not demonstrate the described plaque morphology.
Another glycoprotein involved in egress is gl. Equal expression of gl from 
recombinant viruses, 1716 and 17+ was determined by Western blotting. Finally, gD 
expression from all viruses was shown by Western blotting.
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7. FINAL DISCUSSION
7.1. ICP34.5 and ORF P Recombinant Viruses
A complicating feature o f RL1 mutants has been the discovery of two overlapping 
antisense open reading frames (O and P) to RL1. Transcripts spanning the long short 
repeat region (L/STs) o f HSV-1 were reported by two independent groups (Bohenzky et 
al., 1993; 1995; Yeh and Schaffer, 1993). These RNAs are transcribed in the same 
orientation as LATs. A strong binding site for ICP4 is at the 5’ terminus of the L/STs (Yeh 
and Schaffer, 1993; Samaniego et al., 1997; Randall et al., 1997) and mutagenesis of this 
site resulted in over production of ORF P and L/STs during normal lytic infection, 
demonstrating that ICP4 represses transcription of L/STs (Lagunoff and Roizman, 1995; 
Lee and Schaffer, 1998). Lagunoff and Roizman, (1995) hypothesised that expression of 
ORF O and P would only be expected in infected cells lacking functional ICP4, a condition 
satisfied by latency (Preston, 2000). The observation predicted that a positive feedback 
system could control HSV gene expression. During latency in the absence of ICP34.5, 
ORF O and P would be expressed and prevent the synthesis or function of IE proteins, 
thereby maintaining the remainder o f the genome in a stable nontranscribed state. 
Reactivation could result from interference with ORF O or P function during latency 
(Preston, 2000), but is disputed by the observations that latency was established by a 
normal virus mutant which ORF P was specifically interrupted (Lee and Schaffer, 1998); 
mutants with derepressed synthesis of ORF P established latency inefficiently and were 
also highly attenuated (Bruni and Roizman 1996; Lee and Schaffer, 1998).
The RL1/ORF P deletion mutant, 1716, has been well characterised in vitro and in 
vivo and shown to be avirulent upon IC inoculation in BALB/c mice (MacLean et al., 
1991). 1716 infection resulted in “abortive” plaques on mouse embryo fibroblast 3T6 cell 
monolayers (Brown et al., 1994 a,b; Brown et al., 1997). 1716 infected cells were studied 
by electron microscopy which showed 1716 was not released from the lamellae of the cell. 
To gain a better understanding of the function of the deleted sequence in 1716 the two 
identified genes, RL1 and ORF P, shown to express proteins ICP34.5 and ORF P, 
respectively, were re-introduced independently into 1716.
The basic design of all recombinant viruses was the following: an expression 
cassette was inserted, into the 1716 UL43 locus, which contained the gene of interest under 
a HSV-1 gD promoter with a HSV-2 IE5 polyadenylation signal, and in the opposite 
orientation a lacZ gene under a SV40 promoter with a polyadenylation signal. Cloning of
these recombinant viruses required several steps which have been described in Section 4.1.
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The selection of the insertion locus, UL43, was based on previous studies 
(MacLean, C. et al., 1991) which demonstrated deletion o f this gene conferred no affect on 
virus replication in vitro or in vivo. The UL43 locus was found in this study to have 
additional points o f interest which will be discussed in relation to Section 6.1. The HSV-1 
gD promoter was used to express RL1 or ORF P as it was believed that this would express 
the gene o f interest strongly with the same kinetics.
The first recombinant virus, 1622, expressed the 17+ RL1 ORF singly. A second 
mutant, 1623, expressed RL1 with 134 bp additional upstream sequence.
The third recombinant virus, 1624, expressed the 17+ ORF P ORF singly. 1624 was 
constructed to understand the individual role of ORF P. Unfortunately, there was an initial 
delay in cloning this gene (Section 4.4). Characterization of 1624 could not be done here. 
However, work is currently under way in the laboratory to purify and subsequently 
investigate its in vitro and in vivo properties.
Although 1624 was not characterised in this study, observations were made on ORF 
P expression from wild type strain 17+ and other RL1 mutants. Infected cells extracts were 
analysed by SDS-PAGE and Western blotted using newly generated ORF P antisera (R. 
Reid). Expression of ORF P from 17+ infected BHK cells was observed. Additionally, an 
abundant transcript of 2 kbp was detected following infection of BHK cells at 37°C by 
HSV-1 strain 17+ and strain F, even though both produced functional ICP4 protein (McKie, 
personal communication). Previously published data suggested that only a mutated ICP4 
binding site allowed synthesis of ORF P in strain F (Bruni and Roizman, 1996) and in 
strain KOS (Lee and Schaffer, 1998). Confirmation that ORF P expression from 17+ was 
genuine was made when a tsK mutant also showed expression of a similar protein. A 
second confirmation o f ORF P protein expression was made with a mutant virus, 1621. 
The ORF P protein migrated more slowly from 1621 infected BHK cells due to an epitope 
tag sequence at the 3’ terminus of ICP34.5. ORF P was not detected from 1716 infected 
cells.
The fourth and fifth intertypic recombinant viruses, 1627 and 1628, contained the 
HSV-2 strain HG52 RL1 gene in the UL43 locus of 1716. These mutants were constructed 
to address the second main objective: the identification o f HSV-2 ICP34.5 protein 
expression. 1627 and 1628 will be described in detail later in respect to HSV-2 
characterization.
The first objective o f this study was to individually express ICP34.5 in the 1716
background to ascertain its role in the 1716 phenotype. Western blotting analysis of 1622
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infected BHK cells determined at least an 8-fold increase in ICP34.5 level compared with 
wild type, 17+. 1623 infected BHK cells, unexpectedly demonstrated a reduction (8-fold) 
of ICP34.5 expression compared to 17+ by Western blotting. One hypothesis for the 
reduction in ICP34.5 expression from 1623 infected cells is the additional 134 bp which 
includes three methionines. An experimental approach to examine this is to compare RNA 
levels in 1622 and 1623 infected cells. If  the gD promoter is not as efficient as the wild 
type promoter and multiple methionines in the sequence could be competing, this may 
result in less ICP34.5 expression. Another strategy would be to construct a new mutant 
lacking the gD promoter but maintaining the RL1 ORF with the additional 134 bp. This 
mutant could demonstrate if the 134 bp leader sequence was sufficient to promote ICP34.5 
expression. If this new mutant expressed ICP34.5 with normal kinetics, it could also be 
analysed in experiments in vivo to clarify two questions posed by 1622: (1) if the location 
of ICP34.5 in the UL43 locus is attributed to its small reduction in neurovirulence and/or 
(2) if gD promoting RL1 affected the time of ICP34.5 expression in 1622 resulted in 
decreased replication kinetics in vivo.
Expression of ICP34.5 from 1622 infected cells was believed to be responsible for 
the restored ability of 1716 to replicate to wild type levels in 3T6 cells. Additional cell 
lines were examined for replication kinetics of 1622, 1623, 1716 and 17+. In HeLa cells 
demonstrated to be non-permissive for 1716 and 1623 infection at a low m.o.i., 1622 and 
17+ replicated with similar kinetics.
In permissive BHK cells, 1623 showed slightly impaired levels of replication. At 
high m.o.i., 3T6 cells failed to allow replication of 1623, with titres lower than 1716. In 
low m.o.i. infection of Vero cells, 1623 demonstrated replication with only a slight 
reduction (5-fold) compared to 1622 and 17+ and replicated slightly better (2-fold) than 
1716. In HeLa cells, at low m.o.i. 1716 and 1623 did not replicate. These results correlate 
with host and viral protein synthesis experiments. One hypothesis for the observed 
reduction in 1623 replication in 3T6 and Vero cells and lack of replication in HeLa cells is 
the lower level ICP34.5 expression. An alternative hypothesis for the poor replication of 
1623 is the occurrence o f a secondary mutation elsewhere in its genome. One approach to 
test this would be to carry out recombination experiments with cosmids spanning the entire 
HSV-1 genome and co-transfecting with 1623 DNA. This strategy was applied in this 
study to examine the 1716 genome (Section 6.2).
An interesting observation was made when examining the replication o f several
viruses in rabbit skin cells. Virus stocks which were grown on rabbit skin cells were able
227
Final Discussion: 7
to yield higher titres on these cells than virus stocks which were generated on BHK cells. 
There was no apparent replication defect for RL1 mutants on rabbit skin cells.
Restoration of ICP34.5 function in 1622 infection was confirmed in vitro  with 
analysis o f host cell and viral protein synthesis in neuroblastoma (SK-N-SH) and HeLa 
cells. R3616 had been previously shown to cause preclusion of host and viral protein 
synthesis in two human derived cells lines, SK-N-SH and HFFF. However, R3616 
maintains protein synthesis similar to wild type in primate Vero cells. These studies had 
not previously been done using 1716. Here it is reported that 1716 also precludes protein 
synthesis in SK-N-SH cells and (to a lesser extent) in HeLa cells. It was not clear why total 
protein synthesis shutoff was not observed in HeLa cells. The replication kinetics 
experiments demonstrated an inability of 1716 to produce a productive infection in HeLa 
cells which suggests the lack o f protein synthesis.
ICP34.5 is naturally a diploid gene located in the long repeats but in 1622 the single 
RL1 gene has been positioned in the middle of the unique long region. This may attribute 
to a difference in the transcription o f ICP34.5 in 1622 and 1623 by different antisense and 
5' leader sequences.
The ICP34.5 level expressed from 1623 is sufficient to maintain protein synthesis in 
neuronal SK-N-SH cells at late times (16 h) post infection but does not contribute to 
replication.
Due to the unexpected phenotype and questionable genotype of 1623 in vitro, it was 
not included in pathogenicity studies in vivo. Instead, 1622 which demonstrated a restored 
wild type in vitro  phenotype was examined in vivo.
When this project was initiated there was no previous examination o f the role of 
ICP34.5 independently from ORF P in vivo. During this study, two groups attempted to 
characterise the role(s) of ORF P in strain F (Lagunoff et al., 1996) and in strain KOS (Lee 
and Schaffer, 1998). Attempts to define ORF P role(s) were carried out by site directed 
mutagenesis experiments and these mutants were characterised in vivo  (see Introduction).
Initially, 1622 was used in intracranial L D 50  experiments. L D 50  values between 
HSV-1 strains and RL1 mutants vary considerably between groups. The L D 50  reported for 
17+ is <3.5 pfu/mouse while in strain F it is 101 and KOS 103. The strain F, RL1 mutant, 
R4009, has an L D 50  of >1 x 107 p.f.u./mouse (Chou et al., 1990a), but the same RL1 
mutant in strain 17+, 17termA, has an L D 50  of 1 x 104 (Bolovan et al., 1994). Another RL1 
stop codon mutant in strain 17+, 1771, has an L D 50  value of >1 x 106 pfu/mouse (McKie et
al., 1994), again comparable to the RL1 deletion mutant, 1716 (MacLean, A. et al., 1991).
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al., 1991). Although 1622 had a slightly increased LD5 0  value it was not significantly 
different from 17+ in these studies. One aspect to consider when interpreting LD5 0  values is 
the difference in protocols between laboratories. In this laboratory, a LD5 0  is a measure of 
any neurological distress and/or death. In other laboratories neurological distress is not 
included in LD5 0  quantification and animals are left until death occurs, or in some rare 
instances, lytic infection is cleared.
The LD5 0  originally reported for 1716 was confirmed in this study. The LD5 0  for 
1622 and 17+ were similar. This determined that the function o f ICP34.5 for allowing viral 
replication in the CNS was restored in 1622. Another study to examine the ability of 1622, 
17+ and 1716 to replicate at the periphery and to the ganglia was carried out in Dr. 
Sawtell’s laboratory (Children’s Hospital, Cincinnati). Samples were taken after initial 
infection (day 0) to determine an equivalent input dose of infection (1x10s pfu/ml) and 
virus replication was examined starting 2 d pi. All viruses replicate by day 2 in the snout, 
however, 17+ was replicating dramatically better (10-fold) than 1622 and 1716. The 
replication of 17+ continued and stayed constant throughout the study (4 d pi) but 1622 and 
1716 failed to replicate. In the TG of these infected mice, replication o f 17+ and 1622 was 
observed but replication of 1622 was less and there was no observed replication of 1716.
1622, 17+ and 1716 were studied in in vitro reactivation experiments. In a direct 
comparison using one dose, 1622 and 17+ reactivated equally well. One theory why the 
reactivation frequency from 1716 infected mice is reduced it that the amount of virus 
getting to the ganglia to establish latency is probably low. As seen by the 
immunohistochemistry experiments, the lack of HSV positive antigen in the ganglia of 
1716 represents a lack of virus replication. An in situ experiment, looking at RNA levels 
of 1716 and 1622 in ganglia, could elucidate a more quantitative answer to the amount of 
1716 and 1622 replicating to the ganglia.
7.2. HSV-2 ICP34.5 Expression
Another aim of this project was to verify expression of HSV-2 ICP34.5 and 
determine if HSV-2 ICP34.5 could complement HSV-1 ICP34.5.
This work provides the first demonstration that RL1 in HSV-2 strain HG52
expresses a homologue of HSV-1 ICP34.5. This is not surprising, as deletion of RL1 in
both HSV-1 and 2 produces a similar avirulent phenotype (Taha et al., 1989, MacLean, A.,
et a l, 1991). Antisera raised against the HSV-1 homologue did not cross-react with the
HSV-2 ICP34.5 protein (Brown et a l, 1997). Therefore, we constructed a GST fusion
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protein containing the whole of the HSV-2 RL1 ORF. This was used to raise rabbit 
polyclonal antisera 596 and 597. Recombinant viruses, 1627 and 1628, expressing the 
HSV-2 ICP34.5 with and without the 154 bp intron, respectively, were constructed to also 
aid in the detection of ICP34.5. 1627 and 1628 did not express detectable levels of
ICP34.5 by Western blotting with HSV-1 ICP34.5 antisera. However, 596 and 597 
specifically recognized two proteins of 27 and 37 kDa from wild type HSV-2 and 1627 
infected cells. Infection with viruses expressing HSV-2 RL1 without the intron led to 
expression of only the 37 kDa protein. To indicate its close relationship to ICP34.5, we 
have named the 27 kDa protein ICP34.5A. The origin o f the 27 kDa protein requires 
further investigation. One possible explanation is translation of a non spliced transcript, or 
one terminating before the intron acceptor site, to the first in frame stop codon in the intron. 
This would produce a 185 amino acid protein containing the first exon of ICP34.5 plus an 
additional 21 amino acids from the intron, approximately two-thirds of the 261 amino acid 
length and the Mr of ICP34.5. Alternatively, ICP34.5A is expressed from an unspliced or 
5’ truncated transcript, initiating in the intron and containing exon 2. This is less likely 
because there is no in-frame ATG in the intron to initiate translation. However, this type of 
transcript has been shown in another HSV-2 gene, UL16. In UL16, a protein is initiated 
with a Leu instead of the usual Met (Dolan et al., 1998). This hypothesis requires 
experimental proof by RNA mapping. Determination of the nature o f ICP34.5A will 
require analysis of viruses with mutations either in exon 1, 2 ,or the intron. The generated 
antisera recognize ICP34.5 and ICP34.5A by Western blotting and immunoprecipitation 
indicating recognition of both denatured and native epitopes. Similarly to the anti- 
HSV-1 ICP34.5 sera, the anti-HSV-2 sera do not cross react with HSV-1 ICP34.5. This is 
probably because the epitope with the highest homology is at the carboxy terminus and 
antisera are directed against the amino terminus (Brown et a l, 1997).
By constructing recombinant HSV-1 RL1 deleted viruses expressing the HSV-2 
gene under a strong HSV-1 promoter (gD) of similar kinetic class to ICP34.5, we have also 
demonstrated that the HSV-2 gene can, at least in vitro, functionally complement the loss 
o f the HSV-1 gene in a HSV-1 background. Future experiments will assess whether this 
complementation also applies in vivo regarding pathogenicity and latency.
The functional importance (if any) of ICP34.5A has yet to be determined. In all
assays carried out, both in vitro and in vivo, a virus with the RL1 intron deleted and hence
only expressing the 37 kDa ICP34.5 behaves like wild type. However, in viruses
containing the wild type gene (i.e. including the intron) only low levels of the 37 kDa
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ICP34.5 are detected by the antisera and the predominant protein is ICP34.5A. It seems 
unlikely that a protein expressed at such high levels does not have some function. The 
ability of HSV-2 ICP34.5 to interact with PCNA as illustrated by GST pull-downs 
indicates at least one common function with HSV-1 ICP34.5. This interaction is likely to 
be mediated by the highly conserved 63 amino acid carboxy terminal region.
7.3. 1716 and Recombinant Viruses
The locus used in this study for insertion of expression cassettes is the non-essential 
UL43 gene of HSV-1. If the level of the desired gene expression is critical, then this study 
suggests that the gene should be inserted in the UL43 Nsil site in the same transcriptional 
orientation as UL43.5. Additional transcriptional studies o f RNA could be carried out to 
assess this phenomenon., as well as sequence investigation to compare the UL43 and 
UL43.5 promoters. It was not known that the orientation in the UL43 Nsil locus might 
cause an effect on inserted gene expression. Looking more closely at the UL43 and 
UL43.5 sequence we can see that by inserting a gene in the Nsil locus the gene is placed at 
the immediate 5’ terminus of UL43. Inserting a gene in this locus would stop translation of 
UL43, while allowing translation of UL43.5. UL43.5 expression was analysed by a
UL43.5 antiserum (Ward et al., 1996). Although there was no apparent expression of 
UL43.5 by Western blot analysis we cannot conclude that a truncated protein was not 
synthesised. An experiment for future would be to look at possible recognition of this 
truncated UL43.5 protein.
Initial studies of HSV mutants focussed on plaque morphology. Different genes 
have been studied which demonstrate a role in syncitia formation in certain cells (Section
1.12). Other genes expressing glycoproteins have been studied for their role in absorption 
and penetration into cells and cell to cell spread (Section 1.4.1). Antisera against gC, gD 
and gl were available at the Institute and used by Western blotting to examine expression 
from 1716 and recombinant virus infected BHK cells. The recombinant viruses did not 
express gC (UL44). Although gC is considered non-essential, it may, as yet, have 
unknown role(s) in vivo. The lack of gC expression could be contributing to the decrease 
in 1622 replication kinetics in the snout and TG. Expression of the other glycoproteins (gD 
and gl) was similar among viruses.
It was previously reported by Brown et al (1994 a,b) that RL1 is responsible for an
unusual plaque morphology. 1716 gives small “abortive” plaques in 3T6 cells (Brown et
al., 1994a). The size of plaques was called abortive because 1716 did not replicate to wild
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type levels on 3T6 cells. Here it is reported that 1716 and all recombinant viruses 
containing functional ICP34.5, produce small plaques on BHK and 3T6 cells, regardless of 
a productive infection or not. Analysis of the particle to p.f.u. ratio by electron 
microscopy did not elucidate any further evidence that 1716 recombinant viruses did not 
produce wild type particles. In an attempt to pin-point a second mutation in the 1716 
genome, recombination experiments were carried out, using a series o f cosmids with co­
transfection of 1716 DNA. These experiments showed that wild type plaque size was 
rescued by recombination with sequences in the long repeats. However, additional 
recombination experiments using plasmids containing smaller sequences spanning the long 
repeat region could give a better definition of the mutated sequence. A final experiment to 
address if there may be a single amino acid mutation which results in this unusual 
phenotype could be carried out by sequencing the BamHl k  region.
7.4. Future work
Two novel findings from this study include (1) the construction and characterization 
of 1622 and (2) detecting expression of ICP34.5 and ICP34.5A from HSV-2 strain HG52 
infected cells.
Before any definitive conclusions can be drawn from the 1622 expression of 
ICP34.5 and 1622 pathogenicity, characterization of 1624 must be carried out. This would 
allow a direct comparison between these mutants in vitro and in vivo. An experiment to 
examine the increased level of ICP34.5 expression from 1622 infection could include 
Northern blotting of ICP34.5 transcripts in vitro and in situ hybridisation in vivo. Western 
blotting with HSV-1 ICP34.5 antisera consistently recognised a virally induced 70 kDa 
protein from 17+, 1716 and 1622 BHK infected cells. Brown et al (1997) identified this 
protein from virally infected BHK cells and only 17+ infected 3T6 cells, but not mock or 
1716 infected 3T6 cells. The 70 kDa protein is dependent upon productive infection and 
not dependent upon ICP34.5 expression (Brown et al., 1997). The 70 kDa protein was not 
detected until 8 h pi and not induced in the presence of PAA, suggesting it is a late 
consequence of infection. Further investigation to identify this protein is currently 
underway by using cDNA libraries. The yeast-two-hybrid system could be used to analyse 
full protein interactions with ICP34.5.
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Appendix A. List of the identified HSV-1 genes and proteins.
The staus o f each gene is indicated as E=essential, NE=nonessential E?= 
proabably essential, E/NE=non-essential under certain conditions, ?=status unknown. 
(Adapted from McGeoch et al., 1993; Fields, 1996.)
Gene Protein Status
Names Names
RL1 ICP34.5, y134.5 NE
ORF P OPP NE
ORF 0 OPO NE
RL2 (IE-1) ICPO, VmwllO NE
LAT NE
UL1 gL E
UL2 NE
UL3 NE
UL4 NE
UL5 E
UL6 E
UL7 ?
UL8 E
UL8.5 ?
UL9 E
UL9.5 ?
UL10 gM NE
UL11 NE
UL12 E
UL13 ' NE
UL14 ?
UL15 E?
UL16 NE
UL17 E
UL18 VP23 E
UL19 VP5 E
UL20 E/NE
UL21 NE
UL22 gH E
UL23 tk NE
UL24 NE
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UL25 E
UL26 E
UL26.5 E
UL27 gB E
UL27.5 ?
UL28 E
UL28.5 ?
UL29 ICP8 E
UL30 E
UL31 ?
UL32 E
UL33 E
UL34 ?
UL35 VP26 E
UL36 Vmw273, VP 1-2 E
UL37 ?
UL38 VP19C E
UL39 R l, Vmwl36, ICP6 E/NE
UL40 R2, Vmw38 E/NE
UL41 vhs NE
UL42 E
UL43 NE
UL43.5 NE
UL44 gC NE
UL45 NE
UL46 VP11 and VP12 NE
UL47 VP13 and VP 14 NE
UL48 Vmw65, VP 16, aTIF E
UL49 VP22 ?
UL49A VP22 NE
UL50 NE
UL51 E/NE
UL52 E
UL53 gK E?
UL54 (IE-2) Vmw63, ICP27 E
UL55 NE
UL56 NE
RSI (IE-3) Vmwl75, ICP4 E
US1 (IE-4) Vmw68, ICP22 E/NE
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US 1.5 NE
US2 NE
US3 NE
US4 gG NE
US5 gJ NE
US6 gD E
US7 gl NE
US8 gE NE
US8.5 NE
US9 NE
US10 NE
US11 NE
US 12 (IE-5) Vmwl2, ICP47 NE
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Appendix B. Hyperthermia Induced Reactivation of Herpes Simplex Virus in a 
Mouse Model
This document was written for approval by the British Home Office of the 
“hyperthermia induced reactivation of HSV-1 in a mouse model”. The contents are 
outlined below.
I. Introduction.
A. The virulence of herpes simplex virus.
B. Current in vivo methods to study latency and reactivation.
i. Different species.
ii. Mice.
II. Protocol.
A. Description o f existing procedure.
B. Description of modified procedure for Glasgow.
III. Bibliography.
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I. Introduction
Herpes simplex virus (HSV) is currently being studied in this laboratory to gain a 
better understanding o f its molecular mechanisms in the establishment of latency and the 
reactivation from a latent infection. Reactivation is thought to be due to stresses such as 
heat and UV light. Several animal models have been developed to look at this. One 
method developed by Sawtell and Thompson (1992) closely mimics the host’s natural 
response to reactivation of HSV.
In order to study the difference between genuine reactivation and a reduction in 
replication efficiencies we would like to use this method in addition to other in vivo and in 
vitro replication methods currently in studies using 17+, 1716 and recombinant viruses 
singly expressing RL1 or ORF P.
A. The Virulence of Herpes Simplex Virus
The herpes simplex virus type 1 (HSV-1) genome consists o f 2 unique sequences 
(U l) and an unique short sequence (U s) which are flanked by re-iterated repeat sequences. 
The repeat regions contain 3 categories o f transcripts; 1) transcripts which are known to be 
translated (IEO, IE4 and RL1), 2) latency associated transcripts (LATs), and 3) transcripts 
that span the long/short junction of the repeat sequence (L/STs). It has been shown that the 
2 immediate early genes (IE) which encode polypeptides, ICPO and ICP4, are essential for 
the lytic replication of the virus and are thought to be significant in the establishment of 
latency.
The other translated gene located in the repeats, RL1, encodes the infected cell 
protein (ICP) 34.5. Deletion of RL1 results in mutant viruses that are incapable of 
replicating in the neurones in the central nervous system and do not cause encephalitis or 
death in mice. Both the HSV-1 mutant 1716 (759 bp deletion in RL1) and the mutant 1771 
(stop codon insertion immediately downstream of the initiating methionine) grow as well 
as their parental virus in tissue culture, but do not replicate in vivo when injected into the 
cerebral hemisphere o f mice (MacLean et al., 1991; McKie et al., 1993). Furthermore, 
ICP34.5 mutants have severe replication defects in vivo when injected in the periphery. 
We hypothesise that this replication defect may play a role in the viruses ability to cause a 
latent infection and reactivate.
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B. Current in vivo Methods to Study Latency and Reactivation
i. Different Species
Some laboratories have experimented with animal model systems to study latency 
and reactivation of herpes simplex virus. Many initial in vivo studies were carried out in 
rabbits. There are several reasons why using rabbits is not a good practical method among 
them is that a significant level o f spontaneous reactivation occurs in these animals and the 
expense and space incurred in the upkeep of rabbits. Publications which discuss this in 
more detail are as follows: Gerdes et al., 1983; Hill et a/., 1987; Gordon et al., 1990; and 
Beyer et al., 1990.
ii. Mice
Many laboratories have developed different methods for looking at reactivation of 
HSV using mice. Here they have shown a relatively low frequency of spontaneous 
reactivation and they are much easier to house and to handle economically and practically.
The method currently employed in Glasgow is called “co-cultivation” or “m vitro 
reactivation”. In this method, mice are injected with HSV in the footpad and the virus 
travels by axonal transport to the dorsal root ganglia (DRG). Following incubation, mice 
are sacrificed, ganglia explanted and reactivating virus looked at in vitro.
In more detail, mice are injected in the right rear footpad and placed in cages for at 
least 42 d pi to allow the establishment o f a true latent infection. Forty-two d pi, mice are 
sacrificed, dissected, and dorsal root ganglia (DRG) dissected using a microscope. Whole 
ganglia are individually placed in 96-well tissue culture plates containing media. The 
media is subsequently plated onto fresh baby hamster kidney (BHK21/C13) cell 
monolayers every two days to look for reactivating virus by cytopathic effect. 
Replacement of media on the DRG occurs every 2 d and is perpetuated for a subsequent 21 
d (Robertson et al., 1992). In this method, wild type virus, 17+, shows reactivating ganglia 
starting at day 4 post explantation and continues to show c.p.e. up to day 21 post 
explantation. However, the ICP34.5 mutant virus, 1716, yields reactivating virus at lower 
level and is delayed from that o f 17+ by 2 weeks post explantation.
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II. Protocol
A. Description of Procedure
This procedure was adapted by Sawtell and Thompson (Germain et al., 
1985 and German et al., 1984). Thirty days after infecting outbred Swiss Webster mice via 
snout scarification and inoculation of HSV, mice are handled individually by the scruff and 
placed in a 50 ml Falcon tube with holes throughout (Fig. 1). In the original work, a 
temperature probe was placed 3 cm into the rectum. This step was done initially to ensure 
body core temperature but due to the critical timing in the bath this is not done routinely. 
A group o f mice in their respective containers are carefully placed in a metal basket and
o
slowly lowered into an equilibrated 43 C water bath (Fig. 2). The animals are carefully 
monitored in the water bath for exactly 10 min to watch for signs of stress caused by heat 
or high levels o f water. If  this occurs the animals are immediately removed from the water 
bath and from the experiment. Mice are generally complacent in this environment with 
some movement within the tube. After the water bath the mice are removed from the tubes 
and blotted dry with paper towels. They are put back in their appropriate cages placed in a 
warm incubator (34°C) for 30 min. to prevent hypothermia. Twenty-four h later mice are 
killed and the ganglia (trigeminal or dorsal root ganglia, depending on the site of infection) 
are removed asceptically and homogenised in 0.5 ml media. The homogenates are plated 
onto fresh rabbit skin cell monolayers and monitored for c.p.e.
Different times (14, 24 and 48 h) post hyperthermic stress have been studied by 
Sawtell et al (1992’, personal communication) to see if there is a variation in the amount of 
reactivating virus. It was shown that 24 h is optimum for the highest levels of 17+ virus 
(60%). The length o f time between hyperthermic treatment and reactivation is within 14 h 
post induction. This is expected because it is the time which is required for one round of 
viral replication in tissue culture in vitro. The results of time course studies also showed 
that the number of virus positive ganglia 48 h posttreatment was only half that at 24 h 
posttreatment. Using a light microscope to view individual neurones Sawtell and 
Thompson found that an immune response modulated destruction of the reactivating virus 
and/or neurones which is why there was a decrease in virus positive ganglia at 48 h 
posttreatment.
Appendix B
a
b
c
Figure 1. Scetch of a 50 ml Falcon tube used in the “HSV in vivo 
reactivation” method to contain individual mice when placed in the water 
bath. a. Holes cut out for water and air to enter the tube, b. Sponge to 
adjust the heigth of the mouse in the tube, and c. Lid with a slit cut 
out for the tail screwed on the the tube.
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Figure 2. a. Metal basket representing components involved (1) metal basket, (2) rubber hose to 
contain the tubes with mice and (3) tubes containing mice. b. (1) water bath and (2) schematic 
representation of the level the water should be when metal basket is placed therein.
IX
Appendix B
B. Description of Modified Procedure for Glasgow
Most of the procedure described above we are proposing to practice at the 
University o f Glasgow’s Central Research Facility (CRF) with a few minor changes which 
includes the following: three-week old BALB/c mice. This is the breed of animals we 
routinely use for all current work carried on HSV and allows a standardised conformity 
among results.
Due to the low frequency o f reactivation each virus dose will include no fewer than 
10 mice. The number of mice is particularly significant when studying mutant viruses as 
they tend to have lower amounts o f reactivating virus. In the original publication by 
Sawtell and Thompson (1992), they reported, 1 to 3 HSV antigen positive neurones per 
ganglia, 24 h after heat stress.
As previously described in our project licence (No. 60/2215, “Herpes simplex 
latency and virulence”), HSV and mutant viruses derived from HSV-1, will be injected in 
the right rear footpad. This method is less traumatic for the animal. The mice will be 
housed for 30 d to allow a true latent establishment of HSV. The heat stress and thermal 
warming takes approximately 1 h per group and the animals are housed for a subsequent 
24 h and killed.
The DRG are removed asceptically using a dissecting microscope and homogenised 
in 0.5 ml media. The homogenates are plated onto fresh BHK21/C13 cell monolayers and 
monitored for c.p.e.
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